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Abstract: 
  
 The post-translational modification of histones and their interaction with 
transcription factors is essential to gene regulation. Furthermore, these targets would 
greatly benefit from probe molecules to fully elucidate their biological actions and to 
potentially lead to therapeutics. However, these protein-protein interactions have been 
considered difficult to inhibit and few high-quality chemical probes currently exist for the 
study of epigenetic biological systems in particular.  
The bromodomain and extra-terminal (BET) domain family are readers of acetyl 
lysine marks on histones and some nuclear proteins. They share a common domain 
architecture comprising two N-terminal bromodomains which exhibit high levels of 
sequence conservation. BETs are important to transcription in a number of systems, 
especially transcriptional elongation, making them interesting targets for biological 
investigation and cancer therapeutics. My work developed and improved direct 
inhibitors of these targets. Here we present an improved derivative, JQ35, and novel 
chemistry for targeting BETs and other bromodomains.  
Overexpression of MYC has been detected in 30% of all human cancers and, in 
many cases, correlates with aggressive cancers of poor clinical outcome and increased 
frequency of relapse. While MYC can have a restrictive effect on cell growth under 
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normal conditions of tight regulation, it contributes to all six hallmarks of cancer when 
deregulated by amplification, translocation, enhancer mutation, or aberrant expression. 
Thus, we engaged in a deep literature search for strategies to inhibit MYC as well as an 
effort to develop novel direct inhibitors. 
Diffuse Large B-Cell Lymphoma is the most common non-Hodgkin lymphoma 
accounting for 30-40% of new cases. The heterogeneity of this disease makes 
treatment difficult with remission in 40-50% of patients while others suffer from 
aggressive progression. Collaborative research from our group and others has recently 
identified a role for BET bromodomains in supporting the transcription of known DLBCL 
oncogenes (MYC and BCL2) in studies of acute leukemia, multiple myeloma and Burkitt 
lymphoma. Interestingly, overexpression of BRD2 from an engineered immunoglobulin 
heavy-chain promoter-enhancer construct caused an aggressive B-cell neoplasm 
resembling DLBCL in mice. Therefore, we embarked on a study of the efficacy and 
mechanisms of bromodomain inhibition in DLBCL. 
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Introduction: 
The use of chemical probes in biological studies empowers researchers with the 
tools to manipulate and perturb a system to gain insights that would be difficult from 
interpreting still-life snapshots or totally deconstructed systems. However, there exists 
relatively few high-quality and selective chemical probes fit for this purpose. The lack of 
chemical probes available for the study of transcriptional regulation presents a barrier to 
understanding the dynamic events underlying cell identity and fate. Therefore, my work 
sought to discover, develop, and explore the ramifications of chemical probes in cancer. 
This involved screening to find compounds, medicinal chemistry to improve leads, and a 
variety of biological tools to investigate the biological systems related to the 
transcriptional regulatory proteins that I was targeting. 
In my first major project in the Bradner lab, I contributed to the probe discovery 
and biological effort in Nut Midline Carcinoma (NMC) that lead to JQ11, a first in class 
inhibitor of bromodomains used in cancer. Bromodomains are a family of proteins 
involved in the readout of the posttranslational mark of acetyl lysine primarily on nuclear 
factors and histones. In this breakthrough work, a cell-permeable small molecule, JQ1, 
was found that competitively binds to acetyl-lysine recognition motif of the BET 
subfamily of bromodomains. This probe was then deployed against NMC, which hosts a 
recurrent translocation of BRD3 or BRD4 forming a fusion protein and making it 
oncogenically addicted to BET bromdomain acitivty. It was found that inhibition by JQ1 
displaces the BRD4 fusion oncoprotein from chromatin which leads to growth arrest and 
differentiation of these cells. Moreover, this established a rationale for the use of 
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bromodomain inhibition in cancer and provided an academic, open-source probe to the 
scientific community. 
Next, I became involved in one of my most entertaining projects based on the 
observation that JQ1 could inhibit a BET subfamily bromodomain called BRDT2, which 
shows tissue restriction to the testes. As of yet, a pharmacologic method for male 
contraception remains an elusive for biomedical research. To investigate the potential 
for inhibitors of epigenetic targets for this purpose, we explored the anti-spermatogenic 
effects of JQ1. Importantly, BRDT is essential for chromatin remodeling and compaction 
during spermatogenesis. It was found by biochemistry and crystallographic studies that 
JQ1 does indeed block the BRDT acetyl-lysine binding from engaging acetylated 
histone H4. In addition, dosing male mice with JQ1 reduced seminiferous tubule 
volume, testis mass, the quantity of spermatozoa, and the motility of sperm. Moreover, 
associated hormone levels were unchanged. JQ1 did not adversely affect mouse 
behavior but was found to reversibly confer a contraceptive effect on mice. 
From these early projects, I engaged in several highly collaborative probe and 
drug discovery efforts in addition to building a stronger understanding of cancer biology 
by deploying these tools. By pairing probe development with cancer biology I could 
learn not just about the effects of the compounds, but about the nature of the cancer 
specific biology itself. 
Chapter one covers the discovery of JQ35. This work presents a next-generation 
optimized BET bromodomain inhibitor with improved in vivo properties. In addition, I 
developed robust assays and using novel pull-down tools enabling further research on 
bromodomain biochemistry and biology. While the existing probe molecule JQ1 is 
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incredibly useful for interrogating biology in an academic setting, reaching improved, 
drug-like properties must be achieved to enable potential therapeutics. With the overall 
likelihood of approval in oncology is only 6.7% from Phase I trials3 and the dire need of 
new targeted therapies in oncology, we engaged in focused effort to build a second 
generation inhibitor from JQ1, with longer half-life, potency, and in vivo efficacy. In 
addition, this compound was utilized to investigate the nature of NMC, which remains a 
tumor of unknown origin4. 
Chapter two describes efforts to develop alternative chemistries for bromodomain 
inhibition to empower new probes and to engage new targets. BET bromodomain 
inhibition has emerged as both a viable method to probe gene regulation and a 
promising therapeutic option in cancer treatment. As small molecule inhibitors of 
bromodomains begin clinical trials as anti-cancer drugs, there is an obvious opportunity 
and need for novel inhibitors to support medical advances and to elucidate the chemical 
biology of these proteins. Using pioneering, fluorous multicomponent reactions we have 
rapidly developed a chemical library of bromodomain inhibitors around a 3,5-
dimethylisoxazole biasing element with an initial biochemical IC50 of 16 µM. A robust 
chemical screening and development program has allowed rapid optimization of novel 
and selective BET bromodomain pharmacophores with 637 nM biochemical potency 
and 724 nM cellular potency. In addition, these compounds show inhibitory effects 
against TAF1, which currently lacks a probe compound. Computational studies of 
interaction with BET-bromodomain BRD4 suggest the binding modality of this 
compound class is consistent with previous modes of engagement. These compounds 
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showcase novel chemical synthesis methods for the development bromodomain 
inhibitors. 
Chapter three details our deep literature search for methods and strategies to 
inhibit the proto-oncogene MYC. In addition, it describes our effort to make our own 
direct MYC inhibitors in collaboration with the Young Lab. MYC is a master regulator of 
stem cell state, embryogenesis, tissue homeostasis, aging and has been the subject of 
much study in cancer. Many years of biomedical research have demonstrated a central 
role for MYC in the pathophysiology of cancer, inflammation, and heart disease. 
However, it has thus far proven intractable for drug discovery efforts. This chapter 
reviews strategies toward the development of inhibitors of MYC-dependent 
transcriptional signaling, efforts to modulate MYC stability, and the elusive goal of 
developing direct-acting inhibitors of MYC. 
Finally, chapter four describes our study5 of the efficacy and mechanisms 
underlying bromodomain inhibition in Diffuse Large B-Cell Lymphoma (DLBCL). This 
malignancy is a biologically heterogeneous and clinically aggressive disease. Using 
integrative chemical genetics and functional epigenomics we probed effects of 
bromodomain inhibition in this disease. We found highly asymmetric loading of BRD4 
with almost half at enhancers. Moreover, these enhancers show a skewed distribution 
with approximately 33% of all BRD4 localizing to enhancers at 1.6% of occupied genes. 
These “super-enhancers” are particularly sensitive to disruption by bromodomain 
inhibition leading to depletion of their target gene. This helps explain the selective effect 
of BET inhibitors on oncogenic and lineage-specific transcriptional circuits. In addition, 
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functional studies of the super-enhancer marked genes in DLBCL cell lines and primary 
tumors can elucidate novel dependencies.  
Thus, the development of chemical probes enables a path toward clinically useful 
compounds and empowers deeper exploration of the biology related to the probe’s 
target. In this case, I worked on new and improved chemical probes for the BET 
bromodomains and MYC which were then deployed to study transcriptional regulation in 
the setting of cancer biology. 
1 Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073, 
doi:10.1038/nature09504 (2010). 
2 Matzuk, M. M. et al. Small-Molecule Inhibition of BRDT for Male Contraception. Cell 150, 673-
684, doi:10.1016/j.cell.2012.06.045 (2012). 
3 Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development 
success rates for investigational drugs. Nature biotechnology 32, 40-51, doi:10.1038/nbt.2786 
(2014). 
4 French, C. A. NUT midline carcinoma. Cancer genetics and cytogenetics 203, 16-20, 
doi:10.1016/j.cancergencyto.2010.06.007 
S0165-4608(10)00262-1 [pii] (2010). 
5 Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in 
diffuse large B cell lymphoma. Cancer cell 24, 777-790, doi:10.1016/j.ccr.2013.11.003 (2013). 
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Chapter 1 
 
 
 
 
Development of an Improved BET Inhibitor for In Vivo and Human Trials 
Contributors 
Michael McKeown, Jun Qi, Katharin Shaw, Xiang Xu, Chris Ott, Charles Lin, 
Jaime Reyes, Andrew Kung, Teri Bowman, James Bradner 
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Introduction: 
After the discovery of bromodomain inhibitors and their potential against 
cancer with JQ11, we sought to explore the SAR around this scaffold and to 
develop a compound with properties adequate for in vivo use. As part of this 
effort, I became well acquainted with the equipment and technologies employed 
in high-throughput screening. Our lab is equipped with a Biotek liquid handler, a 
Janus workstation, and an Envision. I have learned how to calibrate, program, 
and repair most all aspects of this equipment. In addition to training and running 
this equipment for numerous projects, I also developed novel capabilities for the 
lab, including 1536 well plates for HTS. 
 For this project, I first created AlphaScreen assays for all the BET proteins 
with independent site one and two assays for all except BRDT. This enabled both 
screening for novel warheads (not shown in chapter) and to generate large 
numbers of IC50 curves for medicinal chemistry efforts. In conjunction with Jun 
Qi and Jason Marineau, a large set of aldehyde containing compounds was 
selected and coupled to build a screening deck of about 400 compounds based 
on the JQ1 structure. After analyzing the hits from this initial screen, I worked 
closely with Jun to iteratively improve the properties of JQ1 derivatives. We 
created an excellent synergy of biochemistry and synthetic chemistry where I 
would run AlphaScreen assays and cellular viability on compounds made that 
week, analyze the data over the weekend, and Jun would start a new round of 
chemistry based on the SAR established by the recent assays data. 
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 In the end, JQ35 was the best compound in terms of solubility and 
potency. Moreover, it proved to have a vastly improved half-life over JQ1. I used 
this compound for in depth cellular investigations performing expression studies 
analyzed with Chris Ott, ChIP-seq processed with Charles Lin, and mouse 
studies with Andrew Kung. This improved compound has expanded our 
understanding of Nut-Midline Carcinoma and is superior in mouse studies. 
 Another important milestone achieved in this project was the use of 
formulated JQ35 in the clinic. It is rare for a scientist to see their work achieve the 
full transition from early bench research to use at the bedside, but I am very 
happy to have been part of this process. 
Contribution: 
 MRM wrote the text, composed figures, developed and executed 
biochemical and cellular assays, and planned and analyzed in vivo experiments. 
JQ synthesized compounds. KS synthesized compounds and collaborated on 
biochemistry. XX did crystallography. CO analyzed transcriptional data. CL and 
JR processed ChIP-seq data. AK oversaw execution of in vivo. TB processed 
samples for histology. JB oversaw and mentored research. 
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Background: 
The functional interpretation of epigenetic modifications of chromatin is an 
essential component of gene regulation2. The marks are placed by nuclear 
enzymes called ‘writers’ and removed by a set of enzymes called ‘erasers’ in a 
creating a system of transcriptionally activating and inhibiting post translational 
histone modifications. Thus, a diverse set of chromatin-recognition – or ‘reader’ - 
proteins is critical for the transmission of posttranslational modifications to 
cellular transcriptional machinery by coordinating the local area network of 
transcription factors, polymerases, and remodeling enzymes3. The bromodomain 
containing proteins are readers of lysine acetylation with a conserved structural 
motif composed of a four alpha helix bundle and forming a binding pocket that 
mediates interactions with acetylated lysine side chain on substrates4-7. In 
particular, the bromodomain and extra terminal domain (BET) family of proteins, 
including BRD2, BRD3, BRD4, and BRDT, contains a pair of bromodomains with 
high sequence homology for site 1 and site 2, respectively, among the family 
members. BRD4 has been shown to be important transcriptional coactivators by 
promoting RNA polymerase II (RNAP) pause release and transcript elongation 
through recruitment of the positive transcriptional elongation factor –B (pTEFB)8-
10. Moreover, BRD4 appears to both directly interact with pTEFB through its 
second bromodomain site and promote elongation independent of pTEFB by 
increasing the effective molarity of transcription factors11,12. BRD4 also appears 
to colocalize with sites of active transcription during mitosis and exhibits 
asymmetric loading to enhancers tissue dependencies13,14. 
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Recently, small molecule inhibitors have been shown to effectively and 
selectively inhibit BET bromodomains through direct binding to the acetyllysine 
binding pocket15. The first reports of selective chemical probes for BET 
bromodomains, JQ1 and iBET, are based on a 1,4 diazepine scaffold1,16.  These 
compounds have seen considerable utility as tool compounds in a variety of 
cancer and inflammation-related studies. Since then initial reports, additional 
studies have found potential fragments, alternative binding motifs such as the 
dimethylisoxazole in iBET-151, and alternative chemical scaffolds that greatly 
expand the chemical space for BET bromodomain inhibitors17-22. In addition, 
compounds have been reported to bind other bromodomain-containing proteins 
including CREBBP23. Furthermore,  BET bromodomain inhibition shows great 
therapeutic potential in a wide range of cancer types including NUT-midline 
carcinoma1, acute lymphoblastic leukemia24, multiple myeloma25, Burkitt’s 
lymphoma26, glioblastoma27, neuroblastoma28, diffuse large B-cell lymphoma14, 
and even HPV29 and HIV30. These chemical probes have established great 
promise and rationale for the use of bromodomain inhibitors in human 
therapeutics, but would benefit from further optimization for clinical use. Here we 
report the development of a novel biochemical screening assay utilizing a 
derivatized biotinylated JQ1 as a capture reagent31. This assay along with cell 
viability measurements were deployed to discover an improved probe for BET 
bromodomains which was further validated with ITC, crystallography, 
pharmacokinetic measurements, and an in vivo model of NMC establishing 
11 
 
improved efficacy. This more potent compound also helped shed light on the 
mechanism of action and cell origins of NUT-midline carcinoma. 
 
The nature of BET inhibition in NUT-midline Carcinoma (NMC) needs 
further characterization. Based on previous studies, we hypothesized that the 
observed phenotypic effect would be consistent with an endothelial to epithelial 
conversion since previous studies in our lab found a transition from poorly 
differentiated cells with high nucleus to cytosol ratio into flattened enucleated 
cells with epithelial character1. It has been established that epithelial cells 
undergo epithelial to mesenchymal transitions to promote invasion, metastasis, 
proliferation, repressed growth control, and reduced adhesion32,33. The poor 
differentiation of NMC is also consistent with the more stem-like properties 
created by EMT34. Thus, we explored BET inhibition as a method to reverse EMT 
in NMC on a transcriptional and chromatin level. 
 
Results 
Benzodiazepines have been an important scaffold for drug discovery over years.  
Since our discovery of thienodiazepine as bromodomain inhibitors, we have 
examined well known benzodiazepine family members, including Alprazolam, the 
FDA approved drug anxiety medication better known as Xanax (Figure 1.1A).   
12 
 
Figure 1.1: BET inhibitors and synthetic strategy (A) Current BET bromodomain inhibitors. 
Alprazolam is a benzodiazepine (Xanax) that was originally found to weakly bind the acetyl-lysine 
pocket. Y803, from Mitsubishi, IBET and IBET-151, from GSK, and JQ1S, from the Bradner Lab, 
were among the first BET bromodomain probes. (B) Schema showing starting components and 
accessibility to the JQ1 core structure that enables diversification. (C) The optimized probe 
compound JQ35. 
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Other bromodomain inhibitors, such as Y803 (from Mitsubishi), iBET, share a 
similar structure with substitutions at the C6 position larger than a methyl group 
to prevent binding to the central benzodiazepine receptor and block activity as a 
platelet aggregating factor antagonist35,36. 
 The use of a dimethyl isoxazole moiety distinguishes iBET-151 from the 
other structures. While it demonstrates the potential of alternative structural 
moieties in targeting BETs, it does not show significantly improved in vivo 
efficacy versus the original iBET-762 (also name just iBET)16,22,37. Thus, we set 
out to study the structure activity relationships of BET inhibition to build improved 
inhibitors based on the JQ1 scaffold. Based on the retrosynthetic analysis of 
JQ1, we have designed an optimized synthetic route to modify a variety of units 
in and appending to the core structure to establish structure activities 
relationships (Figure 1.1B).  
 
Assay development 
 We designed and developed a bead-based proximity assay to facilitate 
high-throughput screening of compound libraries. Utilizing the well characterized 
binding of JQ1 to BETs, a capture probe was created by attaching a biotin with a 
two PEG spacer (Figure 1.2A)31. This probe replaces biotinylated tetra acetyl 
histone H4 tail peptides in pulldowns and biochemical assays7. To build a robust, 
high-throughput assay for inhibition of BET family member subunit the 
biotinylated probe was used with 6x histidine tagged proteins of each subunit in a 
Ni+2 chelate AlphaScreen system (Figure 1.2B). In order to optimize this assay  
14 
 
 
Figure 1.2: Biochemical screening assay. (A) Biotinylated JQ1 probe used in HTS read assay. 
(B) Schematic of assay showing nickel coated acceptor bead A with bromdomain attached (BRD) 
linked by the biotinylated probe to the donor bead (D) with streptavidin coating. (C) Z’ 
performance over varying concentrations of free JQ1 showing good detection sensitivity. (D) Data 
for Z’ over dose for all BET proteins by subdomain. (E) Dose response for compounds in Figure 
1.1A using AlphaScreen assay. 
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Figure 1.3: Assay optimization. Dose response z-prime data for site one and site two, 
respectively, of BRD2 (A) and BRD3 (B). BRD4.2 (C) and BRDT.1 (D) are also shown. Assay 
was performed on 384 well plates as described in methods.  
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Figure 1.3 (Continued) 
  
17 
 
system, buffer conditions and reagent concentrations were tested. To maximize 
signal and responsiveness to inhibition while minimizing background signal, 
protein and ligand were titrated with constant bead concentrations and respective 
drop-out conditions. Moreover, a buffer at physiologic pH and salinity (see 
methods) was formulated with high detergent (0.01%) and BSA (0.1%) to 
minimize non-specific interactions. The final version of this fully optimized assay 
provides statistical robustness across a broad range of assay screening 
concentrations for BRD4.1, with a Z’ of 0.69 (Figure 1.2C). BRD4 also showed 
robust performance across a range of doses and with site 2 (Figure 1.2D; 1.3C) 
In addition, this system works comparably well with all BET bromodomains 
(Figure 1.2D; 1.3; 1.4D). The z-prime across doses of JQ1 is shown in the table 
in Figure 1.4B. This assay is also 1536 ready with a Z-prime of 0.57 enabling 
dramatically higher screening capacity (Figure 1.4A). To test out dose response 
behavior and benchmark the assay the known bromodomain inhibitors shown in 
Figure 1.1A were tested and showed potencies in good agreement with 
previously published values (Figure 1.2e; 1.5; Table 1.1). Furthermore, the 
biotinylated JQ1 probe performed as well as the tetra acetylated peptide in the 
same assay configuration (Figure 1.5). Finally, validation of the compounds for 
cellular activity was performed by cell viability in 797 Nut Midline Carcinoma 
lines. Performance over a range of JQ1 concentrations showed good dose 
responsive behavior by ATPlite (Figure 1.4C). 
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Figure 1.4: Assay performance (A) Z-prime performance of assay in 1536-well configuration. 
(B) Table form of z-prime data for all BET bromodomain sites studied. (C) Performance of JQ1 in 
a ATPlite cellular viability assays against the 797 NMC cell line. 
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Figure 1.5: Dose response of chemical porbes 10 point dose response curves generated for 
bromdomain probe molecules. Each series of panels shows site on, left, site two, right, and the 
site one assay using an acetylated peptide instead of the biotinylated JQ1 probe. BRD2 (A), 
BRD3 (B), and BRD4 (C) show both sites. BRDT data for site one shown in (D). 
  
20 
 
 
  
21 
 
Approach to modifying core 
 Based on the crystal structure of BRD4 and JQ11 the following were 
considered potential areas for modification of the JQ1 scaffold: the chlorophenyl 
(I), the thiophene (II), methyl triazole (III), and the C6 position (IV) (Figure 1.6A).  
 The chlorophenyl region is mostly solvent exposed on one face and sits 
against a non-polar surface of the BC loop on the other. Attempts to remove this 
group strongly abrogated binding as seen (JQ9). Also, substitution of the chloro 
to fluoro in JQ43 or changing to a fourth position pyridine in JQ37 in the hopes of 
improving solubility were found to hinder binding to a lesser extent likely due to a 
loss of interaction with this surface (Figure 1.6B). 
 The thiophene region rests in a narrow channel between WPF shelf and 
the ZA loop. As expected, the isosteric substitution to phenyl ring in JQGB 
proved to have no effect on binding while the desmethyl version in KS1 proved 
extremely deleterious (Figure 1.6C). Adding the methoxy group to the benzyl 
substituent in JQGB to yield JQG2A caused a tenfold reduction in potency 
suggesting that mimicking iBET’s methoxy substituent was not beneficial in this 
case. Finally, bulking up the C6 position with a benzyl group in place of the 
thiophene did not compensate for a loss of the chloro at the group I site yielding 
a very poor potency. 
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Figure 1.6: Medicinal chemistry regions (A) The generalized structure of JQ1 from which 
derivatives were made. Color coding illustrates the starting components used in synthesis to 
access each atom on the molecule. The regions focused on for analogs are circled and labeled 
with roman numerals. Biochemical (left) and cellular (right) dose response with the 797 NMC cell 
line are shown for regions I, II, and III in (B), (C), and (D) respectively.  
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Table 1.2: Medicinal chemistry series. Table showing the IC50 generated by AlphaScreen 
assay against BRD4.1 in column two and the EC50 by cellular viability with the 797 NMC cell line 
in column three. Compounds are also labelled by region. N/A indicates that the value was not 
assessed.   
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Compound 
IC50 
BRD4.1 EC50 Group Structure 
JQ1 1.38E-08 
4.33E-
09 
I 
 
JQ9 >100 N/A I 
 
JQ37 2.98E-07 
1.82E-
07 
I 
 
JQ42 3.20E-07 
8.88E-
08 
I 
 
          
JQS 1.87E-08 
1.01E-
08 
II 
 
JQGB 1.92E-08 
7.09E-
08 
II 
 
Table 1.2 (Continued) 
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KS1 2.55E-05 
1.33E-
05 
II 
 
JQG2A 2.04E-07 
1.48E-
07 
II 
 
JQB 7.54E-06 N/A II 
 
        
 
 
JQ10 1.86E-05 N/A III 
  
JQ11 5.68E-06 >100 III 
  
JQ12 3.19E-05 N/A III 
  
Table 1.2 (Continued) 
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JQS 1.61E-08 
1.80E-
08 
III 
 
JQ18 3.23E-05 
1.82E-
05 
III 
 
JQ19 9.84E-06 
2.04E-
06 
III 
 
JQ21 3.78E-05 >100 III 
 
          
JQ1S 2.10E-08 
7.69E-
08 
IV 
 
JQ25 7.07E-05 N/A IV 
 
Table 1.2 (Continued) 
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JQ26A 8.30E-08 
4.25E-
08 
IV 
 
 
JQ26-R 2.94E-05 N/A IV 
  
JQ27 2.47E-05 N/A IV 
  
JQ29 1.65E-08 
8.03E-
09 
IV 
 
JQ30 2.42E-06 
9.06E-
07 
IV 
 
JQ31 >100 
7.37E-
06 
IV 
 
Table 1.2 (Continued) 
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JQ33 9.59E-08 
3.31E-
08 
IV 
 
JQ35 2.43E-08 
1.04E-
08 
IV 
 
JQ37 2.98E-07 N/A IV 
 
JQ38 1.53E-07 N/A IV 
 
JQ39 4.98E-05 N/A IV 
 
JQ40 2.57E-06 N/A IV 
 
Table 1.2 (Continued) 
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JQ41 9.71E-07 N/A IV 
 
JQ42 3.20E-07 N/A IV 
 
JQ43 9.96E-08 
7.51E-
08 
IV 
 
JQ44rac 2.56E-06 
1.56E-
06 
IV 
 
JQ44 7.51E-08 
1.56E-
06 
IV 
 
JQ45rac 5.78E-06 
3.18E-
06 
IV 
 
Table 1.2 (Continued) 
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JQ45-S 5.60E-08 
3.18E-
06 
IV 
 
JQ46 2.85E-06 
1.28E-
06 
IV 
 
JQ47a 7.57E-06 
2.74E-
06 
IV 
 
JQ48-1 1.70E-05 N/A IV 
 
JQ48-2 6.79E-06 N/A IV 
 
JQ49 5.00E-06 
2.79E-
07 
IV 
 
Table 1.2 (Continued) 
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JQ50-1 1.93E-06 
1.28E-
06 
IV 
 
 
JQ51 6.26E-08 
6.35E-
08 
IV 
  
JQ52rac 2.74E-06 
6.33E-
09 
IV 
 
JQ52 4.05E-08 
6.33E-
09 
IV 
 
JQ53 3.17E-06 N/A IV 
 
JQ54 6.64E-06 
5.79E-
06 
IV  
Table 1.2 (Continued) 
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JQB 1.90E-05 N/A IV 
 
JQG2-S 2.20E-07 N/A IV 
 
JQG2-R 6.88E-05 N/A IV 
 
JQG2-S 3.74E-08 N/A IV 
 
JQG3 1.72E-06 N/A IV 
 
  
  
Table 1.2 (Continued) 
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Based on the crystal structure, we hypothesized that the deep waters in 
the bromodomain binding pocket could be displaced or interacted with to 
enhance binding. However, exploration of group III around the methyl thiophene 
proved otherwise (Figure 1.6D). Replacing the methyl group with a methoxy ethyl 
in JQ10 reduced potency dramatically suggesting a clash instead of replacement 
with the waters. A shorter methoxy methylene in JQ18 was tenfold more potent, 
but still less potent than JQ1. A more subtle addition from methyl to ethyl in JQ19 
gave another nearly tenfold improvement, but was still a thousand-fold worse 
than JQ1. Yet the desmethyl JQ21 was one hundred fold weaker than the ethyl 
suggesting that the original methyl is the ideal substituent. Removing the methyl 
triazole altogether in JQ12 almost completely eliminated binding establishing that 
this region is crucial to the binding site interaction. A trifluoro methyl substituent 
aimed at altering the electronics of the engagement with the conserved 
asparagine proved similarly ineffective in JQ11. 
 
Biased Library Generation 
In order to build a focused library to interrogate the more permissive C6 
position, we utilized a hydrazide-aldehyde coupling strategy shown to be 
successful with the development of histone deacetylase inhibitors at efficiently 
exploring diversity around a biasing element38. In this strategy, JQ1 was 
derivatized by hydrolyzing the t-butyl ester to the carboxylic acid and then 
converting the group to a hydrazide (JQ3) (Figure 1.7A). A library of four hundred 
commercially available building blocks were assembled and coupled to the 
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hydrazide by heating the two components at 700C overnight in DMSO (Figure 
1.3A). The library was selected to probe diverse chemical functional groups to 
serve as launching points for a medicinal chemistry lead series. Compounds 
were then tested in eight point dose response in the BRD4.1 AlphaScreen 
(Figure 1.7B) assay as well as a cell viability assay against 797 NMC cells (Not 
shown).   
The most potent compounds were resynthesized and retested in ten point 
dose in the biochemical assay and cell line to verify potency and establish an 
IC50 (Figure 1.7DE). Based on this screening effort, JQ6 was discovered. 
However, the hydrazone linkage was judged to be potentially unstable for future 
in vivo work and thus changed to a readily available amide with comparable 
potency, JQ8. Having established that an amide couple be functionally 
substituted, we then aimed to remove the histamine component as this is itself 
bioactive, leading to a piperazine group on JQ13. These compounds were also 
tested for PK properties yielding half-lives of 2.32, 1.11, and 1.60 hours for JQ6, 
JQ8, and JQ13 respectively compared to JQ1 with 1.27. While more potent than 
JQ1, further optimization was required for improved use in vivo. Finally, multiple 
linkers were tested ending the series with JQ35 (Figure 1.3C,D,E). This final 
series progression was tested against all BET sites with comparable potency 
(Figure 1.8).  
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Figure 1.7: Lead series (A) Synthetic strategy for generating hydrazide library. The acid form of 
JQ1 formed by hydrolyzing the tButyl ester was converted to the hydrazine. This group allows 
rapid and efficient condensations with a library of 400 aldehydes. (B) Eight point dose response 
data from the aldehyde library against BRD4.1. (C) Chemical series leading to the development 
of JQ35. With JQ1 as a starting point, JQ6 was found from the hydrazide-aldehyde library which 
led to JQ35 by iterative medicinal chemistry. Dose response for series members is shown for 
BRD4.1 (D) and 797 cells (E). JQ35 is highlighted in red.  
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Further C6 SAR investigation 
Having established extensive structure activity relationships around the 
potential variable regions in JQ1 and found a promising lead in JQ35, further 
interrogation of this position was performed to establish a thorough 
understanding of the SAR (Table 1.2). Numerous amides were tested at this 
position and found to be suitable replacements for the ester bond as suggested 
from the ethyl amide at this position in iBET. Other substitutions were found to 
have negative consequences to binding. The ester/amide compounds form a 
hydrogen bond and steric interactions with the pocket. Reversing this group, as 
in JQ1 vs JQ25, JQ30 vs JQ31, JQ35 vs JQ36&41, and JQ13 vs JQ40, all 
greatly decreased potency. Also, direct amines without substituents (JQ27), 
secondary amines such as JQ46, and tertiary amines such as JQ52&53, possibly 
fail to pick up this interaction and as they exhibit reduced potency vs comparable 
amides and esters. An indole connected by a one carbon linker also proved to 
lack the potency of JQ1 or JQ35. Finally, an alpha methylation to the C6 carbon 
was attempted to constrain flexibility in the core while keeping the correct 
enantiomer during synthesis. However, these proved to have extremely poor 
potency relative to JQ35 likely due to steric clash with the bromodomain pocket. 
Thus, these improvement culminated in JQ35 which was maintained as the lead 
compound for additional biological and in vivo studies due to significantly 
improved biological properties. 
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Figure 1.8: Lead series dose response. Dose response of the expanded set of lead series 
compounds using the AlphaScreen assay is shown with BRD2 (A) BRD3 (B) BRD4 (C) and 
BRDT.1 (D). Site one is in the left panel and site two on the right. IC50 values are compiled in the 
embedded table (E).   
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Xray Structure Section 
To understand the contribution of the piperazine side chain to BET 
bromodomain engagement, we co-crystalized JQ35 with BRD4 site 1. The critical 
hydrogen bond to the conserved N140 was preserved, as expected (Figure 
1.9A). The elongated side chain rests against the side of the ZA loop between 
this loop and the BC loop region (Figure 1.9B). Space filling and charge 
assignment shows not only increased steric interactions, but a favorable charge 
interaction with the negatively charged area near the aspartic residue on the ZA 
loop (Figure 1.9C). In addition, an interaction diagram illustrates important 
hydrogen bonds to structural water molecules present in the binding site (Figure 
1.9D).  ITC performed on the protein used for crystallography showed a binding 
stoichiometry of 1:1 for BRD4 site 1 and a Kd of 6.3nM in agreement with the 
AlphaScreen assay (Figure 1.9E). Moreover, IV cassette PK for this compound 
showed a dramatic improvement to 5.53 hour half-life by IV injection (Figure 
1.12A). 
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Figure 1.9: JQ35 crystal structure. Crystallographic studies of JQ35 and BRD4.1. The methyl 
triazole makes the expected hydrogen bond to the conserved asparagine in BRD4 (A). The 
larger, positive C6 substituent of JQ35 participates in increased surface complimentarity (B) and 
favorable charge interactions (C). The amide picks up and additional hydrogen bond with a fixed 
water (D). The Kd of JQ35 was assessed by ITC measurement as 15.8nM (E). 
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Expression Changes 
We hypothesized that the oncogenic dysregulation of BRD4 in NMC is key 
to its pro-cancerous state and that inhibition could give insight into the original 
tissue and the programmatic shift enforced by Nut-BRD fusion.  To this end, we 
investigated the effects of JQ35 on NMC cells at the transcriptional level, gene 
expression profiling, and ChIP-seq.  Expression changes in response to JQ35 
treatment at 24 hours showed highly significant gene changes both up and down 
as expected with the pro-differentiation phenotype observed with JQ1 (Figure 
1.10A). The top fifty genes with treatment revealed several expected targets such 
as the upregulation of Ae1/Ae3, ANXA1, and cFOS in agreement with previous 
studies39,40. Down regulated genes such as the proto-oncogene MYB and ACSL5 
were also consistent with previous studies and the noted anti-proliferative effects 
of JQ35 treatment25,41. Furthermore, JQ35 is not acting simply as a broad 
transcriptional repressor, but rather causes greater than fourfold and highly 
significant changes in transcript abundance to both up and down regulate a set of 
genes at 24 hours of treatment where early phenotypic changes were noted in 
previous studies (Figure 1.10B)1. In addition, motif analysis showed a 
downregulation of growth pathways, such as Myc and E2F, as seen previously 
with JQ1 (Figure 1.10C). JQ35 treatment was also significantly consistent with 
the gene set established by siRNA knockdown of BRD4 in NMC supporting its 
on-target mechanism of action40 (Figure 1.10D). 
Since NMC presents as a poorly differentiated squamous carcinoma of 
unknown origin which undergoes a transition with BET inhibition into strong 
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epithelial character, we hypothesized that JQ35 could follow the signature of a 
Mesenchymal to Epithelial transition (MET). We tested established GSEA 
pathways for Epithelial-to-Mesenchymal (EMT) transition and found a significant 
anti-correlation with JQ35 treatment (Figure 1.10D)42,43. Importantly, this was true 
for both directionalities where BET inhibition not only downregulated the 
expected targets but caused upregulation of epithelial signatures. To further 
validate this finding, ChIP-seq analysis of the H3K4Me3 promoter mark and RNA 
Pol II revealed decreased loading and elongation at mesenchymal state genes 
and increased loading and elongation at epithelial associated genes (Figure 
1.10F,G; Figure 1.11). This supports, on a chromatin level, the transcriptional 
changes seen by affymetrix array. Furthermore, this is consistent with inhibition 
of BRD4 at these target genes as BETs are important for transcriptional 
elongation. Thus, inhibition of BET bromodomains appears to disrupt the 
mesenchymal, pro-oncogenic protocol and allow epithelial character to be 
restored. 
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Figure 1.10: Gene expression. Gene expression and ChIP-seq study after 24 hours treatment 
with 500nM JQ35. (A) Top 50 up and down regulated genes by JQ35 treatment. (B) Volcano plot 
comparing significance on y-axis to fold change on x-axis. (C) Graph showing gene set for MYC 
and E2F1 occur at high enrichment, on x-axis by Normalized Enrichment Score, and high 
significance by being below the False Discovery Threshold shown by the dashed line on the y 
axis. (D) Gene set studies for Epithelial to Mesenchymal shift from Sarrio, top, and Jechlinger, 
bottom. Data shows significant anti-correlation indicating a Mesenchymal to Epithelial transition. 
(E) JQ35 shows significant correlation with genes sets defined by BRD4 siRNA. (F) CITED2 
shows increased RNA POL 2 loading and elongation with JQ35 treatment. (G) MCM3 shows 
reduced RNA POL 2. The promoter for bother (F) and (G) is shown with H3K4me3 tracks. JQ35 
treated is highlighted in red. 
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Figure 1.11: Additional ChIP-seq. Tracks shown as with CITED2 and MCM3. (A) RRM2 shows 
loss of RNA POL2 while (B) TFBR3 shows gain with JQ35 treatment. 24 hours, 500nM JQ35.  
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In vivo 
 Having established improved biochemical characteristics and cellular 
potency, JQ35 was tested for in vivo pharmacokinetic properties and 
pharmacodynamic efficacy in a xenograft model of NMC. The half-life of JQ1 is 
less than one hour1 limiting its therapeutic potential and requiring frequent 
dosing. JQ35 was found to have 5.61 hour half-life by IP injection which 
corresponds to the IV value. This enables significantly improved exposure of 
cells to drug as compared to JQ1 with an IP half-life of 1.24 hours (Figure 1.12A). 
Moreover, JQ35 is fully soluble in saline eschewing the need for formulation 
which greater improves the ease of preparation for treatment and potential 
irritation at injection sites. Moreover, during the forty two day study there was no 
significant loss of body mass for the treated versus vehicle only mice indicating a 
relatively well tolerated compound (Figure 1.12B). Previous studies have used 
50mpk1 QD or even up to 50mpk BID14,27 JQ1 to see efficacy. However, even 
20mpk QD dosing of JQ35 shows durable tumor regression with an even more 
pronounced effect at 50mpk as measured by bioluminescent imaging of the mice 
(Figure 1.12C). A Kaplan-Meier plot showed significant prolongation in survival 
(p<0.01 log rank test) (Figure 1.12D). 
Histology for H&E to show overall morphology, Ki67 to mark proliferating 
cells, TUNEL to stain apoptotic cells, and the keratin stain Ae1/Ae3 to mark 
positive differentiation of the tumor further support a strong pharmacodynamic 
effect (Figure 1.12E). Vehicle treatment shows small, poorly differentiated cells 
with strong Ki67, minimal TUNEL staining, and weak Ae1/Ae3. In a dose 
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dependent manner with treatment, the cells take on epithelial characteristics with 
larger cytosol to nuclear size ratios, reduced proliferation, increased apoptosis, 
and very strong Ae1/Ae3 indicating differentiation consistent with previous 
findings44. In fact, at 50mg/kg, the tumor size and cellular density is greatly 
reduced creating the large enucleated regions in the histology. This further 
supports the genetic findings that BET inhibition reverses EMT.  
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Figure 1.12: In vivo studies (A) Pharmacokinetics study of JQ35 in mice for IP injection followed 
with blood samples by MS. (B) Average weights with SEM for vehicle and treated mice. (C) 
Tumor volume over time with JQ35 treatment at 20 and 50 mpk QD versus Vehicle. Asterisk 
shows significance by t-test. (D) Survival of 20mpk versus Vehicle groups. Significance analyzed 
by Log-Rank test. (E) Histology for H&E, Ki67 (proliferation), TUNEL (apoptosis), and Ae1/Ae3 
(keratin, differentiation). Scale bar of 200um shown. 
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Discussion 
Following our work on JQ1, we sought to develop an advanced probe with 
improved chemical and biological properties. While BET bromodomains have 
been reported in the literature, we sought to fully understand the structure activity 
relationships around thienodiazepine binding to the acetyl lysine recognition site 
and to build a probe capable of enhanced in vivo activity. JQ1 is an excellent tool 
compound but has less than one hour half-life and requires formulation in DMSO 
and cyclodextrin depending on the route of administration. Thus, a concerted 
effort to build a next-generation compound was required to provide an agent 
capable of improve in vivo efficacy and potential for human clinical use. 
To this end, a high throughput assay was developed to facilitate rapid 
analysis of compounds. The system incorporates a biotinylated probe for BET 
bromodomains that can also be used in protein pull downs and Chem-seq, where 
biotinylated small molecules can be used in place of antibodies in ChIP-seq31. 
The AlphaScreen based system proved robust enough, working over a range of 
concentrations for a BET family members and sites in 384 well plate format. In 
addition, the assay even worked in 1536 paving the way for efficient HTS in the 
future. However, in this application it was primarily applied for replicate ten point 
dose response formats that generate relative IC50s values that were surprisingly 
close to those determined by ITC. Ongoing work has deployed this assay for an 
HTS campaign on nearly 70,000 compounds in an effort to find novel chemical 
space for acetyl-lysine mimetics both as BET inhibitors and to potentially enable 
lead hopping. 
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Our exploration of the JQ1 scaffold concluded that the C6 position is the 
most amenable to diverse modifications and offered the best opportunity for 
improving on JQ1’s chemical properties. A large, diverse library of 400 
compounds was generated using the aldehyde-hydrazide coupling strategy 
previously employed by our lab for HDAC inhibitors38. In this instance, we 
doubled the size of the library and once again succeeded in finding a direction for 
focused medicinal chemistry efforts. From this library, it was determined that 
improved binding favored nitrogen containing heterocycles and disfavored 
negative charge. The charge relationship fits with the presence of aspartic acid 
residues on the loops around the binding pocket. Based on this observation a 
series of compounds was developed ultimately leading to JQ35 which exhibits 
greatly improved solubility, potency, and half-life. Thus, the methodology of 
improving screening hits by building a diversity library around a biasing element 
followed by iterative medicinal chemistry has proven highly effective and expands 
beyond what could have been inferred in a linear exploration. 
 Nut Midline Carcinoma remains a cancer of unknown origin that is driven 
by an oncogenic translocation of Nut and BRD4 or BRD3. Moreover, it was 
previously established that BET bromodomain inhibition acts to reverse this 
oncogenic program based on the altered phenotype seen after treatment. Using 
JQ35 coupled with transcriptional and ChIP-seq analysis a reversal of an EMT 
signature was found. This is consistent with the invasive and aggressive nature 
of NMC having taken on mesenchymal and stem like characteristics. JQ35 
blocks the oncogene without totally disrupting or halting transcription, allowing 
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the cell to redirect RNA Pol II to genes more consistent with its epithelial origin 
leading to the expression of keratin, cytosol expansion, and growth arrest 
previously observed.  
Indeed, JQ35 strongly induces this phenotype in vivo in a dose dependent 
manner. Actual regression of the tumor was measured as was a significant 
prolongation of survival. Furthermore, histology found a profound phenotypic 
change with less proliferation, more apoptosis, massive upregulation of keratin 
consistent with epithelial cells, and a large expansion of the cytosol relative to the 
small poorly differentiated cancer cells in the vehicle only. 
We present a next-generation optimized BET bromodomain inhibitor with 
improved in vivo properties. In addition, we have developed novel, robust assays 
and pull-down tools enabling further research on bromodomain biochemistry and 
biology. While probe molecules are incredibly useful for interrogating biology in 
an academic setting, drug-like properties must be achieved to enable potential 
therapeutics to take shape. With the overall likelihood of approval in oncology is 
only 6.7% from Phase I trials45 it is vital to take multiple shots on validated targets 
for bench research to reach bedside treatments. 
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Introduction: 
 As part of an effort to expand our capabilities on bromodomains, our lab formed a 
collaboration with Zhang lab at Umass Boston. Based on our previous work with JQ1 
derivatives related to the JQ35 work, we had a suite of assays and technological 
methods prepared to pursue targets. However, we recognized a need for more chemical 
bandwidth to search for new chemical series and structures to enable expansion into 
new targets as well as provide more chemical options for development on the BET 
family. 
 From the efforts directed at generating JQ35 a robust platform was put in place. 
Over the course of several years, I performed biochemical and cellular assays for the 
project. This utilized the previously described AlphaScreen assays and cellular viability 
on Nut Midline Carcinoma cells. In addition, I used structural information and 
hypotheses derived from the SAR from our screening efforts in order to advise the 
chemists at Umass as to what new structures to pursue. Given that the capacity for 
screening and lead characterization far outstripped synthetic capabilities in house, I very 
much appreciated the extra bandwidth placed on chemistry. This proved to be a very 
synergistic and productive relationship. 
Out of these collaborative discussions, a novel series of inhibitors was born. 
While advanced BET bromodomain are available, this new chemistry gave us insights 
into what features were allowable as bromodomain inhibitors, expanded our inventory of 
chemical matter, and gave us a first ever foothold against TAF1. Ongoing work hopes to 
further lead hop, find new and diverse chemistries, and to improve the current chemical 
series. 
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Background: 
Chemical modifications to chromatin are critical to orchestrating transcriptional 
activity. Histone post-translational alterations effected by chromatin-modifying enzymes, 
known as “writers,” lead to both transcription factor localization and gene regulatory 
complex formation1-4. The diverse set of chromatin marks are interpreted by “reader” 
proteins responsible for real-time transmission of histone marks to transcriptional 
consequence by mediating the local area network of transcription factors, polymerases, 
and remodeling enzymes2. As end effectors of signaling pathways, regulators of 
transcription, and potential cancer dependencies, epigenetic reader proteins are 
attractive therapeutic targets in cancer5. However, these events are primarily mediated 
by protein-protein interactions, which are conventionally considered difficult to inhibit6. 
To date, there are few high-quality chemical probes available to study such 
interactions7. Recent work demonstrates that the chromatin-associated bromodomain 
and extra-terminal (BET) domain protein family are susceptible to displacement by small 
molecules capable of mimicking the contacts between acetyl-lysine (KAc) on histones 
and the binding pocket of the bromodomain8-11. 
The BET family consists of BRD2, BRD3, BRD4 and BRDT, which are 
characterized by two tandem bromodomains and an external domain. They act as 
readers of lysine acetylation with a conserved four alpha helix bundle structural motif 
and a hydrogen bond forming asparagine that mediates the interaction with its peptide 
substrate12-16. In addition to binding histones, the BET family members act as scaffolds 
for complex formation to regulate transcription and cell cycle progression16. In particular, 
the BET bromodomain family is an important transcriptional coactivator for promoting 
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RNA Polymerase II (POL II) pause release and transcriptional elongation through 
recruitment of the positive transcription elongation factor B (pTEFB) and the mediator 
complex 16-19. BRD4 interacts directly with pTEFB through its second bromodomain site 
binding to CyclinT and promotes elongation independent of pTEFB by increasing the 
effective molarity of transcription factors 20,21. Indeed, BRD4 colocalizes with sites of 
active transcription during mitosis22 and helps control the reactivation of transcription 
from the M to G1 phase of cell cycle by mediating decompaction of chromatin19,23. 
BET deregulation is observed in various cancers, and notably implicated in the 
pathogenesis of NUT midline carcinoma16,24. This carcinoma is defined by the recurrent 
t(15;19) chromosomal translocation, resulting in aberrant expression of the tandem N-
terminal bromodomains of BRD4 as an in-frame fusion with the NUT protein24. 
Targeting xenotransplanted patient-derived cell lines with recently developed 
thienodiazepine-based BET bromodomain inhibitor, JQ1, established the therapeutic 
potential of BRD4 inhibition 9. Researchers observed complete differentiation of tumor 
cells to epithelial cells and a significant survival advantage in treated animals. 9 JQ1 has 
demonstrated potent anti-proliferative efficacy in models of multiple myeloma, acute 
lymphoid leukemia, and acute myeloid leukemia8-11. 
 With such promising studies related to drugging the epigenome, it is of the 
utmost importance to develop new chemistry capable of reaching these targets. Early-
stage drug molecules, known as “chemical probes,” are invaluable tools in 
understanding disease7. Complex, non-scalable and wasteful reactions can significantly 
impede iterative screening efforts. Techniques involving the use of fluourous reagents 
have shown great versatility, high-yield, rapid deployment, and are relatively eco-
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friendly. Complex molecules may be synthesized in multi-component reactions with 
perfluoroalkyl “phase tags” which can be used to facilitate purification by fluorous solid-
phase extraction (F-SPE).25 Subsequent Suzuki-type reactions may replace the fluorous 
tag to form a biaryl compound.26 Benefits of such reaction include high yielding reactivity 
with facile purification. Reactions have proven viable to create substituted hydantoins,27 
imidazo[1,2-a]-pyridines,28 diazepines29 and  others.30,31 Such heterocyclic compounds 
form easily substitutable, drug-like scaffolds for the discovery of probe compounds. 
 We report a novel class of bromodomain inhibiting compounds using the recently 
identified 3,5-dimethylisoxazole32 biasing element. Drawing upon previously developed 
screening capabilities and robust fluorous chemical synthesis, we have rapidly 
diversified and optimized a set of potent and highly specific inhibitors. In addition to 
demonstrating a new approach to targeting the BET bromodomains, these compounds 
and near derivatives could create opportunities to drug other bromodomain-containing 
of proteins. 
 
 
RESULTS & DISCUSSION 
Analysis of existing small-molecule bromodomain inhibitors, shown in Figure 2.1A, 
has defined a structure-function model in which the competitive small molecule binds 
through two chemical features: an acetyl-lysine mimetic warhead (red) and a core 
region with appending surface-recognition features (black). Kac mimetics, such as the 
triazole ring in JQ1 and the 3,5-dimethylisoxazole ring in iBET151, form a highly 
specific hydrogen bond to the conserved asparagine in bromodomains. The core of the  
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Figure 2.1: Approach to chemistry. Chemical strategies to inhibit BET bromodomain proteins. A 
Existing BET bromodomain inhibitors with biasing moiety in red. B Synthetic strategy for the creation of 
small fragments based on dimethyl isoxazole based BET bromodomain biasing moiety (red). X signifies 
varied heteroatoms and R signifies varied substituents. C Perfluoroalkyl based synthetic strategy. D Small 
fragment dimethylisoxazole inhibitors with potency values indicated. E Inhibitory curves for small fragment 
inhibitors. F Docking of UMB-12 into BRD4 crystal structure. G Ligand interaction diagram of UMB-12. 
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molecule establishes shape complementarity with the contour of the binding pocket 
to increase binding affinity primarily through steric interactions.  Appending groups 
provide an opportunity to enhance potency and selectivity via surface and loop region 
interactions. The 3,5-dimethylisoxazole head group of iBET151 was identified as a 
promising and chemically accessible biasing moiety for further development as a 
chemical probe. Our screening strategy created an extensive series of diverse chemical 
features attached to the 4-position of the 3,5-dimethylisoxazole (Figure 2.1B). As a 
starting point, we focused on small, ligand efficient compounds that could serve as 
starting points for further derivatization. 
This approach to library development was empowered by recent advances in use of 
perfluoroalkyl substituents to enable efficient Suzuki-type ring coupling reactions, shown 
in Figure 2.1C. Purification of reaction intermediates is greatly facilitated by F-SPE. In 
this case, aryl perfluorooctylsulfonates (ArOSO2(CF2)7CF3) were reacted with 3,5-
dimethylisoxazole-4-boronic acid pinacol esters to produce a low-molecular weight 
chemical series. The resulting compounds were purified using F-SPE. Initial compounds 
included positional isomers of carbonyl functionalities around the phenyl ring system 
(Figure 2.1D). Compound potency was assessed by relative IC50 potency determined by 
an AlphaScreen biotin-JQ1 competition assay (Figure 2.1E). IC50 values were found to 
be highly dependent on the steric arrangement of functional groups around the phenyl 
ring. Ortho- and meta-aldehyde substitutions were poorly tolerated, while a para-
aldehyde resulted in excellent potency of 1.89 μM with a ligand efficiency of 54%. 
Substitution with the more chemically sTable 2.para-acetyl group resulted in a 10-fold 
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reduction in potency. Previous study of similar compounds had only explored variation 
at the 3- and 5-ring positions. 
We performed computational modeling to better understand the modality of binding 
and inform further medicinal chemistry (Figure 2.1F). Using previously published crystal 
structures of both JQ1 and iBET151, we were able to dock fragments into the 
structure9,33. As is the case with iBET151, UMB-2 binds through a conserved hydrogen 
bond with D-140 through the ring oxygen, while the ring nitrogen coordinates through a 
structured water interacting with the hydroxyl group of Y-97 (Figure 2.1G). Based on this 
interaction, we proceeded to build off the 4-position of the phenyl ring to improve 
potency by optimizing protein surface interactions near the BC loop region. 
A diverse set of chemical scaffolds was synthesized using reactions previously 
developed around fluorous-tagged multicomponent reactions (Table 2.1). These 
reactions create structural diversity by changing the substituent groups on each 
fractional component, allowing generation of diverse small-molecule libraries around a 
biasing element. The perfluoroalkyl tags can substituted with a binding motif of choice 
via Suzuki coupling (Figure 2.1C).26 Synthesized compounds included tertiary amines, 
pyrimidines and fused heterocyclic ring systems in order to explore the optimal shape 
for exploiting protein-inhibitor contour interactions. In addition to biochemical IC50, these 
compounds were selectively evaluated in a BRD4-dependent cell viability study. EC50 
was collected by assessing viability using PerkinElmer ATPlite kits against the BRD4-
dependent Nut-Midline Carcinoma line 797. The para-imidazo[1,2-a]pyridine scaffold28 
(UMB-11) was found to be a promising lead with biochemical and cellular inhibitory 
values of 11.0 μM and 14.1 μM, respectively. In addition, the UMB-11 scaffold is  
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Table 2.1: Exploration of compound scaffold region 
 
 
Compound Ar BRD4--IC50 (μM) 797--IC50 (μM) 
UMB-5 
 
 
 
16.3  
UMB-13 
 
69.9 >100 
UMB-17 
 
 
>100 9.42 
UMB-18 
 
 
13.0 9.91 
UMB-27 
 
 
2.05 >100 
UMB-11 
 
 
11.0 14.1 
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accessible at a variety of positions for diversification to drive potency and understanding 
of SAR. 
Having picked a core scaffold in UMB11, we built a focused library of compounds to 
optimize placement of heteroatoms and appending groups. Synthesis of the eventual 
lead compound UMB-32 is shown in Scheme 1 as an exemplar of the route used to 
assemble the focused SAR series. The compound was synthesized in a two-step 
reaction. The first step included combination of t-butylisocyanide, 2-aminopyrazine, and 
4-bromobenzaldehyde. The reaction is catalyzed by scandium triflate and microwaved 
at 150ºC for thirty minute in 3:1 dichloromethane / methanol. Flash chromatography 
yielded the pure product 80%. This intermediate was then coupled to 3,5-
dimethylisoxazole-4-boronic acid pinacol ester in a Suzuki coupling. The resulting crude 
mixture was purified by flash chromatography with yield 57%.  
 
Scheme 2.1: Synthesis of UMB11 near analogs. 
Analogs were synthesized similarly to explore the functional role of both sterics and 
electronics of the fused bicyclic scaffold on inhibitor function, shown in Table 2.2. 
Variations of R1 from UMB-11’s benzyl group to bulky, non-aromatic groups like 
cyclohexane (UMB-28) and t-Bu (UMB-29) improved potency. An acid at the R1 position 
(DB-1-064) completely inactivated the compound. Appending R2 groups at the 6, 7, and  
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Table 2.2: Elaboration of imidazopyridine scaffold 
 
 
 
Compound R1 R2 X BRD4--IC50 (μM) 797--IC50 (μM) 
UMB-65 H H CH 3.89  
UMB-6 Bn 6-Me CH >100  
UMB-20 Bn 6-Cl CH 11.8 18.4 
UMB-21 Bn H 7-N 18.8 49.1 
UMB-28 cyclohexane H CH 0.904 5.07 
UMB-30 4-(OMe)Ph H CH 2.76 7.36 
UMB-23 4-(OMe)Ph 6-Cl CH 31.5 20.7 
UMB-24 4-(OMe)Ph 7-OMe CH 2.89 11.8 
UMB-25 4-(OMe)Ph H 7-N 7.86 32.8 
UMB-62 (S)-1-PhEt H 7-N 2.86  
UMB-29 t-Bu H CH 0.479 2.04 
UMB-31 t-Bu 6-Cl CH 1.17 2.19 
UMB-76 t-Bu 6-Me CH 3.17  
UMB-77 t-Bu 8-CF3 CH 11.9  
UMB-82 t-Bu 6-CO2CH2 CH 1.62  
UMB-83 t-Bu 6-COOH CH 0.968  
UMB-56 t-Bu H 6-N 20.7 2.06 
UMB-32 t-Bu H 7-N 0.637 0.724 
UMB-84 t-Bu H 8-N 0.860  
UMB-57 i-Pr H 7-N 0.807 0.494 
UMB-61 n-Bu H 7-N 1.66  
DB-1-064 -CH2CO2H H 7-N >100  
DB-1-038 -CH2CO2Et H 7-N 4.53  
UMB-60 -CH2CO2tBu H 7-N 4.96  
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8 positions of the fused ring system universally decreased potency compared to 
parent compounds. Ring-nitrogens at the 7 and 8 position (UMB-32, and UMB-84, 
respectively) resulted in little biochemical potency change. A 6-position ring-nitrogen 
reduced compound potency from 479 nM (UMB-29) to 20 µM (UMB-56) potency. 
Cellular potency, however, modestly improved between compound UMB-29 and UMB-
32 upon substitution of a 7-N. For this reason, UMB-32 emerged as our lead compound. 
Limited structural study around the linking phenyl ring is shown in Table 2.3. 
Substitution of the phenyl ring for pyridine resulted in decreased potency (UMB-53-54) 
and the addition of electron-withdrawing fluorine (UMB-55) was detrimental as well. 
Electron-donating methoxy substituents appear to be mildly beneficial in biochemical 
assays. Additional work regarding this linking part of the molecule will be a focus of 
continued medicinal chemistry. 
The potency of UMB-32 was driven by two key changes from UMB-11 (Figure 2.2A). 
UMB-32 has substituted t-Bu for benzyl and inserted a 7-N. Comparison of UMB-11, 
UMB-21 and UMB-32 show the critical substitutions in the development of UMB-32 
which led to an improved biochemical IC50 (Figure 2.2B top). Docking of UMB-32 into 
the JQ1 crystal structure, (Figure 2.2D) recapitulates binding similar to that of the 3,5-
dimethylisoxazole fragment. The dimethylisoxazole makes the expected hydrogen 
bonds with the conserved asparagine and critical waters. The additional heteroatom at 
7-N is likely solvent exposed. Notably, the t-Bu group fits into a pocket between the BC 
loop and tryptophan shelf. Also, the secondary amine can possibly participate in 
favorable ionic interaction to the D-145 residue (Figure 2.2E). 
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Figure 2.2: Lead series biochemistry. UMB-32 is a potent, selective inhibitor of BRD4. A Selected 
compounds leading to UMB-32. B Representative biochemical inhibitory curves (top) and 797 viability 
(bottom). C ITC experiment of BRD4 titrated into UMB-32 solution. D Docking of UMB-32 in BRD4 crystal 
structure. E Ligand interaction diagram of UMB-32 in BRD4 crystal. F Evaluation of UMB-11 and UMB-32 
compound selectivity against a panel of bromodomains.  
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Figure 2.2 (Continued)  
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Table 2.3: Variations to UMB-32 linker 
 
 
 
Compound R1 R2 X BRD4--IC50 (μM) 797--IC50 (μM) 
UMB-53 t-Bu H 2-N 51.9 >100 
UMB-54 t-Bu H 3-N 12.9 8.29 
UMB-55 t-Bu 2-F CH 13.0 12.8 
UMB-58 t-Bu 3-OMe CH 0.562  
UMB-59 i-Pr 3-OMe CH 0.474  
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Characterization of UMB-32 by isothermal titration calorimetry (ITC) against BRD4 
site 1 further supported the biochemical affinity (Figure 2.1E). The resultant Kd was 
shown to be 550 nM, in good agreement with the biochemical measurements. The 
binding process is shown to be exothermic and positively entropic with a 1:1 binding 
ratio. Using Bromoscan (a DiscoveRx platform), lead compound UMB-11 and UMB-32 
were analyzed for their selectivity (Figure 2.2F). UMB-11 demonstrates broad activity 
against the tested bromodomains with some selectivity for the BET family. In contrast, 
UMB-32 showed dramatically increased potency for the BET proteins versus most other 
targets with low nanomolar Kd affinities. The one exception in selectivity for BETs is 
against the structurally related TAF1 and TAF1L. While a significantly weaker 
interaction, this presents a potential scaffold for lead hopping into the development of 
TAF1-selective agents. Finally, compounds showed effect in human BRD4-dependent 
cancer cell lines (Figure 2.2B bottom). The addition of 7-N and the benzyl to t-butyl 
substitution clearly establish UMB32 as the front runner with dramatically improved 
biological activity.  
While BRD4 inhibitors already exist, it is important to develop novel chemistries in 
order to reach new classes of bromodomains and to have multiple potential paths toward 
therapeutics. The benzodiazepines9 and previous dimethyl isoxazoles34 have been 
shown to be potent and selective against the BET bromodomain family. Here we report a 
new class of inhibitor that can potently inhibit BETs in vitro and in cell culture. UMB32 
represents a promising lead compound developed with chemistry enabling facile 
derivatization toward ever more potent and selective compounds.  
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Moreover, it exhibits sub micromolar potency on a previously undrugged family of 
bromodomains in TAF1 and TAF1L. Indeed, oncogenic MYC causes inappropriate 
activation and localization of the STAGA complex containing TRRAP, GCN5, TFIID, 
CBP/P300, mediator,35 and Sp120. TAF1 has been shown to block p53 activity,36 and its 
removal by inactivation triggered a DNA damage response.37 Finally, the TFIID complex 
of which TAF1 is a significant member is vital to stem cell reprogramming.38 Thus, a probe 
to the bromodomain TAF1 will be valuable to expanding our understanding of 
transcriptional regulation in normal cell states as well as cancer. 
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Experimental: 
 
General Synthetic Information.  All chemicals and solvents were purchased from 
commercial suppliers and used as received.  1H NMR (300 MHz) and 13C NMR (75 MHz) 
spectra were recorded on a Varian NMR spectrometer.  CDCl3 was used as the solvent 
unless otherwise specified. LC-MS were performed on an Agilent 2100 system with a C18 
(5.0 µm, 6.0 x 50 mm) LC column. The mobile phase is MeOH and water both containing 
0.05% trifluoro acetic acid. A linear gradient was started from 75:25 MeOH/H2O to 100% 
MeOH in 5.0 min at a flow rate of 0.7 ml/min. The chromatograms were recorded at UV 
210, 254, and 365 nm. Low resolution mass spectra were recorded in APCI (atmospheric 
pressure chemical ionization). Flash chromatography separation was performed on 
YAMAZEN AI-580 system with Agela silica gel (12 or 20 g, 230-400 µm mesh) cartridges. 
The microwave reactions were performed on a Biotage Initiator 8 system. 
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General procedures for the synthesis of UMB-6, -11, -20, -21, -23, -25, -28 to -32，-
56，-57，-60 to -62, -65, -76, -82, and -83. The synthesis of these compounds was 
accomplished by a reported two-step synthesis shown in Scheme 2.2.1 The three-
component reaction (Groebke-Blackburn-Bienayme reaction) was followed by the Suzuki 
coupling.   
 
Scheme 2.2 
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Representative procedure for the three-component reaction. Synthesis of 2-(4-
bromophenyl)-N-(t-butyl)imidazo[1,2-a]pyrazin-3-amine 4 (X = N,  R1 = t-Bu, R2 = H).1 A 
sealed 10 mL microwave tube charged with t-butylisocyanide (0.043 g, 0.52 mmol), 2-
aminopyrazine (0.05 g, 0.52 mmol), 4-bromobenzaldehyde (0.074 g, 0.40 mmol), and 
Sc(OTf)3 (0.010 g, 0.02 mmol) in 2 mL of 3:1 CH2Cl2/MeOH) was heated under microwave 
at 150 oC for 30 min.  The mixture was filtered and washed with EtOAc (4 ml).  
Concentration of the organic phase gave a crude product which was purified by flash 
chromatography eluted with 2:8 EtOAc/hexane to provide the product 4 as a yellow solid 
(110 mg, 80%).  
 
Representative procedure for the Suzuki-coupling reaction. Synthesis of N-(tert-butyl)-2-
(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2- -3-amine UMB-32.1 A sealed 
10 mL microwave tube charged with 4 (X = N,  R1 = t-Bu, R2 = H, 0.110 g, 0.32 mmol), 
3,5-dimethylisoxazole-4-boronic acid pinacol ester (0.093 g, 0.42 mmol), 
Pd(dppf)Cl2.CH2Cl2 (0.021 g, 0.026 mmol, 8% mol), and K2CO3 (0.088 g, 0.64 mmol) in 
2 mL of 4:4:1 actone/toluene/H2O was heated under microwave at 130 oC for 40 min. The 
mixture was filtered and washed with EtOAc (4 ml).  Concentration of the organic phase 
gave a crude product which was purified by flash chromatography eluting with 3:7 
EtOAc/hexane to give UMB-32 as brownish solid (66 mg, 57%).  1H NMR (300 MHz, 
CDCl3) δ 9.01 (s, 1H),  8.16 (d, J = 4.8 Hz, 1H), 8.05(d, J = 6.6 Hz, 2H), 7.88 (d, J = 4.8 
Hz, 1H), 7.38 (d, J = 6.6 Hz, 2H), 3.18 (s, 1H, NH),  2.46 (s, 3H), 2.33 (s, 3H), 1.11 (s, 
9H);  13C NMR (75 MHz, CDCl3) δ 165.0, 158.34, 143.0, 141.2, 137.1, 133.2, 129.8, 128.7, 
128.6, 128.3, 124.9, 116.1, 116.1, 56.7, 30.2, 11.4, 10.6; MS(APCI) m/z 362.2 (M+ + 1). 
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N-Benzyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-6-methylimidazo[1,2- -3-
amine UMB-6.  Yellow solid, 45% yield, 1H NMR (300 MHz, CDCl3) δ 7.99 (d, 1H),  7.96 
(d, 1H), 7.62 (s, 1H), 7.39 (d, 2H), 7.27 (m, 5H), 6.97 (d, 2H), 4.14 (s, 2H), 3.42 (s, 1H), 
2.44 (s, 3H), 2.36 (s, 3H), 2.28 (s, 3H). MS(APCI) m/z 409.2 (M+ + 1). 
N-Benzyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyridin-3-amine UMB-11. 
Yellowish brown solid, 52% yield, 1H NMR (300 MHz, CDCl3) δ 8.24(d, 1H),  7.72 (d, 2H), 
7.66 (d, 1H), 7.58 (d, 2H), 7.53 (t, 1H), 7.42 (t, 1H), 7.22 (m, 5H), 4.21 (s, 2H), 3.15 (s, 
1H), 2.42 (s, 3H), 2.37 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 165.2, 158.7, 141.7, 138.9, 
133.5, 129.2, 128.7, 128.1, 127.7, 127.3, 125.7, 124.2, 122.3, 117.5, 116.4, 111.8, 52.5, 
24.8, 11.7, 10.9;  MS(APCI) m/z 395.2 (M+ + 1). 
N-Benzyl-6-chloro-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2- -3-amine 
UMB-20. 1H NMR (300 MHz, CDCl3) δ 8.85 (s, 1H), 8.12 (d, 2H), 8.05 (d, 1H), 8.02 (d, 
1H), 7.96 (d, 2H), 7.34 (m, 5H) 4.22 (s, 2H), 3.51 (s, 1H), 2.42 (s, 3H), 2.37 (s, 3H); 
MS(APCI) m/z 429.1 (M+ + 1). 
 N-benzyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]-pyrazin-3-amine UMB-
21.  1H NMR (300 MHz, CDCl3) δ 8.11(d, 1H), 8.05 (d, 1H), 8.01 (s, 1H), 7.92 (d, 2H), 7.52 
(d, 2H), 7.42 (t, 1H), 7.28 (m, 5H), 4.22 (s, 2H), 3.51 (s, 1H), 2.43 (s, 3H), 2.37 (s, 3H); 
13C NMR (75 MHz, CDCl3 .3, 133.9, 131.1, 129.3, 129.1, 
128.9, 128.8, 128.1, 128.0, 126.3, 116.5, 115.2, 52.3, 11.6, 10.8; MS(APCI) m/z 396.2 
(M+ + 1). 
6-Chloro-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-N-(4-methoxy-phenyl)imidazo-[1,2-
-3-amine UMB-23. 1H NMR (300 MHz, CDCl3) δ 8.07 (s, 1H), 8.02 (d, 1H), 7.62 
(d, 1H), 7.40 (d, 2H), 7.38 (d, 2H), 7.30 (d, 2H), 7.23 (d, 2H), .3.77 (s, 3H), 2.42 (s, 3H), 
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2.28 (s, 3H); 13C NMR (75 MHz, CDCl3
146.4, 137.5, 129.3, 127.4, 126.6, 118.2, 117.6, 115.4, 114.6, 109.4, 100.0, 55.7, 29.7, 
29.4; MS(APCI) m/z 445.9 (M+ + 1). 
2-(4-(3,5-Dimethylisoxazol-4-yl)phenyl)-7-methoxy-N-(4-methoxy-phenyl)imidazo[1,2-
c]pyrimidin-3-amine UMB-24.  1H NMR (300 MHz, CDCl3) δ 8.51 (s, 1H), 8.09 (d, J = 
8.4Hz, 2H), 7.31 (d, J = 8.4Hz, 2H), 6.85 (d, J = 8.7Hz, 2H), 6.78 (s, 1H), 6.65 (d, J = 
8.7Hz, 2H), 5.38 (s, 1H), .3.97 (s, 3H), 3.76 (s, 3H), 2.42 (s, 3H), 2.29 (s, 3H);  MS(APCI) 
m/z 442.4(M+ + 1). 
N-Benzyl-2-(3-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyridin-3-amine UMB-26. 
1H NMR (300 MHz, CDCl3) δ 7.99 (d, 1H), 7.91 (s, 1H), 7.59 (d, 1H), 7.54 (t, 1H), 7.52 (d, 
1H), 7.32 (m, 5H), 7.21 (t, 1H), 7.17 (d, 1H), 6.81 (t, 1H), 4.23 (s, 2H), 3.42 (s, 1H), 2.42 
(s, 3H), 2.29 (s, 3H); MS(APCI) m/z 395.2 (M+ + 1). 
N-Cyclohexyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyridin-3-amine 
UMB-28. 1H NMR (300 MHz, CDCl3) δ 8.11(d, 1H), 8.05 (d, 2H), 7.57 (d, 1H), 7.35 (d, 
2H), 7.08 (t, 1H), 6.81 (t, 1H), 3.01 (s, 1H), 2.42 (s, 3H), 2.27 (s, 3H), 1.12 (m, 11H); 
MS(APCI) m/z 387.2 (M+ + 1). 
N-(t-Butyl)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyridin-3-amine UMB-
29. 1H NMR (300 MHz, CDCl3) δ 8.15(d, 1H), 7.99 (d, 2H), 7.45 (d, 1H), 7.22 (d, 2H), 7.03 
(t, 1H), 6.71 (t, 1H), 3.01 (s, 1H), 2.40 (s, 3H), 2.25 (s, 3H), 1.01 (s, 9H);  MS(APCI) m/z 
361.2 (M+ + 1). 
2-(4-(3,5-Dimethylisoxazol-4-yl)phenyl)-N-(4-methoxyphenyl)imidazo-[1,2-α]pyridin-3-
amine UMB-30. 1H NMR (300 MHz, CDCl3) δ 8.03 (d, J = 8.4Hz, 2H), 7.80 (d, J = 6.6Hz, 
1H), 7.59 (d, J = 9Hz, 1H), 7.21 (d, J = 8.4Hz, 2H), 7.17 (t, 1H), 6.75 (d, J = 6.6Hz, 2H), 
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6.73 (t, 1H), 6.50 (d, J = 6.6Hz, 2H), 5.43 (s, 1H), 3.68 (s, 3H), 2.33 (s, 3H), 2.20 (s, 3H), 
+ + 1). 
N-(t-Butyl)-6-chloro-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-imidazo-[1,2-α]pyridin-3-
amine UMB-31. 1H NMR (300 MHz, CDCl3) δ 8.19 (s, 1H), 7.93 (d, J = 6.6Hz, 2H), 7.44 
(d, J = 9.6 Hz, 1H), 7.27 (d, J = 6.6 Hz, 2H), 7.07 (d, J = 9.6 Hz, 1H), 3.03 (s, 1H),  2.35 
(s, 3H), 2.25(s, 3H), 1.01(s, 9H);  MS(APCI) m/z 395.2 (M+ + 1).  
Tert-butyl (2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyrazin-3-yl)glycinate 
UMB-60.  1H-NMR (300MHz, CDCl3) δ 9.01 (s, 1H), 8.19 (m, 3H), 7.89 (d, J=4.5Hz, 1H), 
7.38 (d, J=7.2Hz, 2H), 3.77 (s, 2H), 2.46 (s, 3H), 2.33(s, 3H), 1.47(s, 9H). MS (APCI) m/z 
420.2 (M+ + 1). 
N-butyl-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-amine UMB-61. 
1H-NMR (300MHz, CDCl3) δ 9.02 (s, 1H), 8.07 (d, J=8.4Hz, 2H), 7.98 (d, J=4.2Hz, 1H), 
7.89 (d, J=7.8Hz, 1H),7.39 (d, J=8.1Hz, 2H), 3.15 (s, 2H), 2.46 (s,3H), 2.34 (s, 3H), 1.64 
(m, 2H), 1.48 (m, 2H), 0.95 (t, 3H). MS (APCI) m/z 362.2 (M+ + 1). 
(S)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-N-(1-phenylethyl)imidazo[1,2-α]pyrazin-3-
amine UMB-62. 1H-NMR (300MHz, CDCl3) δ 8.96 (s, 1H), 8.05 (m, 2H), 7.78 (d, J=9.6Hz, 
2H), 7.36 (d, J=2.1Hz, 2H), 7.27 (m, 5H), 4.38 (m, 1H), 2.48 (s,3H), 2.35 (s, 3H), 1.51 (s, 
3H). MS (APCI) m/z 410.2 (M+ + 1). 
2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-α]pyridin-3-amine UMB-65. 1H-NMR 
(300MHz, CDCl3) δ 8.06 (m, 3H), 7.55 (m, 2H), 7.36 (d, J=6.3Hz, 2H), 7.15 (m, 1H), 6.83 
(m, 1H), 3.45 (2, 2H), 2.44 (s, 3H), 2.31 (s, 3H). MS (APCI) m/z 305.1 (M+ + 1). 
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N-(tert-butyl)-2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-6-methylimidazo[1,2-α]pyridin-3-
amine UMB-76. 1H-NMR (300MHz, CDCl3) δ 8.06 (m, 3H), 7.55 (m, 2H), 7.36 (d, J=6.3Hz, 
2H), 7.15 (m, 1H), 6.83 (m, 1H), 3.45 (2, 2H), 2.44 (s, 3H), 2.31 (s, 3H). MS (APCI) m/z 
305.1 (M+ + 1). 
Scheme 2.3 
 
Procedures for the synthesis of ethyl-3-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-5-ethyl-1-
methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate UMB-17. UMB-17 was 
prepared by a reported two-step synthesis shown in Scheme 2.3.2 The three-component 
[3+2] cycloaddition is followed by the Suzuki coupling to afford UMB-17 as a yellow semi-
solid in 10% yield. MS (APCI) m/z 426.1(M+ + 1). 
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Scheme 2.4 
 
Procedures for the synthesis of UMB-1, -2, -3, -4, -8, -9, -10, -12, and -15. These 
compounds were prepared by direct Suzuki coupling of fluorous arylsulfonates with the 
boronic ester (Scheme 2.4).  The Suzuki coupling reactions were carried out following the 
general procedure shown in Scheme 2.2. 
3-(3,5-Dimethylisoxazol-4-yl)benzaldehydes UMB-1. Yellow oily compound, 63%, yield, 
1H NMR (300 MHz, CDCl3) δ 10.3 (s, 1H), 7.91 (d, 1H), 7.78 (s, 1H), 7.71 (d, 1H), 7.64 (t, 
1H), 2.42 (s, 3H), 2.27 (s, 3H). MS (APCT) m/z 202.2 (M+ + 1). 
1-(4-(3,5-Dimethylisoxazol-4-yl)phenyl)ethanone UMB-2. Yellow oily compound, 60% 
yield, 1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.7Hz, 2H), 7.38 (d, J = 8.7Hz, 2H), 2.64 
(s, 3H), 2.44 (s, 3H), 2.30 (s, 3H). MS(APCT) m/z 216.2 (M+ + 1). 
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(3,5-Dimethyl-4-(quinolin-6-yl)isoxazole UMB-3. Yellow-brownish oily compound, 71% 
yield,  1H NMR (300 MHz, CDCl3) δ  8.95 (d, 1H), 8.21 (d, 1H), 7.75 (d, 1H), 7.62 (s, 1H), 
7.61 (d, 1H), 7.55 (t, 1H), 2.44 (s, 3H), 2.34 (s, 3H). MS(APCT) m/z 225.1 (M+ + 1). 
4-(2,2-Dimethyl-2,3-dihydrobenzofuran-4-yl)-3,5-dimethylisoxazole UMB-4. Brown semi-
solid, 37% yield, 1H NMR (300 MHz, CDCl3) δ  7.20 (d, 1H), 7.00 (d, 1H), 6.92 (t, 1H), 
3.05 (s, 2H), 2.38 (s, 3H), 2.25 (s, 3H), 1.47 (s, 6H);  MS(APCT) m/z 244.2(M+ + 1). 
3,5-Dimethyl-4-phenylisoxazole UMB-8. Yellow oily compound, 58% yield, 1H NMR (300 
MHz, CDCl3) δ 7.15-7.62 (m, 5H), 2.41 (s, 3H), 2.25 (s, 3H) ; MS(APCT) m/z 174.1 (M+ + 
1).  
2-(3,5-Dimethylisoxazol-4-yl)benzaldehydes UMB-9. Yellow oily compound, 17% yield, 
1H NMR (300 MHz, CDCl3) δ  9.92 (s, 1H), 8.06 (d, J=7.2Hz, 1H), 7.69 (m, 1H), 7.54 (m, 
2H), 2.28 (s, 3H), 2.16 (s, 3H); MS(APCT) m/z 202.1 (M+ + 1). 
3-(3,5-Dimethylisoxazol-4-yl)-4-methoxybenzaldehyde UMB-10. Yellow oily compound, 
27% yield; MS(APCT) m/z 232.1 (M+ + 1). 
4-(3,5-dimethylisoxazol-4-yl)benzaldehyde UMB-12. Yellow oily compound, 35% yield; 
1H NMR (300 MHz, CDCl3) δ 10.07 (s, 1H), 7.99 (m, 2H), 7.46 (d, J=6.6Hz, 2H), 2.47 (s, 
3H), 2.31 (s, 3H); MS(APCT) m/z 202.1 (M+ + 1). 
4-(3,4-Dimethylisoxazol-4-yl)-3-methoxybenzaldehyde UMB-15. Brown oily compound, 
18% yield; MS(APCT) m/z 232.1 (M+ + 1). 
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Synthesis of Ethyl-2-(N-(4-(3,5-dimethylisoxazol-4-yl)benzyl)-4-methoxybenzamido)-
propanoate UMB-5.  This compound was prepared following the reported procedure 
(Scheme 2.5).3 Reductive amination of 3 afforded compound 6, which was then N-
acylated to give compound 7.  The Suzuki coupling of 7 afforded UMB-5 as a brown solid 
(17% yield). 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 5.7Hz, 2H), 7.70 (d, J = 5.7Hz, 2H), 
7.49 (d, J = 9.0 Hz, 2H), 7.46 (d, J = 9.0 Hz, 2H), 4.24 (q, 2H), 4.21(s, 2H), 4.18 (m, 1H), 
3.82 (s, 3H), 2.42 (s, 3H), 2.28 (s, 3H), 1.58 (m, 2H), 1.27 (d, 3H), 0.95 (t, 3H);  MS(APCT) 
m/z 437.2 (M+ + 1). 
 
Scheme 2.5 
Synthesis of 4-butyl-3-(4-(3,5-dimethylisoxazol-4-yl)-3-methoxyphenyl)-3,4-dihydro-1H-
benzo[e][1,4]diazepine-2,5-dione UMB-18.  This compound was prepared following the 
reported procedures (Scheme 2.6).4 The Ugi 4-component reaction gave compound 8 
which was cyclized to form 9.  The Suzuki coupling of 9 afforded UMB-18 as a brown 
semisolid in 44% yield.  MS(APCT) m/z 434.2 (M+ + 1). 
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Scheme 2.6 
 
Synthesis of 10-(3-(3,5-dimethylisoxazol-4-yl)phenyl)-3,4,9,10-tetrahydro-1H-
benzo[b]furo[3,4-e][1,4]diazepin-1-one UMB-27. The synthesis of UMB-27 was 
accomplished by a two-step synthesis shown in Scheme 2.7. A mixture of benzene-1,2-
diamine (54 mg, 0.5 mmol), tetronic acid (53.5 mg, 0.5 mmol),  and acetic acid (3 µL) in 
1 mL H2O was stirred at room temperature for 30 min. Then 3-bromobenzaldehyde (92.5 
mg, 0.5 mmol) was added to the reaction mixture and heated under microwave at 110 oC 
for 10 min.  The reaction mixture was filtered and the residue was washed with 1 mL of 
50% ethanol. The solid obtained was purified by flash chromatography (6:4 
hexanes/EtOAc) to afford 10 (87 mg, 49% yield). A mixture of 10 (32 mg, 0.09 mmol), 
3,5-dimethylisoxazole-4-yl boronic acid (19 mg, 0.135 mmol), Pd(pddf)Cl2 (5.7 mg, 0.007 
mmol), and K2CO3 (25 mg, 0.18 mmol) in 2 mL of 4:4:1 acetone:toluene:H2O was heated 
under microwave at 130 oC for 30 min. The reaction mixture was filtered and the residue 
was washed with EtOAc. The concentrated filtrate was purified by flash chromatography 
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(6:4 hexanes/EtOAc) to afford 132 UMB-27 (18 mg, 54% yield). 1H NMR (300 MHz, 
CDCl3) δ 8.05 (d, J = 8.4Hz 1 H), 7.96 (m, 2 H), 7.47 (m, 1 H), 6.9 (m, 3H), 6.5 (d, J = 
8.4Hz 1H), 5.1 (b, 1H), 4.87(s, 2H), 4.62 (s, 1H), 2.35 (s, 3 H), 2.21 (s, 3 H); MS (APCI) 
m/z: 374.1 (M++1). 
Scheme 2.7 
 
Synthesis of UMB-13 and UMB-14. The synthesis of UMB-13 and UMB-14 were 
accomplished following the literature procedures (Scheme 2.8). The cycloaddition of α,β-
unsatuated ketone 11 with benzimidamide afforded pyrimidine 12.5 This compound was 
subjected to the Suzuki coupling to give the final product. 
4-(4-(6-(4-Methoxyphenyl)-2-phenylpyrimidin-4-yl)phenyl)-3,5-di-methylisoxazole UMB-
13.  Yellow oily compound,   12% yiled, MS(APCT) m/z 434.1 (M+ + 1). 
(4-(2-Methoxy-5-(6-(3-methoxyphenyl)-2-phenylpyrimidin-4-yl)phenyl-3,5-di-
methylisoxazole UMB-14.  Brown semisolid, 11% yield, MS(APCT) m/z 464.2 (M+ + 1). 
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Scheme 2.8 
 
General procedures for the synthesis of UMB-53 to -55, UMB-58 and -59. The 
synthesis of these compounds was accomplished by a two-step synthesis shown in 
Scheme 2.9. The three-component reaction (Groebke-Blackburn-Bienayme reaction) 
was followed by the Suzuki coupling.   
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Scheme 2.9 
N-(tert-butyl)-2-(6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)imidazo[1,2-a]pyrazin-3-amine 
UMB-53. 1H-NMR (300MHz, CDCl3) δ 8.92 (s, 1H), 8.84 (d, J=2.1Hz, 1H), 7.87 (m, 1H), 
7.52 (d, J=8.1Hz, 1H), 7.35 (d, J=4.8Hz, 1H), 2.65 (s, 3H), 2.50 (s, 3H), 1.46 (s, 9H); MS 
(APCI) m/z 363.1 (M+ + 1). 
N-(tert-butyl)-2-(5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)imidazo[1,2-a]pyrazin-3-amine  
UMB-54. 1H-NMR (300MHz, CDCl3) δ 9.54 (s, 1H), 8.55 (s, 1H), 7.93 (d, J=6.3Hz, 1H), 
7.65 (m, 2H), 7.35 (d, J=4.5Hz, 1H), 2.48 (s, 3H), 2.34 (s, 3H), 1.25 (s, 9H); MS (APCI) 
m/z 363.1 (M+ + 1). 
N-(tert-butyl)-2-(4-(3,5-dimethylisoxazol-4-yl)-3-fluorophenyl)imidazo[1,2-a]pyrazin-3-
amine UMB-55. 1H-NMR (300MHz, CDCl3) δ 9.04 (s, 1H), 7.88 (d, J=5.4Hz, 1H), 7.36 
(m, 4H), 2.43 (s, 3H), 2.31 (s, 3H), 1.51 (s, 9H); MS (APCI) m/z 380.1 (M+ + 1). 
N-(tert-butyl)-2-(4-(3,5-dimethylisoxazol-4-yl)-2-methoxyphenyl)imidazo[1,2-a]pyrazin-3-
amine UMB-58. 1H-NMR (300MHz, CDCl3) δ 9.00 (s, 1H), 8.22 (d, J=4.5Hz, 1H), 7.88 
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(m, 2H), 7.05 (d, J=7.8Hz, 1H), 6.89 (s, 1H), 3.94 (s, 3H), 3.82 (s, 1H), 2.47 (s, 3H), 2.33 
(s, 3H),1.01 (s, 9H); MS (APCI) m/z 392.2 (M+ + 1). 
2-(4-(3,5-dimethylisoxazol-4-yl)-2-methoxyphenyl)-N-isopropylimidazo[1,2-a]pyrazin-3-
amine UMB-59. 1H-NMR (300MHz, CDCl3) δ 9.00 (s, 1H), 8.05 (m, 1H), 7.89 (m, 2H), 
7.05 (d, J=6.6Hz, 1H), 6.91 (s, 1H), 7.05 (d, J=7.8Hz, 1H), 3.94 (s, 3H), 3.15 (m, 1H), 
2.48 (s, 3H), 2.34 (s, 3H),1.03 (d, 6H); MS (APCI) m/z 378.1 (M+ + 1). 
 
Scheme 2.10 
 
Methyl 2-((2-(4-bromophenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetate 
 
Aminopyrazine (95.2 mg, 1.00 mmol, 1 eq), 4-bromobenzaldehyde (278 mg, 1.50 mmol, 
1.5 eq) and methyl isocyanoacetate (0.105 mL, 1.15 mmol, 1.15 eq) were dissolved in 
methanol (2 mL). A 1M solution of perchloric acid in methanol (0.20 mL, 0.10 eq) was 
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added and the solution was stirred for 12 hours at room temperature. The mixture was 
then diluted with EtOAc and washed with saturated sodium bicarbonate, water and 
brine. The crude material was purified by automated column chromatography (50 to 
100% EtOAc/hexanes) to yield a cream colored solid (0.21 g, 0.581 mmol, 58%). 1H 
NMR (400 MHz, CDCl3) δ 8.99 (d, J = 1.5 Hz, 1H), 8.18 (dd, J = 4.6, 1.5 Hz, 1H), 8.02 – 
7.93 (m, 2H), 7.90 (d, J = 4.6 Hz, 1H), 7.68 – 7.51 (m, 2H), 3.83 (d, J = 5.6 Hz, 2H), 
3.74 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 172.22, 143.77, 137.20, 136.97, 132.25, 
132.17, 129.48, 128.82, 122.67, 115.73, 110.16, 52.67, 49.03. MS (ESI) 361.69 
(M+H).39 
Ethyl 2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-
yl)amino)acetate (DB-1-038) 
 
Methyl 2-((2-(4-bromophenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetate (147 mg, 0.408 
mmol, 1 eq), potassium 3,5-dimethylisoxazole-4-trifluoroborate (108 mg, 0.530 mmol, 
1.3 eq), palladium (II) acetate (4.5 mg, 0.020 mmol, 5 mol %) RuPhos (19.1 mg, 0.041 
mmol, 10 mol %) and sodium carbonate (86.5 mg, 0.816 mmol, 2 eq) were dissolved in 
ethanol (2.1 mL) and degassed with nitrogen for roughly 1 minute. The mixture was 
placed in a heat block at 100 °C. After 16 hours, the mixture was filtered through a silica 
plug and concentrated. The crude mixture was purified by automated column 
chromatography (30 to 100% EtOAc/hexanes) to yield the ethyl ester (as a result of 
trans-esterification during the course of the cross-coupling) as a brown solid (88.9 mg, 
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0.227 mmol, 56%). 1H NMR (400 MHz, CDCl3) δ 8.96 (d, J = 1.3 Hz, 1H), 8.21 (dd, J = 
4.6, 1.4 Hz, 1H), 8.18 – 8.10 (m, 2H), 7.85 (d, J = 4.6 Hz, 1H), 7.39 – 7.31 (m, 2H), 4.18 
(q, J = 7.2 Hz, 2H), 4.05 (t, J = 5.7 Hz, 1H), 3.86 (d, J = 5.7 Hz, 2H), 2.43 (s, 3H), 2.29 
(s, 3H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 171.75, 165.45, 158.69, 
143.50, 137.26, 136.86, 132.51, 130.39, 129.47, 129.18, 127.51, 126.60, 116.34, 
115.87, 61.72, 49.27, 14.18, 11.77, 10.98. MS (ESI) 392.90 (M+H)40 
 
 
Scheme 2.11 
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tert-butyl 2-((2-(4-bromophenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetate 
 
Aminopyrazine (95.2 mg, 1.00 mmol, 1 eq), 4-bromobenzaldehyde (278 mg, 1.50 mmol, 
1.5 eq) and tert-butyl isocyanoacetate (0.167 mL, 1.15 mmol, 1.15 eq) were dissolved in 
methanol (2 mL). A 1M solution of perchloric acid in methanol (0.20 mL, 0.10 eq) was 
added and the solution was stirred for 12 hours at room temperature. The mixture was 
then diluted with EtOAc and washed with saturated sodium bicarbonate, water and 
brine. The crude material was purified by automated column chromatography (30 to 
100% EtOAc/hexanes) to yield a yellow oil, which slowly crystallizes upon standing 
(0.34 g, 0.84 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 8.87 (d, J = 1.4 Hz, 1H), 8.08 
(dd, J = 4.6, 1.5 Hz, 1H), 7.93 – 7.78 (m, 2H), 7.75 (d, J = 4.6 Hz, 1H), 7.50 – 7.38 (m, 
2H), 3.98 (t, J = 5.5 Hz, 1H), 3.62 (d, J = 5.6 Hz, 2H), 1.38 (s, 9H). 13C NMR (100 MHz, 
CDCl3) δ 170.74, 143.28, 136.53, 136.39, 132.09, 131.74, 129.01, 128.49, 126.77, 
122.21, 115.65, 82.44, 49.72, 27.99. MS (ESI) 403.76 (M+H).39 
 
tert-butyl 2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-
yl)amino)acetate (DB-1-057) 
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tert-butyl 2-((2-(4-bromophenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetate (0.34 g, 0.843 
mmol, 1 eq), potassium 3,5-dimethylisoxazole-4-trifluoroborate (0.205 g, 1.01 mmol, 1.2 
eq), palladium (II) acetate (5.7 mg, 0.0253 mmol, 3 mol %) RuPhos (23.6 mg, 0.0506 
mmol, 6 mol %) and sodium carbonate (0.179 g, 1.69 mmol, 2 eq) were dissolved in 
ethanol (4.2 mL) and degassed with nitrogen for roughly 1 minute. The mixture was 
placed in a heat block at 90 °C. After 17 hours, the mixture was filtered through a silica 
plug and concentrated. The crude mixture was purified by automated column 
chromatography (30 to 100% EtOAc/hexanes) to yield the product as a brown foam 
(0.284 g, 0.677 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 1.3 Hz, 1H), 8.20 
(dd, J = 4.6, 1.3 Hz, 1H), 8.18 – 8.12 (m, 2H), 7.88 (d, J = 4.6 Hz, 1H), 7.40 – 7.34 (m, 
2H), 3.89 (t, J = 4.5 Hz, 1H), 3.76 (d, J = 5.5 Hz, 2H), 2.45 (s, 3H), 2.32 (s, 3H), 1.46 (s, 
9H). 13C NMR (100 MHz, CDCl3) δ 170.90, 165.50, 158.76, 143.59, 137.29, 136.88, 
132.58, 130.45, 129.54, 129.30, 127.59, 126.90, 116.42, 115.76, 82.74, 50.12, 28.17, 
11.83, 11.04. MS (ESI) 420.83 (M+H).40 
 
2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-yl)amino)acetic 
acid (DB-1-064) 
 
 
tert-butyl 2-((2-(4-(3,5-dimethylisoxazol-4-yl)phenyl)imidazo[1,2-a]pyrazin-3-
yl)amino)acetate (0.284 g, 0.677 mmol, 1 eq) was dissolved in DCM (2.7 mL) and TFA 
 91 
 
(2.7 mL) and stirred at room temperature. After 12 hours, the mixture was concentrated, 
and purified by preparative HPLC (5 to 95% MeCN/water with 0.1%TFA) and lyophilized 
to yield the product as an orange powder (187 mg, 0.515 mmol, 76%). 1H NMR (400 
MHz, MeOD) δ 9.08 (s, 1H), 8.69 (d, J = 5.3 Hz, 1H), 8.16 (d, J = 8.2 Hz, 2H), 7.94 (d, J 
= 5.1 Hz, 1H), 7.66 – 7.46 (m, 2H), 3.99 (s, 2H), 2.48 (s, 3H), 2.32 (s, 3H). 13C NMR 
(100 MHz, MeOD) δ 174.12, 167.40, 159.93, 140.98, 136.86, 135.29, 134.79, 132.95, 
132.23, 130. MS (ESI) 364.76 
 
Biologic and Biochemical Compound Evaluation 
Reagents. Endogenous BRD4-NUT-expressing midline carcinoma cell lines, 79741 was 
described previously. Media, trypsin, and antibiotics for tissue culture were purchased 
from MediatechCloning. cDNA encoding human BRD2, BRD3, BRD4, BRDT, CREBBP 
and WDR9 (NCBI accession number NP 005095, NP 031397.1, NP 055114.1, NP 
001717.2, NP 004371.1, NP 061836.2) were obtained from different sources (BRD2: 
Synthetic, BRD3: Origene, BRD4: FivePrime, BRDT: IMAGE collection, CREBBP: 
Synthetic, WDR9: synthetic) and used as templates to amplify the bromodomain regions 
of the above proteins, using the polymerase chain reaction (PCR) in the presence of 
Platinum® Pfx DNA polymerase (Invitrogen™, UK). PCR products were purified 
(QIAquick PCR Purification Kit, Qiagen Ltd. UK) and further sub-cloned into a pET28 
derived expression vector, pNIC28-Bsa442, using ligation independent cloning43. The 
constructs were transformed into competent Mach1™ cells (Invitrogen™, UK) to yield the 
final plasmid DNA. 
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Protein Expression and Purification. Colonies from freshly transformed plasmid DNA 
in competent E. coli BL21(DE3)-R3-pRARE2 cells (phage-resistant derivative of 
BL21(DE3) cell, Invitrogen™), with a pRARE plasmid encoding rare codon tRNAs were 
grown overnight at 37 oC in 5 ml of Luria-Bertani medium (LB-broth, Merck) with 50 µg/ml 
kanamycin and 34 µg/ml chloramphenicol (start-up culture). The start-up culture was 
diluted 1:1000 in fresh medium and cell growth was allowed at 37 oC to an optical density 
of about 0.5 (OD600) before the temperature was decreased to 18 oC. When the system 
equilibrated at 18 oC the optical density was about 0.8 (OD600) and protein expression 
was induced over night at 18 oC with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG). 
The bacteria were harvested by centrifugation (8,700 x g for 15 min at 4 oC, JLA 81,000 
rotor, on a Beckman Coulter Avanti J-20 XP centrifuge) and were frozen at -20 oC as 
pellets for storage. Cells expressing His6 tagged proteins were re-suspended in lysis 
buffer (50 mM HEPES, pH 7.5 at 25 oC, 500 mM NaCl, 5 mM Imidazole, 5 % glycerol and 
0.5 mM TCEP) in the presence of protease inhibitor cocktail (1 μl/ml) and lysed using an 
EmulsiFlex-C5 high pressure homogenizer (Avestin - Mannheim, Germany) at 4 oC. 0.15 
% of PEI was added with an incubation of 30 min on ice and the lysate was cleared by 
centrifugation (16,000 x g for 1 h at 4 oC, JA 25.50 rotor, on a Beckman Coulter Avanti J-
20 XP centrifuge) and was applied to a nickel-nitrilotiacetic acid agarose column (Ni-NTA, 
Qiagen Ltd., 5 ml, equilibrated with 20 ml lysis buffer). The column was washed once with 
30 ml of lysis buffer then twice with 10 ml of lysis buffer containing 30 mM Imidazole. The 
protein was eluted using a step elution of imidazole in lysis buffer (50, 100, 150, 2x250 
mM Imidazole in 50 mM HEPES, pH 7.5 at 25 oC, 500 mM NaCl). All fractions were 
collected and monitored by SDS-polyacrylamide gel electrophoresis (Bio-Rad Criterion™ 
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Precast Gels, 4-12 % Bis-Tris, 1.0 mm, from Bio-Rad, CA. Gel run conditions: 180 V, 400 
mA, 55 min in XT MES buffer). After the addition of 10 mM dithiothreitol (DTT), the eluted 
protein was treated overnight at 4 oC with TEV protease to remove the hexa-histidine tag. 
The protein was further purified with size exclusion chromatography on a Superdex 75 
16/60 HiLoad gel filtration column (GE/Amersham Biosciences) on an ÄktaPrime™ plus 
system (GE/Amersham Biosciences). Samples were monitored by SDS-polyacrylamide 
gel electrophoresis and concentrated to 10-40 mg/ml in the elution buffer, 10 mM Hepes 
pH 7.5, 150 mM NaCl, 0.5 mM TCEP and were used for crystallization. Samples for 
isothermal calorimetry were dialysed over night at 4 oC in a D-Tube™ Dialyser Midi, 
MWCO 3.5 kDa to a final buffer of 50 mM HEPES, pH 7.4 (at 25 oC), 150 mM NaCl. 
Protein handling was carried out on ice or in a cold room in all the above steps. 
 
AlphaScreen BRD Binding Assay. Assays were performed with minor modifications 
from the manufacturer’s protocol (PerkinElmer, USA). All reagents were diluted in 50 mM 
HEPES, 150 mM NaCl, 0.1% w/v BSA, 0.01% w/v Tween20, pH 7.5 and allowed to 
equilibrate to room temperature prior to addition to plates. After addition of Alpha beads 
to master solutions all subsequent steps were performed in low light conditions. A 2x 
solution of components with final concentrations of BRD at 40 nM, Ni-coated Acceptor 
Bead at 25 μg/ml, and 20 nM bJQ1 was added in 10 μL to 384-well plates (AlphaPlate - 
384, PerkinElmer, USA). Biotinylated JQ1 derivative was synthesized as previously 
described. After a 1 minute 1000rpm spin-down, 100 nL of compounds in DMSO from 
stock plates were added by pin transfer using a Janus Workstation (PerkinElmer, USA). 
The streptavidin-coated donor beads (25 μg/ml final) were added as with previous 
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solution in a 2x, 10 μL volume. Following this addition, the plates were sealed with foil to 
block light exposure and to prevent evaporation. The plates were spun down again at 
1000rpm for 1 minute. Next, the plates were incubated in the room with the plate reader 
(for temperature equilibration) for 1 hour prior to reading the assay. Signal is sTable 2.for 
up to 3 hours after donor bead addition. AlphaScreen measurements were performed on 
an Envision 2104 (PerkinElmer, USA) utilizing the manufacturer’s protocol. 
Cell Viability Assay. Cells were counted and adjusted to 60,000 cells/mL. Using a 
Biotek EL406, 50μL of cells are media were distributed into 384 well white plates from 
Thermo. Immediately after plating, compound in DMSO was distributed to plates. For 
large plate sets, cells were returned to 37oC incubator while not in use. 
Compounds were added to plates using a 100nL 384 well pin transfer manifold on a 
Janus workstation. Stocks were arrayed in 10 point quadruplicate dose response in 
DMSO stock in 384 well Greiner compound plates. After addition of compound, plates 
were incubated for three days in a 37oC incubator. 
Cell viability was read out using ATPlite from Perkin Elmer. Plates were removed from 
the incubator and brought to room temperature prior to use. Lyophilized powder was 
resuspended in lysis buffer and diluted 1:2 with DI water. 25μL of this solution was 
added to each well using the Biotek liquid handler. Plates were sealed with adherent 
aluminum seals prior to vortexing and spinning down at 1000g for 1 minute. Plates were 
incubated for 15 minutes at room temperature before signal was read on an Envision 
Plate Reader. 
Isothermal Titration Calorimetry. Experiments were carried out on a VP-ITC titration 
microcalorimeter from MicroCal™, LLC (Northampton, MA). All experiments were 
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carried out at 15 oC while stirring at 295 rpm, in ITC buffer (50 mM HEPES pH 7.4 at 25 
oC, 150 mM NaCl). The microsyringe (250 μl) was loaded with a solution of the protein 
sample (300 μM protein for the BETs, 950 μM protein for CREBBP and 600 μM for 
WDR9(2), in ITC buffer). All titrations were conducted using an initial control injection of 
2 µl followed by 34 identical injections of 8 µl with a duration of 16 sec (per injection) 
and a spacing of 250 sec between injections. The heat of dilution was determined by 
independent titrations (protein into buffer) and was subtracted from the experimental 
data. The collected data were implicated in the MicroCal™ Origin software supplied with 
the instrument to yield enthalpies of binding (∆H) and binding constants (KB) as 
previously described by Wiseman and coworkers44. Thermodynamic parameters were 
calculated (∆G = ∆H - T∆S = -RTlnKB, where ∆G, ∆H and ∆S are the changes in free 
energy, enthalpy and entropy of binding respectively). In all cases a single binding site 
model was employed. 
Computational Methods 
All computational work was performed in Schrodinger Suite (Schrodinger, LLC). 
Conformational analysis of lead compounds was performed using Schrodinger’s 
Conformational Search function. Possible poses were prepared for docking by Ligprep. 
In both cases, default settings were used (OPLS2005 force field, water solvent). 
Docking was conducted using Glide. The co-crystal of BR4 and JQ1 (PDB: 3MXF) was 
used to define the ligand receptor grid. Water molecules outside the binding pocket 
were excluded, and hydrogen bonding interactions were optimized prior to docking.  
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Introduction: 
As part of my research into chemical probes, I especially focused on potential 
methods to target cancer growth. While direct inhibition of MYC has proven difficult, it 
remains one of the most important undrugged cancer dependencies. Utilizing new 
biochemical techniques I led the screening effort in our lab to create a MYC inhibitor. 
The depletion of MYC in multiple myeloma1 after treatment with JQ1 revealed the 
potential of alternative pathways to MYC inhibition. As consequence, Dr. Bradner and I 
did extensive literature searches on the topic. Our findings were eventually compiled 
into the book chapter contained herein. I co-authored the following chapter with Dr. 
Bradner, for Cold Spring Harbor Perspectives in Medicine. 
 The direct inhibition effort created a team with myself on biochemistry, Jason 
Marineau (formerly Bradner Lab) on synthetic chemistry, and Peter Rahl (formerly 
Young Lab) on MYC biology. Both of these collaborators were post-docs at the time and 
now work at Syros Pharmaceuticals. Due to the historical difficulties of developing small 
molecule inhibitors against protein-protein interactions, proteins lacking defined 
structures, and transcriptional complexes in general, MYC was chosen as a challenging 
target with strong therapeutic potential, and unmet need. Also, the lack of a chemical 
probe against MYC means that previous studies have had to rely on genetic 
manipulation of the system with tet-off2-4 or dominant negatives, like omomyc5-7. I 
hypothesize that small molecule inhibition will of MYC will decrease the level of MYC on 
chromatin and its total protein amount. At the same time, MAX should stay constant and 
stay on chromatin. As a result, I will investigate the gene signature of MYC loss and its 
return after transient suppression by Affy array expression and ChIP for MYC and MAX 
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binding to chromatin. In addition, the binding of a small molecule to a poorly structured 
protein, such as MYC, may stabilize the structure. 
A high throughput technology to screen for inhibitors of MYC/MAX dimerization 
and DNA binding  
The in vitro high throughput assay uses AlphaScreen technology (Perkin Elmer), 
a bead-based proximity assay, purified biological components, nucleotide polymers 
containing protein binding sites and candidate inhibitors with full-length human MYC 
and MAX proteins. This reports on formation of the MYC/MAX/Ebox DNA ternary 
complex using singlet oxygen transfer between AlphaScreen beads resulting in 
production of luminescent signal. Inhibitors preventing complex formation will diminish 
signal intensity. Significantly, the assay wass amenable to miniaturization, automation 
(automated plate filling and compound pin transfer) and high throughput screening in 
either 384- or 1536-well plate formats.   
This assay is superior to alternative methodologies such as FRET or FP for a 
variety of reasons. First, the cost per well for protein is dramatically reduced by using 
protein concentrations in the tens of nanomolar or lower which is significantly lower than 
alternatives such as thermal melt or FP. The low concentration of protein components is 
important for detection of low affinity ligands that are often identified in high throughput 
screens. Second, the assay is unaffected by molecular orientation or proximity which 
can have a large impact on FRET. Third, AlphaScreen effectively displays an anti-
Stokes shift greatly reducing the impact of intrinsically fluorescent molecules on the 
assay. Since the transfer of energy is mediated by singlet oxygen, the readout 
wavelength can be blue-shifted relative to the excitation wavelength, which is 
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impossible in traditional fluorescent assays. Fourth, the relatively long signal distance of 
200 nm that singlet oxygen can travel allows reporting on full protein complexes and not 
just single target binding. Fifth, the assay proved highly amenable to miniaturization with 
and can be scaled down to smaller volumes with relative ease. Finally, neither the small 
molecules being assays nor the target protein, MYC, need to be chemically, 
conformationally or behaviorally altered by tethering them to a surface or reporter which 
can induce artifacts.  We have the option of having MYC free in solution (as it is inside a 
cell) and having MAX and DNA bound to a bead.  But as described below, this assay 
has the flexibility of alternative configuration where MYC and DNA are bound to a bead 
and MAX is free in solution.  Thus, it allows for various configuration depending on the 
protein target. 
 
Assay Development and Validation 
Two complimentary assays have been developed to monitor MYC/MAX/Ebox 
DNA complex formation. The AlphaScreen assay (Perkin Elmer) is comprised of an 
acceptor and a donor bead in solution (Figure 3.1).  The donor bead is illuminated at 
680nm, which generates a singlet O2 molecule.  If the acceptor bead is within 200nm 
2 half-life), it will transfer the energy and generate 
luminescent signal at a wavelength of 520-620nm.   
The assay consists of biotinylated Ebox DNA ([Biotin-
triethyleneglycol]GGAAGCAGACCACGTGGTCTGCTTCC) used in conjunction with 
strepavidin donor bead.  His6-MAX is used with Ni++ acceptor beads.  Free MYC 
(purified as his6-MYC, followed by a thrombin cleavage reaction to remove the his6 tag) 
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is added free in solution. A reciprocal assay (not shown in schematic) uses biotinylated 
Ebox DNA with strepavidin donor beads. His6-MYC is used in conjunction with the Ni++ 
acceptor bead.  Recombinant free MAX (purified as his6-MAX followed by thrombin 
cleavage of the his6 tag) is added free in solution. The different assay set-ups offer 
flexibility in which components are bound to beads or free in solution. 
All reagents are diluted in reaction buffer (50 mM HEPES, 150 mM NaCl, 0.2% 
w/v BSA, 0.02% w/v Tween20, 40 μg/ml glycogen, 100 nM DTT, pH 8.0 and allowed to 
equilibrate to room temperature, where glycogen and DTT are added immediately prior 
to use.) prior to addition to plates.  The composition of the reaction buffer can vary and 
be optimized depending on the complex of interest.  We found that adjusting the pH 
from 7.4 to 8.0 better mimics the nuclear conditions and favours Myc/MAX heterodimer 
formation over MAX/MAX homodimer formation. Also, the BSA and Tween20 
concentrations were optimized to reduce background, non-specific associations and 
aggregation. DTT was added to mimic the reducing conditions of the cellular interior. It 
is also thought that BSA reduces background signal by sequestering errant singlet 
oxygen. Early attempts to use automation were confounded by a gradient of signal 
across the plate, in the direction of plate filling, which we reasoned was caused by 
adsorption of oligos onto polypropylene tubing.  We discovered that the addition of 
glycogen, serving as a carrier, corrected the defect in assay automation. Full 
automation is critical when screening compound libraries and therefore, this was an 
essential modification that we discovered had a profound effect on assay performance. 
The precise ratio of components proved very important for optimal signal to background 
and each was titrated as shown in Figure 3.1. Under fully optimized conditions, the 
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assay was found to be fully screening ready and generate a robust z-prime score using 
a positive control compound made by Jason Marineau called JJM288 (Figure 3.2). 
Having established the proper configuration (schema in Figure 3.3A). The assay gives 
IC50 values when used in dose response against screening hits and medicinal 
chemistry products (Figure 3.3B). In addition, over a several thousand compound 
screening effort, the assay showed good reproducibility between duplicates (Figure 
3.3C) and clean normal distribution of hits (Figure 3.3D). 
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Figure 3.1: Assay optimization for MYC-dependent signal.  Signal (RLUs) of bead 
proximity is dependent on MYC and Max protein concentrations.  A fixed DNA 
concentration was used.   
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Figure 3.2: Z-prime analysis for assay robustness.  This assay has a 0.82 Z-prime, 
indicating a highly robust assay.  Z-prime in 16-plicate using JJM288 as a positive control 
compound (Positive).  Leaving MYC out of the reaction (No Myc) also reduces signal, 
indicating MYC-dependent signal. 
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A. 
C. D. 
B. 
Figure 3.3: MYC Screening A) Schematic of cMyc assay. B) Characteristic dose response showing 
retest of hits from a library. C) Scatter Plot of all cMyc screening to date. D) Histogram showing 
performance of assay. 85% fall within 70-120% of DMSO mean. 
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MYC as a Target for Probe Discovery: 
 One particular compound series based on the hit resynthesized as JJM288, has 
shown potential. It had 4μM potency in biochemical assays and 19μM in H2171 lung 
cancer cell line, used due to its exceptionally high expression of MYC. Our collaborator 
Pete Rahl in the Young lab at the Whitehead performed gel shifts, nanostring of a MYC, 
ChIP, and caspase cleavage assays, which all looked favorable. 
 Having established a reasonable lead molecule, work on derivatization was 
performed in collaboration with Jason Marineau in the Bradner lab. Progressive 
iterations of compound development were pursued where biochemical and cell viability 
studies informed development of the next compound series. Based our own earlier work 
on a previous lead series with mitorubrinic acid and 10058-F4 (data not shown), we 
hypothesized that adding negative charge would be beneficial and were able to make a 
leap forward with a focused library that generated JJMII288-C02 (Figure 3.4A). 
Furthermore, we hypothesized that greater restriction of the bond angles and 
replacement of the hydrazide would increase potency which led to JJMIII-61 (Figure 
3.4B). C02 has been further validated in gel shift assays, cellular viability, and reporter 
lines (Figure 3.4C&D). An important note caveat with regard to cellular assays is the 
use of an acetoxymethyl protecting group for free acids. Upon noting a lack of potency 
in cellular assays, it was hypothesized that masking the free acid would help deliver the 
molecule into cells. Moreover, an acetoxymethyl group was selected due to its 
preferential cleavage by cellular esterases, allowing accumulation in cells and 
preventing cleavage in media or the blood stream8. 
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C. D. 
B. A. 
Figure 3.4: MYC dose response A) Alphascreen dose response of JJM288 derivatives made by 
hydrazide coupling. B) Alphascreen of constrained amides and ureas to replace hydrazide. C) Gel 
shift of JJM288 derivatives. Inhibition of Myc-Max-DNA complex results in increased Max homodimer 
and free DNA. D) Reporter assay with Ebox driven luciferase compared to MTT control assay for 
viability over 24 hours. 
. 
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Scheme 3.1: Chemical Progression Chemical series starting from JJM288. The AM ester is used to 
make all compounds in the series functional on cells. Potency (Where tested) is given as biochemistry, 
cellular.  
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 While numerous previous attempts have been made against the classically 
difficult target MYC it is an incredibly important target for drug discovery as the next 
section will elaborate one. Our approach using biochemical and cellular assays with 
large chemical libraries and focused libraries developed around hits identified in high 
throughput screens has shown success in developing inhibitors of transcription factor 
function that will require much ongoing work. 
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Background: 
MYC (v-myc myelocytomatosis viral oncogene homologue) is a nuclear DNA-
binding transcription factor that orchestrates transcriptional regulatory pathways 
underlying cell growth, cell cycle progression, metabolism and survival (Conacci-Sorrell 
et al. 2014) 1.  MYC was first described 30 years ago in the context of viral oncogenesis 
2-4, and subsequently a human homologue was identified and characterized 5,6 Since its 
discovery, MYC has emerged as a master regulator of numerous biological and disease 
processes.  
MYC is the most frequently amplified oncogene in human cancers, and MYC 
alteration is observed in a wide range of tissue types including breast, lung, and 
prostate cancer 7. MYC overexpression occurs in 30% of all human cancers and 
frequently predicts for a poor clinical outcome, aggressive biological behavior, increased 
likelihood of relapse and advanced stage of disease 8,9. An estimated 450,000 
Americans each year are diagnosed with a MYC-dependent cancer. Deregulated 
expression of MYC is a hallmark feature of cancer (Conacci-Sorrell et al. 2014; Gabay 
et al. 2014), uncoupling physiologic growth-factor dependent proliferation. Deregulated 
expression of MYC in cancer occurs through gene amplification 10, chromosomal 
translocation 11,12, focal enhancer amplification 13, germline enhancer polymorphism 14-
18, or commonly through constitutive activation of upstream signaling pathways. Each of 
these mechanisms serves to uncouple physiologic, growth-factor dependent 
proliferation.  
MYC has been multiply validated as essential for tumor initiation and 
maintenance in numerous tumor histologies (Gabay et al. 2014; Huang and Weiss 
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2013; Roussel and Robinson 2013; Schmitz et al. 2014). Studies in transgenic mouse 
models identify that MYC inactivation leads to prompt tumor regressions, often 
associated with phenotypes of differentiation and cellular senescence with or without 
apoptosis 19-24.  In models of osteosarcoma, even brief MYC inactivation significantly 
improved survival rates owing to terminal differentiation of tumor cells 23.  
The pleiotropic role of MYC in developmental biology and tissue homeostasis 
has prompted reasonable concern that targeting MYC may provoke severe, untoward 
toxicity.  Indeed, genetic ablation of MYC in mice is embryonic lethal at an early stage of 
gestation (between days 9.5 and 10.5), with failed hematopoietic development 25 (Hurlin 
2013). While subsequent studies have demonstrated tolerance of tissue-specific MYC 
loss or downregulation, such as in the liver and small intestine 26 (Hurlin 2013), 
concerns remain that pharmacologic inhibition of MYC may feature a narrow therapeutic 
index. For example, tolerance of MYC loss in intestinal epithelium could be conferred by 
compensatory upregulation of MYCN 26 (Hurlin 2013), suggesting that selective 
inhibition of MYC-family isoforms may be required to firmly establish a therapeutic 
index. 
Recently, a powerful genetic instrument developed by Evan and colleagues has 
provided compelling evidence that a therapeutic index does exist for targeting MYC. 
Structure-guided design allowed the optimization and characterization of a 93 residue, 
dominant-negative peptide comprising the bHLHZ domain (see Conacci-Sorrell et al. 
2014) called Omomyc 24,27. Four amino acid substitutions in the extended leucine zipper 
domain relieve repulsive charge interactions allowing for a coiled-coil binding event to 
occur, presumably with endogenous MYC. Thus, Omomyc functions to competitively 
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bind MYC in a manner preventing MYC:MAX heterodimerization, and expression of 
Omomyc prompts rapid growth arrest and downregulation of MYC target genes 28,29. 
Tetracycline-inducible expression of Omomyc has allowed a simulation of what 
pharmacologic modulation of MYC function may hold, in vitro and in vivo. As described 
in Gabay et al. (2014), constitutive induction of Omomyc prompts tonic inhibition of 
MYC:MAX heterodimerization associated with significant toxicity in proliferative tissue 
compartments in rodents (bone marrow and bowel). However, periodic induction of 
Omomyc has proven well-tolerated.  Dosing regimens have already been identified 
which provoke unprecedented responses in aggressive murine models of cancer, 
notably including the KRAS:TP53 model of non-small cell lung carcinoma 30. This 
research further validates MYC as a therapeutic target in cancer, importantly 
downstream of other intractable protein targets and tumor suppressors, and establishes 
a therapeutic index for MYC inhibition, in vivo. 
Beyond cancer, MYC is also a positive effector of tissue inflammation. Activation 
of MYC is observed in immune cells during inflammatory cell expansion 31.  MYC 
amplifies the transcriptional response to inflammatory transcription factor signaling in 
conditions such as rheumatoid arthritis 32. MYC function has also been implicated in the 
pathophysiology of heart failure, during tissue remodeling associated with hypertrophy 
and dilatation 33.  Hence, the ability to inhibit MYC could extend beyond cancer therapy. 
 
Toward direct inhibition of MYC 
In the post-genomic era, the emergent paradigm of drug discovery is increasingly 
target directed.  Disease biology identifies a critical effector mediating the 
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pathophysiology of illness or the maladaptive response, and target-directed ligand 
discovery is undertaken.  Innovation in the science of therapeutics over the last three 
decades has generated diverse strategies, which may be deployed to realize direct-
acting inhibitors of protein targets.  Still, the prioritization of targets is heavily influenced 
by perceptions of success and the horizons of supported research 34-36.  
As a class, transcription factors have proven particularly evasive in the discipline 
of ligand discovery 37,38. Transcription factors are master regulators of cell state, 
controlling gene expression programs driving cell type specification and contributing to 
the pathophysiology of a broad range of diseases 39,40. As a class, transcription factors 
are highly desirable proteins for therapeutic targeting. Yet, also as a class, transcription 
factors biophysically associate through extensive inter-facial associations featuring large 
surface areas, a lack of hydrophobic invaginations, and noncontiguous contacts. These 
features are at odds with traditional binding models for small organic drug molecules 41. 
The number of transcription factors successfully approached to-date with discovery 
chemistry is therefore rather small. It has been our experience, developing the first 
direct-acting inhibitors of the NOTCH1 transactivation complex for probe and 
therapeutic development in T-cell acute lymphoblastic leukemia, that significant 
challenges exist in each phase of assay development, small molecule optimization, 
biophysical characterization, mechanistic validation and cellular permeability 42.  For 
these and other reasons, despite a confluence of detailed mechanistic insights and 
unmet medical needs, direct inhibition of MYC remains a historic challenge 1.  Indeed, 
MYC has emerged as arguably the prototypical example of an “undruggable target,” a 
 116 
 
term reserved for protein targets that have proven intractable to coordinated efforts in 
ligand discovery. 
MYC presents specific, significant obstacles to discovery chemistry. MYC lacks 
enzymatic activity, limiting many effective approaches to direct inhibition. Rather, MYC 
functions via protein-protein interactions, which remain a technical and psychological 
barrier to organized efforts in drug discovery 43. Structurally, MYC lacks globular 
functional domains, which might be approached with structure-based or empirical 
biochemical screening. MYC is comprised of a largely unstructured amino-terminal 
region involved in transactivation and protein stability (Conacci-Sorrell et al. 2014; 
Farrell and Sears 2014). Four highly conserved functional modules exist at the amino-
terminus, termed MYC Boxes (MBI-IV).  MBI possesses a degron targeted by FBW7 
44,45.  MBII recruits a chromatin modifying complex containing TRRAP, GCN5 and TIP60 
(Hann 2014)46.  MBIII and MBIV contribute to MYC-specific phenotypes, such as MYC-
induced apoptosis, but are not clearly relevant for MYC-induced cell proliferation and 
survival 47,48. Among the MYC Boxes, structural data is only available for MBI. 
Arrowsmith and colleagues have reported a structural model for MBI binding to the SH3 
domain of the BIN1 tumor suppressor 49. However this interaction does not present a 
compelling therapeutic rationale, and the structure is limited to 13 residues of MYC 
(Figure 3.5A).  
The carboxy-terminus of MYC encodes a 100 residue basic helix-loop-helix-
leucine-zipper (bHLH-LZ) DNA binding domain.  The leucine zipper forms a coiled coil 
heterodimer with a homologous region on the transcriptional repressor, MAX, which 
together engage E-box DNA binding sites (see Conacci-Sorrell et al. 2014). Localization  
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Figure 3.5: Structural studies of MYC. Structural studies of MYC reveal challenges of developing direct-
acting inhibitors of (A) MYC Box I (MBI as red ribbon and BIN1 as white space-fill; PDB: 1MV0) and (B) 
the MYC:MAX heterodimer (MYC as red ribbon and MAX as white ribbon on white DNA; PDB: 1NKP). 
  
MYC Box 1 (PDB: 
1MV0) 
B
. 
MYC:MAX (PDB: 
1NKP) 
A
. 
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of the heterodimer to promoter and enhancer regions positively regulates transcription 
of proliferation-associated genes through control of transcription elongation 1,50,51. 
Heterodimerization of MYC and MAX is required for transcriptional activation and 
oncogenic transformation, validating this interaction for further study. A seminal 
structural study by Nair and Burley 52, however, elegantly displays the extended 
interaction between the two proteins that offers no apparent site for positioning a small 
molecule inhibitor (Figure 3.5B). The structurally and functionally similar MYCN and 
MYCL are comparably organized, posing then identical challenges for direct-acting 
therapeutic development in diseases attributable to these two oncogenes. 
Intrinsically disordered proteins, such as MYC, comprise more than 30% of 
eukaryotic proteins 49,53,54. Many such proteins are found at signaling nodes, where 
rapid physiologic response and dynamic cell state changes demand finely tuned post-
translational regulatory mechanisms which may be facilitated by intrinsic disorder 55. 
Disordered proteins are often encoded by transcripts featuring short polyA tails, which 
reduce mRNA stability, and feature amino-terminal degrons and internal PEST 
sequences allowing for precise control of protein half-life 56. As discussed in detail in 
Farrell and Sears (2014), MYC has an ephemeral half-life (20–30 minutes), and is 
tightly regulated by E3 ubiquitin ligase recruitment and proteasomal degradation 
through at least two complexes (SKP2 and FBW7) and an evolutionarily conserved 
PEST domain 57,58. Perhaps the intrinsic disorder of MYC and additional counter-
regulatory measures (short protein and mRNA half-lives, transcriptional attenuation) are 
then ancient evolutionary safeguards to having such a dangerous oncogene in the 
genome. 
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 Despite the apparent obstacles involved in studying the function of intrinsically 
disordered proteins, several research groups have organized around the challenge of 
developing first direct-acting inhibitors of MYC.  The concept underlying these studies is 
theoretical in nature, arguing that the inherent, intrinsic disorder of native MYC 52,59,60, 
establishes an opportunity for small-molecule mediated induction of a neomorphic 
binding site, a perhaps extreme example of induced fit. Induced fit implies a 
conformational change in the protein target provoked by a ligand, which may be 
accompanied by target inhibition or functional modulation as has been characterized 
extensively in enzymology and protein-nucleic acid interactions 61,62. The concept of 
induced fit applied to intrinsically disordered proteins possesses additional 
considerations.  The lack of secondary structure in proteins such as MYC limits 
competing native intramolecular interactions, which are often low affinity, yet is 
complicated by the need for significant binding energy to overcome entropic penalties 
53, and the likelihood of multiple binding states.  This latter consideration presents 
challenges in establishing modes of molecular recognition, capturing low energy 
assembly states for structural characterization, or even rigorously validating inhibitory 
biochemistry. As such, current described inhibitors of the MYC:MAX interaction serve as 
early, provocative examples of prototypical compounds, but as a group lack properties 
of target specificity, biophysical characterization and demonstrated utility in cell and 
model organism assays of MYC biology, that would define these compounds as 
chemical probes of MYC function and bona fide leads for therapeutic development 63. 
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Figure 3.6: Small molecule inhibitors of MYC. From top left o bottom right: Berg et al. 2002, Yin et al. 
2003, Kiesssling et al. 2006 & 2007, Shi et al. 2009, Xu et al. 2006, Jeong et al. 2010, Yap et al. 2013. 
These compounds are the current putative direct inhibitors of MYC. 
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To our knowledge, the first efforts to inhibit MYC:MAX heterodimerization were 
reported by Vogt and colleagues in 2002 64. Using a CFP/YFP fluorescence resonance 
energy transfer (FRET) assay, the bHLH-LZ domains of MYC and MAX were studied for 
inhibition of dimerization by a library of 7,000 small molecules. These studies identified  
a series of related, substituted isoindolines (e.g., IIA4B20; Figure 3.6), which exhibited 
weak but reproducible inhibitory activity in FRET and ELISA assays (75–210 μM).  Soon 
thereafter, Prochownik and colleagues 65, studied a commercial library of 10,000 
compounds using a Gal4-based yeast two-hybrid assay and the minimal bHLH-LZ 
interacting domains. Emerging from these studies were a series of structurally diverse 
compounds which impaired MYC:MAX binding by electrophoretic mobility shift assay 
(EMSA), including compounds which have been subsequently studied in cellular models 
of MYC biology (10074-A4, 10074-G5, and 10058-F4; Figure 3.6). A second study by 
Yang and co-workers reported curcuminoid inhibitors of MYC:MAX binding, in the 
context of a study aiming to establish binding constants for the heterodimeric interaction 
on DNA 66. By measuring binding of MYC:MAX heterodimers to a fluorescein-labeled 
oligonucleotide, Berg and colleagues screened 17,298 compounds to discover 
pyrazolo-pyrimidine inhibitors with measurable biochemical inhibitory activity for MYC 
(e.g., Mycro1; Figure 3.6; IC50 = 30 μM) and a narrow window of selectivity for 
MAX:MAX homodimers (IC50 = 72 μM) 67,68.  Additional efforts to target the MYC:MAX 
heterodimerization event have been undertaken subsequently, including efforts using 
further FRET screens 69, cellular transformation assays 70, and further EMSA screens 71. 
These and other studies have led to a list of structurally diverse compounds with 
reported activity against the MYC:MAX:DNA binding event (Figure 3.6) 72. 
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As described above, this research comprises more than a decade of study to 
identify the first qualified chemical probes of MYC function, for mechanistic use in 
cellular biology. Medicinal chemistry efforts directed at improving the limited potency of 
these compounds are described in the published and patent literature (WO2010083404 
A2). However, many of the active species belong to structural classes annotated as 
non-selective ligands in pharmaceutical screening libraries, so called pan-assay 
interference compounds (PAINS) 73,74, establishing important first directions for follow-
up chemistry. Perhaps consistent with this behavior, incisive and important studies have 
observed multiple binding events of bioactive compounds along the MYC protein by 
circular dichroism 60, NMR 60, and most recently by mass spectrometry 75. The relatively 
low potency, demonstrable selectivity and durable biostability of lead compounds have 
prevented use in MYC model systems in vivo 76,77, but insights are emerging from this 
work and structural modeling. Still needed are direct-acting MYC inhibitors with 
properties commensurate with a bona fide chemical probe, such as defined by Steven 
Frye 63. There exists, therefore, an opportunity to revisit this biochemistry with new 
screening methodologies, new types of expansive chemical libraries and new 
measurements to characterize the mode of molecular recognition of candidate 
inhibitors. 
Beyond the MYC:MAX heterodimerization interface, functional studies highlight 
MBII as a putative target for chemical probe development.  The requirement for MBII in 
MYC-specific transactivation and cellular transformation highlights the emerging 
validation of this protein-protein interaction.  Unfortunately, limited biochemical and no 
structural information is available for MBII. Focused biophysical and structural studies of 
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MBII may pave the way to miniaturized assays capable of interrogating MBII with 
discovery chemistry. 
Inhibition of MYC-dependent transcriptional signaling 
 MYC-dependent transcription requires the assembly and function of critical 
transcriptional and chromatin-modifying enzyme complexes 51,78 (also see Hann 2014) 
(Figure 3.7). Communication of transcriptional impulses is initiated by promoter- and 
enhancer-bound MYC, which serves to organize histone acetyltransferases (such as 
TIP60, GCN5, and CBP/P300) and the mediator complex. These events promote the 
preparation and stabilization of accessible euchromatin, as well as bridging interactions 
with initiated RNA Pol II. Recently, the Young laboratory described a pivotal role of MYC 
also in genome-wide transcriptional elongation mediated by proximal promoter pause 
release. 50.  MYC importantly functions to promote CDK9-dependent phosphorylation of 
RNA Pol II, triggering the release of paused polymerase to execute definitive target 
gene transcription (see Rahl and Young 2014; Levens 2013; and Sabò and Amati 
2014).  
These insights support a model of targeting MYC via co-activator proteins critical 
to MYC-specific initiation and elongation.  The pronounced effect of MYC on local 
chromatin acetylation (via HAT recruitment) 79,80, and the emerging role for MYC in 
elongation (via recruitment of CDK9), prompted our consideration that the bromodomain 
and extra-terminal domain (BET) family of co-activator proteins (BRD2, BRD3, BRD4, 
and BRDT) figure prominently in MYC-mediated transcriptional pause release.  BET 
bromodomains bind to poly-acetylated histone tails via molecular recognition of ε-acetyl-
lysine (Kac) by an anti-parallel bundle of four alpha-helices that forms a hydrophobic  
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Figure 3.7: A model for MYC transcriptional complex. Chromatin-dependent MYC transcriptional 
signaling. MYC and MAX bind at Ebox motifs (boxes) in enhancers and promoters. Protein complex 
formation causes looping to engage promoters adjacent to MYC target genes (arrow to gene body), 
inducing RNA Pol II (RNA POL2) loading to initiation site. Recruitment of TRRAP and histone 
acetyltransferases (HAT) leads to covalent modification of nucleosomes (clustered gray spheres) with 
lysine side-chain acetylation (Kac; small black circles). Acetylated, open chromatin is bound by 
bromodomain containing proteins, including HATs (CBP, EP300, GCN5) and BET-family co-activators 
(BET; yellow). BET bromodomains recruit the P-TEFb elongation complex (CyclinT and CDK9; cyan) 
phosphorylates (small green circles) the carboxy terminal domain of RNA POL2, causing pause release 
and leading to elongation. 
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pocket with a conserved asparagine and an organized network of deep water molecules 
81-84. Prior research established a role for BET bromodomains in cell cycle progression 
and mitotic memory 85. Biochemical studies in virology by Verdin and co-workers 
importantly established that BET bromodomains possess a high-affinity binding motif for 
the CDK9-containing positive transcription elongation factor complex (P-TEFb) at the 
distal carboxy-terminus 86. We thus hypothesized that BET bromodomains may function 
to recruit CDK9 to sites of hyperacetylated chromatin in cancer cells, thereby facilitating 
MYC-specific transcription elongation. 
 Having developed and characterized the first bromodomain inhibitor 87, targeting 
the BET family of bromodomains, we performed a chemical genetic study of BET 
inhibition on MYC transactivation in vitro and in vivo 88. Mechanistic studies performed 
in translational models of multiple myeloma (a MYC-dependent plasma cell 
malignancy), revealed that chemical displacement or genetic silencing of BET 
bromodomains results in the selective, coordinate down-regulation of the MYC 
transcriptional program.  Concurrent, collaborative studies of BET inhibition in acute 
myeloid leukemia with Vakoc and Lowe, comparably demonstrated pronounced MYC 
pathway inhibition associated with marked downregulation of transcription of the MYC 
gene itself 89. In both studies, abrogation of chromatin-dependent MYC gene 
transcription via BET bromodomain inhibition elicited meaningful therapeutic responses 
in murine models of these aggressive hematological malignancies. Targeting MYC 
function via BET bromodomain inhibition has now been validated by studies in Burkitt 
lymphoma 90, B- and T-cell acute lymphoblastic leukemia 91, non-small cell lung 
carcinoma 92 and diffuse large B-cell lymphoma 93. In model systems of neuroblastoma, 
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MYCN transcription and function was found to be comparably sensitive to BET 
inhibition.  This hypothesis is presently being assessed in clinical trials of BET 
bromodomain inhibitors in MYC-dependent solid and hematopoietic tumors.  
 Another noteworthy approach to targeting MYC transcription derives from a 
unique and well-characterized feature of the MYC locus, namely a predisposition for 
formation of G-quadruplex DNA 94,95. Small-molecule stabilizers of G-quadruplex DNA 
have been developed as tool compounds, which establish an impediment to RNA Pol II 
transcription of MYC.  Further optimization is required before these compounds can be 
clinical deployed, but MYC-specific biological consequences have been observed with 
these compounds in experimental systems 96-101.  
 Beyond BET bromodomains, additional MYC-associated co-activator proteins 
may also then be considered for therapeutic development.  As shown in Figure 3.8 (and 
as described in Conacci-Sorrell et al. 2004; Hann 2014) the MYC interactome features 
known critical mediators of transcriptional output, among them protein targets amenable 
to small molecule discovery. Through MBII, MYC recruits the TRRAP complex that 
includes the histone acetyltransferases TIP60 and GCN5.  The successful development 
of P300 histone acetyltransferase inhibitors by Cole and colleagues 102,103, suggests that 
discovery chemistry directed at these validated effectors of MYC-dependent chromatin 
remodeling and transcription is within reach. As P300 is a known binding partner of 
MYC via interactions in the trans-activation domain 104, the C646 inhibitor of P300 could 
contribute to the further understanding of this enzyme in MYC stability and function.  
Downstream of enhancer-bound factors such as these, MYC-mediated recruitment of  
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Figure 3.8: The MYC protein interactome (STRING). Connections between MYC and other critical 
regulatory proteins and complexes are shown.  
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mediator and TFIIH suggests consideration for the development of selective inhibitors of 
transcriptional kinases, such as CDK7, CDK8 and CDK9, as MYC-directed tools and 
prototype therapeutics. Small-molecule inhibitors of transcriptional kinases are being 
intensively pursued in academia and industry, and a partial list of emerging compounds 
is presented in Table 3.1. 
 Insights from developmental and disease biology suggest additional opportunities 
to target MYC function at the level of nuclear chromatin. Functioning alongside MYC-
dependent transcription are parallel transcriptional networks which may be approached 
for synthetic lethality. Eisenman and colleagues discovered and characterized a 
functional interaction between Drosophila Myc and the Trithorax group protein Little 
imaginal discs (Lid) 105, a homologue of the human proto-oncogene JARID1. They 
hypothesize a role for JARID1 in MYC-dependent neoplasia 106,107, supported by recent 
evidence that the NUP98-JARID1A oncogene in AML functions, in part, through an 
essential interaction between a plant homeodomain (PHD) finger encoded by JARID1A 
and histone 3 lysine 4, providing functional validation of JARID1A in a MYC-dependent 
tumor 108,109. 
 Beyond chromatin-dependent MYC transcriptional signaling, other chromatin-
associated factors such as the PIM1 kinase may contribute to high global transcriptional 
output at MYC target genes 110,111. PIM1 phosphorylates histone H3 and, interestingly 
and similar to MYC, PIM1 regulates transcriptional elongation 112,113.  PIM1 inhibitors are 
in development as anti-tumor agents, including the ADP-competitive inhibitor SGI-1776. 
Additional small molecules targeting MYC-associated transcriptional regulators such as 
Table 3.1. 
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Table 3.1: MYC pathway and regulator inhibitors  
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Targeting pathways upstream of MYC 
 As an end-effector of numerous upstream signal transduction pathways, it is 
highly likely that effective targeting of dominant growth-factor independent signaling 
networks will mute upstream activation of MYC. Often, mitogenic signaling pathways 
activate intermediary effector transcription factors that integrate upstream surface-to-
nuclear signaling with the common transcriptional language of MYC-dependent cell 
proliferation. A classic example is KRAS activation, which is among the most prevalent 
alterations in human cancer.  KRAS activation in cancer drives MYC activation.  Both 
genetic (Omomyc) 30, and chemical (BET inhibition with JQ1) 92, perturbation of MYC 
function arrest proliferation downstream of KRAS and validate MYC as a target in 
KRAS-dependent tumors.  
 Indeed, many other upstream signaling pathways lead to deregulated MYC 
function, including the MAPK, PI3K, Wnt/β-catenin and Notch pathways (see Conacci-
Sorrell et al. 2014; 1,51. The Wnt/β-catenin pathway regulates MYC expression through 
signaling to the Tcf4 transcription factor that binds tissue-specific enhancers upstream 
of the MYC gene 18.  Stabilization of NOTCH1 by juxtamembrane or PEST domain 
alteration in T-ALL leads to deregulation of MYC expression and function. Targeting the 
Notch pathway with upstream inhibition of gamma-secretase 114, or direct inhibition 
using stabilized alpha-helical peptides 42, leads to prompt downregulation of MYC 
associated with anti-proliferative consequences. Exemplary, additional inhibitors of 
upstream signal transduction pathways, such as MAPK and PI3K are presented in 
Table 3.1. As targeted agents are brought forward for clinical trials, pre-clinical studies 
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assessing combinations of upstream and downstream modulators of MYC function 
should be pursued. 
 
Modulating MYC stability 
 MYC has a naturally short half-life 49. Regulation and preservation of the short 
transcript and protein half-life is essential to long-term survival without cancer. MYC 
protein homeostasis is considered in detail in Farrell and Sears (2014) and elsewhere 
by Sears and colleagues 115.  Here, we describe only briefly the opportunity to target 
MYC protein stability using therapeutic approaches. The transactivating domain is 
subject to phosphorylation, acetylation, and ubiquitylation, which serve to regulate 
stability and binding interactions 49,58. Alterations in MYC and associated protein 
homeostatic pathway effectors are observed in human tumors, leading to the 
inappropriate post-translational processing and stability of the MYC oncoprotein.  
The facile development of kinase inhibitors warrants consideration of approaches to 
target MYC degradation, as MYC degradation is heavily influenced by serine and 
threonine phosphorylation. Biochemical and functional studies have established that 
phosphorylation of serine 62 (pSer62) by ERK pathway kinase activity stabilizes MYC 
and promotes proliferation. In contrast, phosphorylation of threonine 58 (pThr58) by 
GSK-3β destabilizes MYC.  Notably, mutations of Thr58 are observed in Burkitt’s 
lymphoma resulting in constitutive MYC stabilization. Thus, therapeutic approaches to 
MEK-ERK pathway inhibition, or efforts to inhibit GSK-3β such as inhibition of PI3K-AKT 
signaling, may favorably modulate MYC stability for therapeutic benefit.  This may be 
particularly true in tumors with upregulated MEK-ERK signaling (KRAS or EGFR 
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activated) or PTEN loss.  Table 1 lists exemplary compounds, which may be used as 
chemical probes of pathway function. 
 Opposing MYC phosphorylation at serine 62 is protein phosphatase 2 (PP2A), 
which functions as a heterotrimeric enzyme complex to indirectly and directly modulate 
MYC protein stability. The Sears group has demonstrated that pSer62 is a direct target 
of PP2A, supporting a model where PP2A loss (a common tumor suppressor loss in 
cancer) promotes MYC stability.  Presently, pharmaceutical compounds targeting PP2A 
do not exist.  However, in collaborative research with the laboratories of Thomas Look, 
Jon Aster and Hanno Steen, we recently discovered PP2A as the anti-proliferative 
target of perphenazine (and other phenothiazines), by ligand-affinity chromatography 
116. As small molecules targeting and activating tumor suppressors are rarely described, 
we are interested now to optimize these compounds for enhanced PP2A binding and 
activation, to destabilize MYC and modulate other critical PP2A target proteins. 
Recently, Eilers and colleagues reported a novel approach to destabilize MYCN via 
inhibition of Aurora A kinases 117.  MYCN is targeted for degradation by the FBXW7 
ubiquitin ligase.  MYCN protein stability is promoted by an interaction with the Aurora A 
mitotic kinase.  Though the kinase activity of AURKA is not required for MYCN protein 
stability, two ATP-competitive azepine inhibitors of AURKA (MLN-80545 and MLN-
8237) disrupted binding to MYCN. In mechanistic and translational experiments 
performed in MYCN-dependent neuroblastoma models, AURKA inhibition prompted 
MYCN degradation and an anti-proliferative effect. 
 A final opportunity for therapeutic targeting of MYC protein stability is presented 
by MYC-associated histone acetyltransferases.  Beyond their established role in 
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promoting chromatin remodeling, bromodomain recruitment and gene expression, 
acetylation of MYC by CBP/P300, GCN5 and TIP60 promotes MYC stability and 
transcriptional activity 58. As above, inhibition of these acetyltransferase enzymes may 
display favorable activity in cancer model systems, in support of further clinical 
development. 
MYC and Synthetic Lethality 
 MYC addicted cancer cells may harbor unique dependencies that a normal cell 
may not require. Such synthetic lethal interactions with MYC may prompt the 
development of context-specific inhibitors. Two kinase targets have been identified 
which are required for cell survival in the context of enforced MYC expression, Aurora 
kinase B 118 and Cdk1119. Inhibition of these kinases with cell-permeable small 
molecules has demonstrated compelling evidence of a leveraged anti-prolifeartive effect 
in MYC-dependent cancer models, albeit with a narrow therapeutic index.  Emerging 
research approaches using highly parallel reverse genetic screens (RNA interference; 
RNAi), has reinvigorated efforts to identify MYC-specific tumor dependencies. Recently, 
two laboratories performed RNAi screening in a MYC-dependent context leading to the 
suggestion of CSNK1e kinase 120 and the SAE1/2 SUMO-activating enzyme 121 as 
putative targets for the development of synthetic lethal small molecules. Rational 
approaches to synthetic lethality have included consideration of metabolic adaptation to 
MYC-mediated tumorigenesis. Observing therapy-associated cellular senescence in 
treated Eµ-MYC cells, Schmitt and colleagues targeted glucose uptake and autophagy 
with impressive anti-proliferative results 122.  Together, these studies establish a new 
path to MYC-specific therapeutic development, revealed by powerful new technologies 
 134 
 
and a detailed mechanistic understanding of MYC biology at the interface of 
transcription, translation and metabolism.  
Concluding Remarks 
 The centrality of MYC to the pathogenesis of cancer, illustrated in granular detail 
in the accompanying cited literature, demands the creativity and commitment of the 
allied fields of ligand discovery.  In this review, we provide a rationale for targeting MYC 
that balances high-risk, high-reward approaches of direct MYC:MAX modulation with 
near-term opportunities to approach MYC transcriptional signaling via chromatin-
dependent processes and pathways of protein homeostasis. Still, direct inhibition of 
MYC remains an elusive goal in cancer medicine––an inadequacy of current therapeutic 
science perhaps at the heart of our inability to eradicate this disease. 
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Introduction 
Diffuse Large B-Cell Lymphoma (DLBCL) is a biologically heterogeneous and 
clinically aggressive disease. Here, we explore the role of BET bromodomain proteins in 
DLBCL, using integrative chemical genetics and functional epigenomics. We observe 
highly asymmetric loading of BRD4 at enhancers, with approximately 33% of all BRD4 
localizing to enhancers at 1.6% of occupied genes. These super enhancers prove 
particularly sensitive to bromodomain inhibition, explaining the selective effect of BET 
inhibitors on oncogenic and lineage-specific transcriptional circuits. Functional study of 
genes marked by super enhancers in DLBCL cell lines and primary tumors leads to the 
identification of novel dependencies. Translational studies performed on a 
comprehensive panel of DLBCLs establish a therapeutic rationale for evaluating BET 
inhibitors in this disease.  
 Although oncogenic transcription factors underlie the pathophysiology and 
biological heterogeneity of DLBCL, studies of transcriptional co-activator proteins are 
limited in this disease. In this chemical genetic study, we demonstrate the efficacy of 
BET inhibition and characterize the broad function of BET bromodomains in supporting 
the transcriptional growth program in all subclasses of DLBCL, including co-activation of 
E2F and MYC target genes. We define an asymmetry in the localization of BRD4 to 
enhancer regions nearby oncogenic and master regulatory genes and expand the 
finding to a representative panel of cell lines and primary samples. This finding likely 
explains the specific transcriptional effect of BET inhibition which modulates the 
expression of master transcription factors that control B-cell fate and germinal center 
formation.  
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 The origins of this project came from a close collaboration between Michael 
McKeown (Bradner Lab) and Bjoern Chapuy (Shipp Lab). One of the most important 
questions that came out of the development of JQ1 was how it works to reduce 
proliferation in such a wide set of cancer backgrounds. Moreover, the heterogeneity of 
DLBCL has typically caused drugs to have varying effects based on the subtype was 
found to be conspicuously absent with JQ1. Therefore, we hypothesized that a deep 
study of the biology of JQ1 in DLBCL on the chromatin level would help to explain this 
effect. Our initial hypothesis that JQ1 was acting primarily through MYC and E2F1 
proved incorrect and had a mild, partial impact. The resultant validation of large 
enhancers, BRD4 loading asymmetry, and discovery of novel dependencies is detailed 
below. 
Originally, a large, exploratory cell screening effort involving forty experimental 
oncology compounds and sixty cell lines composed of DLCBL, Hodgkin’s Lymphoma, 
and Burkitt’s Lymphoma was run (data not shown). The paper in Cancer Cell1 from 
which this chapter is derived contains a subset of that data. Methods and operation of 
screening equipment including the Biotech EL406 liquid handler, Envision plate reader, 
and Janus pin transfer system were developed and executed by McKeown. In order to 
carry this out, optimized plate designs, cell loading volumes and concentrations, 
equipment protocols and programs, and data processing methods were developed. This 
amount of screening required large amounts of cells which were expanded and cared 
for by Chapuy and McKeown. 
 The mouse studies were carried out at the DFCI Lurie Center. However, 
processing of mice for pharmacodynamics measurements were carried out by Chapuy 
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and McKeown at the termination of these experiments. McKeown assisted with 
dissections by weighing spleens and prepping them for flow cytometry. In addition, 
McKeown prepped samples for histology and processed images in ImageScope and 
ScanScope software to prepare images. 
 The expansion of cells, treatment, and preparation for ChIP-seq was carried out 
by McKeown following a modified Agilent protocol. Methods for performing primary 
tissue ChIP-seq on human tissue were developed by McKeown as these had not 
previously been executed in the Bradner Lab. The concept of Super-Enhancers 
originated in experiment being carried out in the Young lab2 and Bradner lab1 at 
overlapping time frames. McKeown surveyed known oncogenes in DLBCL by viewing 
gene tracks and noted large enhancer regions in their proximity. This was found to 
agree with the Young lab findings in Multiple Myeloma. Charles Lin then developed 
metrics and analyses for genome wide characterization. 
 Based on the initial findings in cell lines, we expanded our search to look at 
primary tissues and confirmed the presence of Super-Enhancers here as well. 
Furthermore, the well transcriptionally characterized sub-types of DLBCL were 
hypothesized to correlate with enhancer placement, which ultimately proved accurate 
and allowed correct segregation of subtype by enhancer loci. Tracks and graphs used in 
figures for ChIP-seq data were prepared by Lin and McKeown. 
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Background 
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-
Hodgkin lymphoma in adults. The majority of DLBCLs arise from antigen-exposed B-
cells during the germinal center (GC) reaction, a process that optimizes the affinity of 
antibodies for antigens 3. Despite significant advances in the biological understanding of 
DLBCL pathogenesis, current treatment regimens include empiric combination 
immuno/chemotherapy at induction and relapse. Mechanistic insights guiding the 
development of targeted therapeutic agents are urgently needed, as relapsed and 
refractory disease comprise significant unmet medical needs 4. 
 
DLBCL exhibits significant biological heterogeneity. Gene expression profiling 
has allowed functional classification of tumors into distinct subgroups. Presently, DLBCL 
is described using two transcriptional classifications, commonly referred to as the cell of 
origin (COO) and the consensus clustering classification (CCC). The COO classification 
relates subsets of DLBCL to specific stages of normal B-cell development, assigning 
tumors to either a germinal center-B (GCB) or activated B-cell (ABC) subtype 5. The 
CCC classification defines 3 groups of DLBCLs on the basis of transcriptional 
heterogeneity solely within tumors. Here, DLBCL subtypes rely on B-cell receptor (BCR) 
survival signals and glycolysis (BCR), BCR-independent fuel utilization and oxidative 
phosphorylation (OxPhos), or exhibit an increased inflammatory and immune cell 
infiltrate (host response; HR) 6-8. Both classifications provide insights into disease 
pathogenesis and suggest potential tumor cell dependencies and rational therapeutic 
targets.  
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Several genome sequencing studies of DLBCL have revealed substantial genetic 
heterogeneity and defined the mutational landscape 9-12. In contrast to Burkitt 
lymphoma, another germinal center-derived tumor characterized by a hallmark t(8;14) 
translocation of MYC into the immunoglobulin heavy or light chain enhancer region, 
DLBCLs have high genotypic diversity. These tumors exhibit multiple low frequency 
copy number alterations (CNAs), additional chromosomal translocations and over 50 
recurrent somatic mutations 9,10,13. In DLBCL, the underlying biological and genetic 
heterogeneity are associated with highly variable clinical outcomes, ranging from long-
term overall survival (“cure”) to rapidly progressive disease 13.  
 
Mechanistically, the transcriptional heterogeneity of DLBCL is conferred, in part, 
by pathologic activation or inactivation of lineage-specific and growth-associated master 
regulatory 5, BCL6 14, MYC 15 and p53 13, and 
also through upstream pathway deregulation. Recently, we demonstrated that multiple, 
low-frequency CNAs converge functionally to deregulate p53 and cell cycle resulting in 
increased proliferation and enhanced signaling from the master regulatory transcription 
factor, E2F1 13. In this study, deregulated cell cycle and increased expression of E2F1 
target genes were associated with inferior outcome 13. In recent studies, a newly defined 
subset of “double-hit” DLBCLs which overexpress MYC in association with BCL2 also 
have an unfavorable outcome 16,17. Together, these findings underscore the centrality of 
master regulatory TFs in DLBCL.  
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TFs control cancer cell state by binding proximal (promoter) and distal 
(enhancer) regulatory elements 18. The subsequent recruitment of multiprotein 
complexes leads to local remodeling of chromatin, which establishes mitotic memory, 
and transmission of transcriptional signals to RNA polymerase II (RNAP) poised at 
genes associated with growth and survival 19,20. Chromatin associated with TF binding 
sites is markedly enriched in histone proteins post-translationally modified by lysine 
side-chain acetylation 21. This mark biophysically facilitates opening of chromatin and 
recruits an emerging class of co-activators which recognize ε-acetyl lysine through a 
specialized recognition motif or bromodomain 22. 
 
Among the 47 known bromodomain-containing proteins 23, the sub-family of 
bromodomain and extra-terminal domain (BET) co-activators (BRD2, BRD3 and BRD4) 
are particularly appealing targets in DLBCL.  Structurally, BET proteins possess twin 
amino-terminal bromodomains that facilitate binding to hyperacetylated 
promoter/enhancer regions 23,24, as well as a distal carboxy-terminal binding site for the 
positive transcription elongation factor (P-TEFb) 25. In cancer, BET bromodomains 
promote M to G1 cell cycle progression 26 and contribute to mitotic memory 27,28. 
Collaborative research from our group and others has recently identified a role for BET 
bromodomains in supporting the transcription of known DLBCL oncogenes (MYC and 
BCL2) in studies of acute leukemia, multiple myeloma and Burkitt lymphoma 29-33. 
Interestingly, overexpression of BRD2 from an engineered immunoglobulin heavy-chain 
promoter-enhancer construct caused an aggressive B-cell neoplasm resembling DLBCL 
in mice 34.  Together, the findings establish a compelling hypothesis that BET 
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bromodomains serve as chromatin-associated modulators of major gene regulatory 
pathways in DLBCL.  
 
In an effort to study the role of BET bromodomains in cancer, we recently 
developed the first inhibitors of bromodomain and extra-terminal domain (BET) 
transcriptional co-activator proteins 35 including a prototypical triazolo-diazepine inhibitor 
of the acetyl-lysine binding site, JQ1. Here, we report first, detailed and genomewide 
mechanistic studies exploring the role of BET bromodomains in oncogenic transcription 
by master regulatory TFs, and an assessment of BRD4 as a therapeutic target in 
DLBCL. 
 
BET bromodomain inhibition exerts pan-subtype growth arrest in DLBCL and in 
Burkitt lymphoma (BL) 
To assess the role of BET bromodomains as cancer cell dependencies in 
DLBCL, we first studied the effects of four structurally dissimilar BET bromodomain 
inhibitors on a comprehensive panel of 34 human lymphoma cell lines (21 DLBCL, 
capturing all transcriptionally defined subtypes, 6 BL and 7 Hodgkin Lymphoma [HL]), in 
comparative high-throughput format. In addition to the prototypical BET inhibitor, JQ1 
(JQ1S) 35, we resynthesized and tested an analogous thienodiazepine from Mitsubishi-
Tanabe Pharmaceutical Corportation (Y803, OTX015; Oncoethix SA) which was 
developed for inflammatory bowel disease, (Figure 4.1A 36, a benzodiazepine inhibitor 
(iBET) 37 and a dimethylisoxazole inhibitor (iBET-151) from GlaxoSmithKline 29. 
Analyses of cellular proliferation at 72 hr revealed a potent (nanomolar) class effect of 
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BET bromodomain inhibitors on the DLBCL and BL cell lines irrespective of subtype and 
the lack of effect of an inactive enantiomer, (JQ1R; Figure 4.1A). The HL cell lines were 
comparatively less sensitive to BET inhibition and HL line, L428, was resistant to all 4 
compounds.  
 
The effects of BET inhibition on growth over time, cell cycle progression, and apoptosis 
were then studied in a representative panel of nine DLBCL cell lines, using the L428 HL 
line as a negative control (Figure 4.1B-C; 4.2B-C). BET inhibition with JQ1 significantly 
attenuated growth in a dose-responsive manner in all tested DLBCL cell lines (Figure 
4.1B).  In three representative DLBCL cell lines, genetic depletion of BRD2 or BRD4 
similarly decreased DLBCL proliferation, consistent with an on target effect of JQ1 
(Figure 4.2D-G). We observed a profound S phase and G2 peak reduction following 
JQ1 treatment consistent with a G1 cell cycle arrest (Figure 4.1C, 4.2B). BET inhibition 
(500 nM) did not induce apoptosis in most cell lines studied, evidenced by low 
AnnexinV/7AAD staining (Figure 4.2C) and absence of a sub-G1 peak (Figure 4.1C). 
Neither enantiomeric (JQ1R) nor vehicle (DMSO) controls affected DLBCL proliferation 
or survival (Figure 4.1C; 4.2B-C). Treatment with 500 nM JQ1 was similarly cytostatic in 
Burkitt lymphoma cell lines (Figure 4.2C). The L428 HL cell line was resistant to BET 
inhibition in all tested assays.  
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Figure 4.1: In vitro analyses of BET Bromodomain inhibition in various B-cell lymphomas 
(A) Hierarchical clustering of mean EC50s of the four BET inhibitors (72 hr treatment) in the indicated 
panel of B-cell lymphoma cell lines. EC50 values in a colorimetric scale: very sensitive (≤1µM) in red; 
sensitive (=1µM) in white; to resistant (≥10µM) in black. Corresponding structures are shown. (B) 
Proliferation of the indicated DLBCL and HL cell lines treated with vehicle or 250-1000 nM JQ1 for 1-4 
days. (C) Cell cycle analysis following 72 hr treatment with JQ1 (500 nM) or inactive enantiomer JQ1R 
(500 nM). Error bars represent the SD of triplicates. (D) Bioluminescence of JQ1 (30mg/kg IP BID) or 
vehicle-treated NSG mice xenotransplanted with luciferized mCherry+ Ly1 cells. Asterisks indicate p < .05 
using a one-sided t-test. Error bars represent SEM. (E) Lymphoma infiltration of bone marrow in a 
representative set of animals was assessed by flow cytometric analysis of  mCherry+ cells and visualized 
as scatter plots (median, line; whiskers, SEM). p values were obtained with a one-sided Mann-Whitney U 
test. (F) Immunohistochemical analysis of lymphoma (Ly1) BM infiltration in JQ1- and in vehicle-treated 
mice: H&E; anti-human CD20, and anti- -
Meier plot of the remainder of the Ly1 cohort (n = 21) treated with either vehicle or JQ1 30 mg/kg bid. The 
p value was obtained by Log-rank test.  
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Figure 4.1 (Continued) 
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Efficacy of BET inhibition in DLBCL xenograft models 
We next explored the therapeutic potential of BET inhibition in two independent DLBCL 
xenotransplantation models (Figure 4.1D-G; 4.2H-K). First, the human DLBCL cell line 
Ly1 was engineered to ectopically express firefly luciferase and mCherry allowing 
surrogate measurement of tumor growth in vivo. NOD SCID Il2rγnull (NSG) mice 
xenotransplanted with Ly1-Luc-mCherry cells had a statistically significant reduction in 
tumor burden when treated with JQ1 (30 mg BID by intraperitoneal (IP) injection; Figure 
4.1D). A representative cohort of animals was sacrificed on day 13 of treatment for full 
hematological analysis. JQ1-treated animals had significantly decreased lymphoma 
infiltration of the bone marrow (BM) as measured by flow cytometric assessment of 
mCherry+ cells (Figure 4.1E). Morphological and immunohistochemical analyses 
revealed that the highly proliferative (Ki67+) human CD20+ lymphoma cell infiltrate 
(Figure 4.1F, upper panel) was markedly reduced in animals treated with the BET 
bromodomain inhibitor (Figure 4.1F, lower panel). In the remainder of the Ly1 xenograft 
cohort, the JQ1-treated mice had a significant median overall survival advantage of 9 
days (p = 0.003) (Figure 4.1G). 
 
  
 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Dose response curves of OTX015 (Y803) and JQ1S in vitro, assessment of apoptosis in 
JQ1-treated lymphoma cell lines and proliferation in BRD2- and BRD4-depleted DLBCLs in three 
representative DLBCL cell lines and an additional xenograft model of JQ1 treatment. 
 (A) Potency of the Mitsubishi BET bromodomain inhibitor Y803 (licensed as OTX015), visualized in a 
dose-response curve. The competition assay uses AlphaScreen beads to observe the inhibited binding of 
bromodomain 2, 3, 4, and T site 1 against biotinylated acety-histone 4 tail in the presence of Y803 in a 
dose-dependent manner. Non-linear regressions were fit to the mean of four replicates over ten 
concentrations with the standard deviation at each point indicated by error bars. JQ1 was used as 
positive control. (B) Assessment of cell cycle following 72 hours of treatment with either 500nM of the 
active enantiomer, JQ1S, 500nM of the inactive enantiomer, JQ1R, or vehicle control (DMSO). (C) 
Apoptosis assessment by Annexin V-APC/7AAD staining in nine DLBCL, one Hodgkin lymphoma (L428) 
and two Burkitt lymphoma cell lines, Raji and CA46, following 72 hr of treatment with vehicle (DMSO), 
500nM active JQ1S or 500nM of the inactive enantiomer JQ1R.  (D/E) Assessment of proliferation 
following lentiviral-mediated knock down of BRD2 (D), and BRD4 (E) with two independent hairpins (sh1 
and sh2) and a control (ev=empty vector) in representative DLBCL cell lines for each transcriptional-
defined subtype (Ly1, BCR/GCB; Toledo, OxPhos/unclass.; HBL1, BCR/ABC). (F/G) Efficacy of 
knockdown of BRD2 (F) and BRD4 (G) was determined by immunoblot. Membranes were stripped and 
re-probed with GAPDH as loading control. (H) Bioluminescence of JQ1 (30mg/kg IP BID)- or vehicle-
treated NSG mice xenotransplanted with luciferized mCherry+ Toledo cells. Asterisks indicate p < .05 
using a one-sided t-test. Error bars represent SEM. (I) Spleen weights of JQ1- and vehicle-treated 
animals xenografted with Toledo cells are visualized as scatter plots (median, line; whiskers SEM). The p 
values were obtained with a one-sided Mann-Whitney U test. (J) Lymphoma infiltration of animals was 
assessed by by flow cytometric analysis of mCherry+ cells and visualized as scatter plots (median, line; 
whiskers, SEM). The p values were obtained with a one-sided Mann-Whitney U test. (K) 
Immunohistochemical analysis of lymphoma (Toledo) cell infiltration in BM of JQ1 and DMSO-treated 
mice was assessed in JQ1- and in vehicle-treated mice: H&E; anti-human CD20, and anti-Ki67 
immunostaining. Scale bar represents 100 µm.  
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Figure 4.2 (Continued) 
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Figure 4.2 (Continued) 
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To confirm the pharmacodynamic findings, a second xenotransplantation model 
was established using the Toledo DLBCL cell line. NSG mice with established tumors 
had delayed tumor progression when treated with JQ1 (Figure 4.2H).  Full 
hematological analysis revealed that JQ1-treated animals had decreased spleen weight 
(Figure 4.2I) and lymphomatous infiltration of bone marrow and spleen (Figure 4.2J). 
Morphological and immunohistochemical analysis of the BM revealed significantly 
reduced the infiltration of CD20+/Ki67+ human lymphoma cells following BET inhibition 
(Figure 4.2K).  
 
BET inhibition downregulates oncogenic transcriptional pathways  
To gain insights into the transcriptional pathways regulated by BET bromodomain co-
activator proteins, we performed kinetic transcriptional profiling of vehicle and JQ1-
treated DLBCL cell lines. Five human DLBCL cell lines which captured the recognized 
transcriptional heterogeneity (Ly1, BCR/GCB; DHL6, BCR/GCB; Ly4, OxPhos/unclass.; 
Toledo, OxPhos/unclass; and HBL1, BCR/ABC) were treated with JQ1 (500 nM) or 
vehicle control for 0, 2, 6, 12, 24, 48 hours.  At each timepoint, differential analysis was 
performed between the vehicle and JQ1-treated samples (24 hr comparison, fold 
change (FC) > 1.3, false discovery rate (FDR) < 0.01, Figure 4.3A). Consistent with 
prior studies of BET bromodomain function and inhibition, HEXIM1 was markedly 
upregulated by JQ1 in all DLBCL cell lines (Figure 4.3B) 38,39. 
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Figure 4.3: Transcriptional modulation of TLR pathway members and BCR signaling pathway 
components following BET inhibition, pathway enrichment analysis in COO subtypes, transcript 
and protein abundance of MYC and E2F1 following JQ1 treatment, transcription factor binding site 
enrichment in COO subtypes and MYC rescue experiments following JQ1 treatment. 
(A) Heatmap of the most differentially expressed genes (FDR < 0.01, FC > 1.3) following 24 hr treatment 
with 500 nM JQ1 or vehicle. TLR10 and HEXIM1 are highlighted as representative genes. (B) Mean 
transcript abundance of HEXIM1 in all 5 lines treated with vehicle or JQ1 (500 nM) over time. (C) Heat 
map of TLR pathway components in vehicle- or JQ1-treated DLBCL cell lines over time (0 – 48hr). The 
row order is derived from unsupervised clustering in Ly1 cells and fixed across the remaining cell lines. 
(D) Heat map of BCR signaling pathway components in vehicle- or JQ1-treated DLBCL cell lines over 
time (0 – 48 hr). (E) Hyperenrichment analysis of differentially expressed genes (FDR < 0.05, FC > 1.3) in 
2 GCB cell lines (DHL6, Ly1) treated with JQ1 (vs. vehicle) was performed using a pathway compendium 
(MSigDB, C2.CP). Results at each time point were ranked by FDR and visualized as a color-coded 
matrix. Intensity of color correlates with FDR significance levels as indicated. Highlighted down-regulated 
pathways included: MYD88/TLR signaling, blue; BCR signaling, green; and Cell cycle/E2F, turquoise). (F) 
Visualization of pathway enrichment analysis of differentially expressed genes (FDR < 0.05, FC > 1.3) in 
HBL1, an ABC cell line. See legend to (E) for details. (G) Transcription factor binding site motifs were 
analyzed in the most differentially expressed genes (FDR < 0.05, FC > 1.3) in 2 GCB  (DHL6, Ly1) cell 
lines. Results at each timepoint were ranked using a color-coded matrix. Up-regulated motifs in red, 
down-regulated motifs in blue. Genes with MYC binding sites in blue and E2F binding sites in turquoise. 
(H) Transcription factor binding site motifs were analyzed in the most differentially expressed genes (FDR 
< 0.05, FC > 1.3) in one ABC (HBL1) cell line.  (I) GSEA plots of functionally defined MYC and E2F target 
gene sets in two vehicle- vs. JQ1-treated GCB cells (DHL6, Ly1) at 24 hr. (J) GSEA plots of functionally 
defined MYC and E2F target gene sets in one vehicle- vs. JQ1-treated ABC cell (HBL1) at 24 hr. (K-N) 
Mean transcript abundance of MYC (K) and E2F1 (M) in all 5 DLBCL cell lines following JQ1 (red) or 
DMSO (black curve) treatment is plotted over time. Error bars represent SEM. Protein abundance of MYC 
(L) and E2F1 (N) was determined by western blot (Figure 4.2G), quantified using Image J 
(http://rsb.info.nih.gov/ij/, 40), and normalized to the quantified GAPDH signal. (O) Enforced expression of 
MYC in the three indicated DLBCL cell lines, Ly1, Toledo and HBL1, was not able to rescue JQ1-
mediated proliferation inhibition. Proliferation was compared to enforced expression of a control insert, 
GFP, in the same vector. (P) Immunoblot analysis of the cell lines from (O) with enforced expression of 
either MYC or GFP. (Q) Quantification of protein abundance of (P) with ImageJ, see (K) for details.  
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Figure 4.3 (Continued) 
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Figure 4.3 (Continued) 
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Figure 4.3 (Continued) 
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The most differentially expressed genes were assessed for pathway enrichment 
using a comprehensive pathway compendium (C2, CP; MSigDB 3.0) and each 
timepoint was ranked by FDR and visualized as a color-coded matrix (Figure 4.4A). We 
observed the early downregulation of MYD88/toll-like receptor (TLR) pathway 
components following JQ1 treatment, including TLR10 and MYD88 (Figure 4.3C; 4.4A-
C). These data are consistent with previous studies in which the anti-inflammatory effect 
of BET inhibition in normal B cells was attributed to TLR pathway downregulation 37. In 
the JQ1-treated DLBCL cell lines, we also observed downregulation of multiple 
components of the BCR signaling pathway, E2F transcriptional targets and additional 
cell cycle transition gene sets (Figure 4.3D; 4.4A). Similar results were obtained when 
GCB and ABC DLBCL cell lines were analyzed separately (Figure 4.3E-F). 
 
BET inhibition modulates MYC and E2F target gene transcription  
Cell state transitions are influenced by the function of specific regulatory TFs. To 
identify candidate TFs associated with BET bromodomain co-activators, we assessed 
the effects of JQ1 on sets of genes with common TF binding motifs (C3, MSigDB 3.0). 
The differentially expressed genes in vehicle vs. JQ1-treated DLBCL cell lines were 
tested for enrichment of candidate TF targets at 2 to 48 hr. Results at each timepoint 
were ranked by FDR and visualized as a color-coded matrix (Figure 4.4D).  
 
Of interest, gene sets with MYC and E2F binding motifs were significantly 
downregulated following JQ1 treatment (Figure 4.4D). To further evaluate the effects of 
BET bromodomain inhibition on MYC and E2F transcriptional programs, we used  
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Figure 4.4: Transcriptional response to BET inhibition in representative DLBCL cell lines    
(A) Hyperenrichment analysis of differentially expressed genes in all 5 lines (FDR < 0.01, FC > 1.3) 
following 24 hr of treatment with 500 nM JQ1 or vehicle was performed using a pathway compendium 
(MSigDB, C2.CP). Results at each timepoint were ranked by FDR and visualized as a color-coded matrix. 
Upregulated motifs in red, downregulated motifs in blue. Intensity of color correlates with FDR 
significance levels. Highlighted pathways included: Toll-like receptor MYD88, blue; BCR signaling, green; 
and Cell cycle/E2F, cyan. (B) Mean transcript abundance of TLR10 in all 5 lines (left) and MYD88 (right). 
(C) Heatmap of TLR pathway components in vehicle- or JQ1-treated DLBCLs (all 5 lines, 24 hr). (D) The 
most differentially expressed genes (FDR < 0.01, FC > 1.3) were analyzed for common transcription 
factor binding sites in the regulatory region using the MSigDB.C3 compendium. Results at each timepoint 
were ranked using a color-coded matrix as in (A). Genes with MYC binding sites in green and E2F 
binding sites in cyan. (E) GSEA of multiple functionally defined MYC and E2F transcription factor targets 
was performed. Results are reported over time in a color-coded matrix with color intensity reflecting 
significance level. (F) GSEA plots of functionally defined MYC and E2F target gene sets in vehicle- vs. 
Q1-treated cells (24 hr). (G) Protein abundance of MYC and E2F in the indicated DLBCL lines treated 
with vehicle or JQ1S or JQ1R (500 nm) (24 hr).  
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Figure 4.4 (Continued) 
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multiple functionally validated MYC and E2F target gene sets to perform directed 
pathway analyses. Following JQ1 treatment, there was highly significant early 
downregulation of well defined and functionally validated MYC and E2F target gene sets 
(Figure 4.4E-F). In complementary studies, we performed gene set enrichment analyses 
(GSEA) of multiple independent MYC and E2F target gene sets in vehicle versus JQ1-
treated samples and found that MYC and E2F targets were significantly less abundant 
in JQ1-treated cells (Figure 4.3G-J; 4.4F). 
 
BET bromodomain proteins may function as co-activators of the MYC and E2F 
proteins and/or direct modulators of MYC and E2F expression. To distinguish between 
these possibilities, we assessed the transcript abundance and protein levels of MYC 
and E2F in vehicle and JQ1-treated DLBCLs. BET bromodomain inhibition resulted in 
an apparent decrease in MYC transcripts and protein in each of the DLBCL cell lines 
(Figure 4.3K-L; 4.4G) suggesting that BET bromodomains directly modulate MYC 
transcription. In contrast, in 4 of 5 cell lines, JQ1 treatment did not measurably alter 
E2F1 transcript or protein abundance over 24 hrs (Figure 4.3M-N; 4.4G). These data 
suggest that BET bromodomains may function at regulatory elements at E2F1 target 
genes, rather than by influencing the abundance of E2F1 itself. 
 
BET bromodomains as promoter-bound co-activators of E2F1-dependent 
transcription 
The consequences of MYC downregulation following BET inhibition have been 
characterized by our group and others in hematologic malignancies 29-32. However, 
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ectopic  expression of MYC failed to rescue DLBCL cell lines from the anti-proliferative 
effects of JQ1 (Figure 4.3O-Q). 
 
We next explored the role of BETs as co-activators of oncogenic E2F1. To 
further understand the role of BET bromodomains in oncogenic E2F transcriptional 
signaling, we performed chromatin immunoprecipitation with next-generation DNA 
sequencing (ChIP-Seq), using a chemical genetic approach. We selected Ly1 cells for 
mechanistic consideration owing to the robust downregulation of E2F target genes in 
the transcriptional profiling (Figure 4.5A) and the lack of effect of JQ1 on E2F1 protein 
expression (Figure 4.4G). Changes in BET localization, chromatin structure and RNA 
polymerase function were studied in Ly1 cells treated with JQ1 (500 nM) or vehicle 
control.  
 
First, we established a chromatin landscape for Ly1 using H3K4me3 to identify 
promoters, H3K27ac to reveal enhancers and H3K27me3 to define repressive regions 
of the genome. Then, we assessed the genome-wide localization of E2F1 and the 
representative BET protein, BRD4, also by ChIP-seq using the respective antibodies. 
Rank-ordering of all transcriptionally active promoters based on H3K4me3 enrichment 
and RNA Pol II occupancy identifies pervasive binding of BRD4 and E2F1 to active 
promoter elements (Figure 6A). Analysis of enrichment data as a metagene of all active 
promoters centered on the transcription start site reveals spatial colocalization of E2F1 
and BRD4 at all transcriptionally active promoters (Figure 4.6B). 
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Figure 4.5: Visualization of leading edge E2F1-target genes in all cell lines and knockdown of E2F1 
in representative DLBCL cell lines.  
(A) Heat map of leading edge genes from the E2F target GSEA (Figure 4.5E, top panel) in all five vehicle- 
or JQ1-treated DLBCL cell lines over time. See also legend of Figure 4.5. (B) Assessment of proliferation 
of three representative cell DLBCL cell lines (Ly1, BCR/GCB; Toledo, OxPhos/unclass.; HBL1, BCR/ABC) 
following lentiviral-mediated knockdown of E2F1 with two independent hairpins (shE2F1-#1 and shE2F1-
#2) and a control hairpin (ev = empty vector). (C) Immunoblot of E2F1 of cells in (B) to demonstrate 
knockdown efficiency. 
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Figure 4.5 (Continued) 
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Figure 4.5 (Continued) 
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To understand the mechanism of BET inhibition on E2F1 target gene 
transcription, we assessed the effect of bromodomain inhibition on transcriptional 
elongation. As BRD4 is reported to recruit the positive transcription elongation factor 
complex (pTEFB) to prompt release of initiated but paused RNA Pol II 41, the 
colocalization of BRD4 and E2F1 at active promoters suggested a positive role of BRD4 
in facilitating elongation at E2F1-driven genes. ChIP-Seq for E2F1 allowed the 
annotation of an E2F1 target gene set, based on the top promoter-bound genes in Ly1 
cells. We then assessed the effect of BET inhibition on transcriptional pause release, by 
deriving traveling ratios for the top E2F1 target genes with or without JQ1 treatment, 
compared to a control gene set of non-E2F1 targets. The travel ratio is a genomewide 
measurement of pausing based on the gene-by-gene ratio of promoter to elongating 
RNA Pol II. We observed a statistically significant reduction of transcriptional elongation 
with JQ1 treatment, limited only to E2F1 target genes (Figure 4.6C).   
 
We next created a gene set of the top 100 ChIP-Seq defined E2F1 targets) and 
performed GSEA in Ly1 and additional DLBCL cell lines, DHL6, Ly4, Toledo, and HBL1. 
JQ1 treatment significantly decreased the transcript abundance of our functionally 
defined E2F1 targets at 24 hr and 48 hr in all cell lines studied (Figure 4.6D [GSEA] and 
E [heatmap]).  
 
These data demonstrate that JQ1 treatment results in a defect in elongating RNA 
Pol II at E2F1 target genes, which is in agreement with the downregulation of E2F target 
genes (Figure 4.6D-E) and the G1 arrest (Figure 4.1B-C). In addition, these data define  
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Figure 4.6: Co-localization and function of BRD4 and E2F1 at active promoters 
(A) Heatmap of CHIP-Seq reads for RNA Pol II (transcriptionally active; black), H3K4me3 (green), BRD4 
(red), and E2F1 (blue) rank ordered from high to low RNA Pol II occupancy centered on a ±5kb window 
around the transcriptional start site (TSS) of all transcriptionally active promoters. Color density reflects 
enrichment; white indicates no enrichment. (B) Metagenes created from normalized genome-wide 
average of reads for designated factors centered on a ±2kb window around the TSS. Note the co-
occupancy of BRD4 and E2F1 at the TSS. (C) RNA Pol II traveling ratio (TR) plots for E2F1 target genes 
(top panel) and non-target genes (bottom panel) following JQ1 (red) or DMSO (black) treatment. E2F1 
targets and non-targets are defined by the 500 genes having the most or least E2F1 occupation at 
promoters. Increased TR values on x-axis indicate a higher ratio of paused promoter to elongating RNA 
Pol II. 24 hr of 500nM JQ1 treatment leads to statistically significant pause defects of E2F1 targets 
compared to non-targets. p values derived from a Welch’s two-tailed t-test. (D) GSEA plots of a ChIP-Seq 
defined E2F1 target gene set in the 5 DLBCL cell lines treated with vehicle vs. JQ1 for 24 and 48 hr.  (E) 
Heatmap of leading edge genes from the E2F target GSEA (D) in Ly1 cells treated with JQ1 or DMSO (24 
hr). (F) Assessment of proliferation in Ly1 cell line following genetic depletion of E2F1 with two 
independent hairpins and a control hairpin (ev). Error bars represent SD, and asterisks show p<0.01 by a 
two-sided Student’s t-test. (G) Immunoblot of E2F1 of cells in (F) to demonstrate knockdown efficiency.  
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Figure 4.6 (Continued) 
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BRD4 functionally as an E2F1 co-activator protein in DLBCL. The E2F1 dependency of 
these DLBCL cell lines was previously reported 13, but was further validated by genetic 
depletion in three representative cell lines (Figure 4.5B-C; 4.6F), suggesting that JQ1 
disrupts the co-activator role of BETs for E2F1 signaling. 
 
Disproportionate binding of BRD4 to overloaded enhancers 
To date, studies of BET bromodomains have mainly focused on effects at 
promoter regions of the genome. Our research in multiple myeloma (MM) identified a 
role for BRD4 in enforcing MYC transcription from the translocated IgH enhancer 
locus30. As oncogenic TFs may signal to RNA Pol II through distal enhancer elements, 
we sought to characterize the genome-wide localization of BRD4 to enhancers in 
DLBCL. Rank-ordering of enhancer regions by H3K27ac enrichment reveals that BRD4 
binds to the vast majority of active enhancers in the Ly1 DLBCL genome (Figure 4.7A, 
blue and red tracks). Given the established role of BCL6 in the pathogenesis of DLBCL, 
we also documented genome-wide co-localization of BRD4 and BCL6 at H3K27ac-
defined enhancers (Figure 4.7A, orange tracks). A metagene for active enhancers 
illustrates focal, superimposable enrichment for BRD4 with H3K27ac (Figure 4.7B). The 
correlation between BRD4 occupancy and H3K27 acetylation is extremely strong 
genome-wide, with 79.1% of H3K27ac regions containing BRD4 and 92.2% of all 
chromatin-bound BRD4 occurring in regions marked by H3K27ac (Figure 4.7C). 
Genome-wide binding data for BRD4 reveal that BRD4 is most commonly associated 
with enhancer regions, defined by the presence of H3K27ac and absence of H3K4me3 
(Figure 4.7D).  
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Figure 4.7: Asymmetric BRD4 loading at enhancer elements of actively transcribed genes  
(A) Heatmap of CHIP-Seq binding for H3K27ac (blue), BRD4 (red), and BCL6 (orange) rank ordered from 
high to low H3K27 occupancy centered on a ±5kb window around enhancers. Color density reflects 
enrichment, white indicating no enrichment. (B) Metagenes created from normalized genome-wide 
average of reads for designated factors centered on a ±4kb window around the enhancers.  (C) Venn 
diagram of BRD4-binding and H3K27ac occupancy. 79.1% of H3K27ac regions contain BRD4 and 92.2% 
of all chromatin-bound BRD4 occurs within H3K27ac regions. (D) Pie chart of BRD4 binding to regions of 
the genome. BRD4 colocalization with H3K27ac without H3K4me3 defined as enhancer-bound (red); 
BRD4 colocalization with H3K4me3 reported as promoter-bound (grey); remaining genomic regions in 
“other” (black). (E) BRD4 loading/binding across enhancers of 18330 genes. 1.6% (285/18330) of 
enhancers contain 32 % of all enhancer-bound BRD4, with super-loading defined as surpassing the 
inflection point. Top BRD4-superloaded enhancers are indicated. (F) Mean transcript abundance of the 
genes associated with the 285 most and least BRD4-loaded enhancers (left and right panel, respectively) 
in 5 DLBCL cell lines treated with vehicle or JQ1 (2–24 hr).  The p-values are obtained using a two-sided 
Mann-Whitney U test. 
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Figure 4.7 (Continued) 
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As predicted, BRD4 load is asymmetrically distributed throughout the genome at 
enhancer sites.  Completely unexpected is the magnitude by which BRD4 load varies 
among active enhancer regions (Figure 4.7E). Only a small subset of BRD-loaded 
enhancers, 285/18330 (1.6%), account for 32% of all of the BRD4 enhancer binding in 
the cell (Figure 4.7E). The BRD4-loaded enhancers in the Ly1 DLBCL cell line are 
considerably larger than typical enhancer elements resembling the super-enhancers we 
recently described with Richard Young 2.  
 
Notably, the top two gene loci with BRD4-loaded enhancers, POU2AF1 (which 
encodes the OCA-B transcriptional co-activator protein) and BCL6 and additional genes 
with disproportionally BRD4-loaded enhancers, PAX5 and IRF8 (Figure 4.7E), are 
essential for B-cell fate determination and germinal center formation 3,14,42,43. In fact, 
mice with genetic ablation of OCA-B, BCL6, PAX5 or IRF8 lack the ability to form 
germinal centers, the physiological structures from which most DLBCLs arise 42-46. 
Additionally, BRD4-superloaded enhancers are found adjacent to known oncogenes 
relevant to DLBCL biology, such as CD79B and MYC (Figure 4.8A-B).  
 
Therefore, BRD4 is predominantly an enhancer-associated factor which 
distributes throughout DLBCL euchromatin in a highly asymmetric manner, adjacent to 
known oncogenes and lineage-specific transcription factors (Figure 4.7E). BET 
bromodomain inhibition selectively decreased the transcript abundance of the 285 
genes with the most BRD4-loaded super enhancers, in contrast to the 285 genes with  
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Figure 4.8: Modulation of BRD4 loading at CD79B and MYC enhancers following JQ1 treatment.  
ChIP-Seq binding density for H3K27ac (blue), and BRD4 (red) at the enhancer of CD79B (A) and MYC 
(B) with JQ1 (+) or DMSO (-). JQ1 treatment significantly reduced BRD4 occupancy at the enhancer 
element of both genes. ChIP-Seq reads at both gene promoters for RNA Pol II (black) and H3K4me3 
(green) following JQ1 (+) or DMSO (-) treatment. (C) Mean transcript abundance of the genes associated 
with all most and least H3K27ac-loaded enhancers in Ly1 treated with vehicle or JQ1 (12 and 24 hr).  The 
p values are obtained using a two-sided Mann-Whitney U test. See also Tab. S4, Fig. S4 and Tab. 4. 
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the least BRD4-loaded enhancers (Figure 4.7F). Similar results were obtained using 
H3K27ac as a surrogate enhancer mark (Figure 4.8C) Taken together, these data 
strongly suggest that BRD4 loading of select DLBCL enhancers determines the 
magnitude of the transcriptional effect of BET inhibition.  
 
JQ1 targets the POU2AF1 super enhancer and decreases OCA-B expression and 
activity 
The POU2AF1 locus emerged as the most BRD4-overloaded enhancer in the 
Ly1 DLBCL (Figure 4.7E), prompting further analysis of the effect of BET inhibition on 
OCA-B expression and function. OCA-B is a gene regulatory factor that interacts with 
the OCT1 and OCT2 TFs at octamer motifs and regulates B-cell development, 
maturation and GC formation42. Although OCA-B is expressed throughout B-cell 
development, it is most abundant in normal GC B cells and GC-derived tumors including 
DLBCL47. OCA-B has a large H3K27ac-defined enhancer, with strong BRD4 binding 
that is abolished by JQ1 treatment (Figure 4.9A). Consistent with this observation, BET 
inhibition reduced RNA Pol II elongation of OCA-B, with a concomitant increase in 
promoter-paused RNA Pol II near the transcriptional start site (TSS; Figure 4.9B). JQ1 
treatment (500 nM) also decreased OCA-B transcript abundance and protein 
expression in Ly1 (Figure 4.9C), as well as additional DLBCL cell lines (Figure 4.10A).  
 
We next assessed the consequences of JQ1 treatment on the OCA-B 
transcriptional program by performing GSEA with a well-defined series of OCA-B target 
genes42. OCA-B targets were significantly less abundant in JQ1-treated  
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Figure 4.9: Modulation of BRD4 super-loading at the POU2AF1 locus following JQ1 treatment 
(A) ChIP-seq binding density for H3K27ac (blue), and BRD4 (red) at the enhancer of POU2AF1 with JQ1 
(+) or vehicle (DMSO) (-). JQ1 treatment significantly reduced BRD4 occupancy at the upstream 
enhancer element of POU2AF1. (B) ChIP-seq reads at the POU2AF1 promoter for RNA Pol II (black) and 
H3K4me3 (green) following JQ1 (+) and DMSO (-) treatment. RNA Pol II showed increased pausing 
following JQ1 treatment. (C) OCA-B transcript and protein abundance in Ly1 cells treated with vehicle or 
500 nm JQ1 or JQ1R (24 hr). (D) OCA-B-target genes (leading edge, OCA-B GSEA) in Ly1 cells treated 
with vehicle or 500 nM JQ1 (500 nm) are visualized as heatmap. (E) Knockdown efficacy of two 
independent shRNAs against OCA-B was detected by western blot (top panel). Proliferation of OCA-B-
depleted cells was measured by alamar blue. The p values for NC vs. each OCA-B shRNA were 
delineated by two-sided Student’s t-test; asterisks show p<0.01. Knockdown efficiency of two 
independent shRNAs against BRD4 (F) or BRD2 (G) and the associated changes in OCA-B expression 
were evaluated by western blot.  
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Figure 4.9 (Continued) 
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Figure 4.10: OCA-B abundance and target genes in DLBCL cell lines treated with JQ1.  
(A) OCA-B protein abundance in each of the 5 DLBCL cell lines treated with vehicle or 500nM JQ1 or 
JQ1R (24 hr). (B) GSEA plot of a curated list of OCA-B targets in all 5 DLBCL cell lines treated with 
vehicle (DMSO) or JQ1 (24 hr). (C) Heat map of the OCA-B target genes (leading edge, OCA-B GSEA) in 
each of the DLBCL cell lines treated with vehicle or JQ1 (24 hr).  (D) Enforced expression of OCA-B or 
control (ev=empty vector) in the pMIG expression vector resulted in a partial proliferative advantage for 
the OCA-B expressed cells at lower JQ1 concentrations following 72hr of JQ1 exposure. (E) Immunoblot 
for OCA-B after enforced expression (upper panel) and its quantification with ImageJ (lower panel). (F) 
Immunoblot of BRD4, OCA-B and GAPDH after genetic depletion of BRD4 with two independent hairpins 
(shBRD4-#1 and shBRD4-#2) and a control (ev=empty vector) in three representative DLBCL cell lines.  
(G) Western blot of BRD2, OCA-B and GAPDH after knockdown of BRD2 with two independent hairpins 
(shBRD4-#1 and shBRD4-#2) and a control (ev=empty vector). 
. 
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DLBCLs as illustrated in Ly1 (Figure 4.9D) and the full DLBCL panel (Figure 4.10B-C). 
OCA-B depletion with two independent shRNAs significantly decreased the proliferation 
of Ly1 (Figure 4.9E), and enforced expression of OCA-B partially rescued the JQ1-
mediated anti-proliferative effects (Figure 4.10D-E). Of note, genetic depletion of BRD2 
or BRD4 (Figure 4.9F-G; 4.10F-G) phenocopied the JQ1-mediated reduction of OCA-B, 
indicating that BET inhibition acts partially via SE disruption. 
 
JQ1 targets the super enhancers of additional critical B-cell TFs and modulates 
the GC program 
Three of the master regulatory TFs with BRD4-loaded super enhancers (BCL6, 
IRF8 and PAX5), promote and maintain the B-cell gene expression program and limit 
differentiation into antibody-secreting plasma cells 44. For these reasons, we further 
assessed the functional consequences of BET inhibition on the critical B-cell TFs with 
BRD4-loaded super enhancers.  
 
Given the known oncogenic function of deregulated BCL6 in GC B-cells 14 and 
the sensitivity of certain DLBCLs to BCL6 depletion 48, we first evaluated the 
consequences of BET inhibition on BCL6 expression and function. The BCL6 locus 
includes a large previously defined upstream enhancer 49 that is severely depleted of 
BRD4 upon JQ1 treatment (Figure 4.11A). Consistent with depletion of BRD4 from the 
BCL6 enhancer, the promoter also shows increased RNA Pol II pausing and reduced 
elongating RNA Pol II (Figure 4.11B). 
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Figure 4.11: Modulation of super-enhancers of B-cell transcription factors following JQ1 treatment  
(A) CHIP-Seq binding density for H3K27ac (blue), BRD4 (red), and BCL6 (orange) at the BCL6 enhancer 
following JQ1 (+) or DMSO (-) treatment. JQ1 treatment significantly reduced BRD4 and BCL6 occupancy 
at the upstream enhancer element of BCL6. (B) ChIP-Seq reads at the BCL6 promoter for RNA Pol II 
(black) and H3K4me3 (green) following JQ1 (+) and DMSO (-) treatment. RNA Pol II showed increased 
pausing following JQ1 treatment. (C) BCL6 transcript abundance in Ly1 cells 12 and 24 hr following 
vehicle or JQ1 treatment (derived from GEP data). (D) BCL6 protein abundance following treatment with 
vehicle or JQ1 or JQ1R (500 nm) (24 hr). (E) CHIP-Seq density of BRD4 (red) at super enhancers of the 
two additional B-cell TFs, PAX5 and IRF8, following treatment with JQ1 (+) or DMSO (-). (F and G) PAX5 
and IRF8 transcript (F) and protein abundance (G) in Ly1 cells following JQ1 treatment.  
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Figure 4.11 (Continued) 
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As BCL6 is known to bind its own enhancer, we used BCL6 localization by ChIP-
Seq to explore the influence of BET inhibition on TF binding to this enhancer region. 
JQ1 treatment caused a marked reduction of BCL6 binding, demonstrating that BRD4 
loss leads to diminished TF loading, enhancer accessibility, and BCL6 protein level 
(Figure 4.11A-B). In an independent ChIP-qPCR experiment, we confirmed that BET 
inhibition decreased TF loading at the BCL6 enhancer (Figure 4.12A). Consistent with 
these findings, JQ1 treatment markedly decreased BCL6 transcript abundance and 
protein expression in Ly1 (Figure 4.11C-D), and additional DLBCL lines (Figure 4.12B). 
Similarly, PAX5 and IRF8 also have BRD4-loaded super enhancers that are severely 
depleted of BRD4 following JQ1 treatment (Figure 4.11E).BET inhibition also decreased 
PAX5 and IRF8 transcript abundance and protein expression (Figure 4.11F-G).  
 
 
Figure 4.12: JQ1 effect on the BCL6 locus, BCL6 protein abundance and the germinal center B-cell 
signature 
(A) ChIP-qPCR shows JQ1-mediated BRD4 depletion at the BCL6 enhancer and promoter. Asterisks 
indicate statistically significant differences by two-sided Student’s t-test with Welch’s correction at a p-
value <.05. PPIA serves as control. (B) BCL6 protein abundance in DLBCL cell lines treated with vehicle 
or 500nM JQ1R vs. JQ1S (24 hr). GAPDH loading control.  
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Super enhancers define developmentally regulated TF in DLBCL cell lines and 
primary tumors 
Using the robust H3K27ac mark to identify and discriminate super enhancers, we 
conducted ChIP-Seq SE analysis on five additional human DLBCL lines (DHL6, 
BCR/GCB; HBL1 and Ly3, BCR/ABC; Toledo and Ly4, OxPhos/Unclass) and a normal 
lymphoid sample (tonsil). Asymmetric enhancer loading was detected in all of the 
DLBCL cell lines (Figure 4.13A-C) and the normal tonsil (Figure 4.13D), confirming the 
ubiquitous nature of this epigenomic structural element.  
 
In all of the DLBCL cell lines and normal tonsil, large SEs were identified 
adjacent to master TFs such as PAX5, OCA-B, and IRF8 (Figure 13A-D; 13E-F, tracks 
and 4.14A) that maintain the B-cell program and limit plasma cell differentiation. Given 
the critical role of these master regulatory TFs in maintaining GC integrity and limiting 
GC exit 44, we assessed the consequences of BET inhibition on the GC program. To 
that end, we used a publically available compendium of GEPs of highly purified human 
B-cell subsets and defined a set of genes that are significantly more abundant in GC 
centrocytes and centroblasts than in post-GC plasma cells (Up_in_GCB_vs_PC). Using 
GSEA, we confirmed that the GC developmental program was downregulated in Ly1 
and in all 5 DLBCL cell lines following JQ1 treatment (Figure 4.13G [GSEA]; 4.13H 
[Heatmap] and 4.14B).  
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Figure 4.13: Analysis of super enhancers in additional DLBCL cell lines and normal lymphoid 
tissue. (A-D) Rank order of increasing integrated H3K27ac fold enrichment at enhancer loci in DLBCL 
cell lines, GCB (A), ABC (B) unclassified (C) and normal tonsil (D). (E) H3K27ac ChIP-Seq fold 
enrichment at the POU2AF1 locus showing the super-enhancer region. (F) H3K27ac ChIP-Seq reads at 
IRF4 locus in the 2 GCB and 2 ABC cell lines. (G) GSEA plot of the “Up in GCB_vs_PC” signature in 5 
DLBCL cell lines following JQ1 treatment. (H) The leading edge genes of the GSEA in (G) were 
visualized as heatmap. (I) Similarity matrix from unsupervised hierarchical clustering of each cell line by 
location of super-enhancers.  
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Figure 4.13 (Continued) 
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Figure 4.14: H3K27ac tracks of POU2AF1 locus, GSEA plots of germinal center B-cell signature in 
individual cell lines and unsupervised hierarchical clustering of super-enhancers in DLBCL cell 
lines. (A) Tracks of the H3K27ac mark for the POU2AF1 locus in indicated cell lines and a human tonsil. 
(B) GSEA plots of germinal center B-cell signature “Up_in_GC_vs_PC” in each of the DLBCL cell lines 
treated with vehicle vs. JQ1 (24 hr). (C) Unsupervised hierarchical clustering of super-enhancer loci in 
DLBCL cell lines.  Magnitudes indicate the log 2 fold H3K27ac signal to typical enhancers. Genes within a 
50kb range of the assigned super-enhancers loci comprising the Wright classifier 50 are indicated with an 
arrowhead. Gene annotations are color coded with GCB, blue, and ABC, red.  
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Figure 4.14 (Continued)  
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We next asked whether genes that were differentially expressed in the 
developmentally defined COO subtypes had adjacent SEs (Figure 4.14C). In the ABC 
DLBCL cell lines, but not the GCB lines, the subtype-specific TF locus, IRF4, had an 
adjacent SE (Figure 4.13A-B and F). The IRF4 SE was also detected in normal tonsil 
suggesting that it represented a developmental epigenetic mark rather than a tumor-
specific feature. Additional genes associated with the developmental ABC signature, 
including PIM1 and CCND2, had adjacent SE in ABC, but not GCB, cell lines (Figure 
4.14C). Consistent with this finding, unsupervised bidirectional hierarchical clustering of 
the DLBCL cell lines by SEs distinguished the ABC from GCB lines (Figure 4.13I and 
4.14C).  
 
To evaluate the clinical significance of these findings, we performed ChiP-Seq 
and SE analysis on 4 primary DLBCLs that were previously subtyped as either GCB or 
ABC 13. All primary DLBCLs exhibited the same characteristic asymmetry in H3K27ac 
enrichment, with readily identified regions consistent with SEs (Figure 4.15A-B). Again, 
SEs were found adjacent to lineage-specific TFs, such as PAX5, and subtype-
associated TFs , such as IRF4 (Figure 4.15A-B, tracks in Figure 4.15C-D). Notably, 
primary samples could also be clustered by SEs reflecting transcriptional developmental 
distinctions (Figure 4.15E). 
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Figure 4.15: Analysis of super enhancers in primary DLBCLs  
(A and B) Rank order of increased H3K27ac fold enrichment at enhancer loci in primary DLBCLs (GCB#1 
and #2 (A); ABC#1 and #2 (B)). (C) Gene tracks showing H3K27ac enrichment at the PAX5 locus in all 4 
primary DLBCLs. (D) Tracks as in (C) comparing the H3K27 enrichment at the IRF4 locus in primary GCB 
vs. ABC DLBCLs. (F) Unsupervised hierarchical clustering of primary DLBCLs using the genomic location 
of all super-enhancers. 
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Figure 4.15 (Continued) 
 
 200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Unsupervised hierarchical clustering of super-enhancers in four primary DLBCL 
samples. Unsupervised hierarchical clustering of all super-enhancers loci in four primary DLBCL 
samples. Naming of primary samples indicates the previously assigned transcriptional COO subtype 13.  
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Figure 4.16 (Continued) 
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DISCUSSION 
DLBCL is a clinically, biologically and genetically heterogeneous disease with 
distinctive transcriptional programs. As transcriptional circuits are ultimately controlled 
by master regulatory TFs and transcription and chromatin-associated factors rank 
among the most commonly altered genes in DLBCL 9,10,13, there is a pressing need to 
identify, characterize and target gene regulatory factors in this disease. We 
hypothesized that targeting oncogenic transcriptional activation at the chromatin level 
might act as a subclass-independent treatment in DLBCL. Here, we provide mechanistic 
evidence of BET bromodomains as transcriptional co-activators at large enhancers in 
addition to E2F1-driven promoters, and data supporting the study of BET inhibitors in all 
recognized subtypes of DLBCL.  
 
In a broad panel of DLBCL cell lines representing all transcriptionally defined 
subtypes, nanomolar dose BET inhibition caused a profound G1 cell cycle arrest. BET 
inhibition also significantly delayed tumor growth in two independent DLBCL xenograft 
models. Gene expression profiling of multiple JQ1-treated DLBCL cell lines confirmed 
the previously described transcriptional downregulation of TLR pathway components, of 
interest in DLBCLs with activating mutations of MYD88 37,51. Transcriptional profiling 
also revealed coordinate downregulation of multiple B-cell receptor signaling 
components, of note given the role of BCR-mediated survival signals in specific DLBCL 
subtypes 8. More broadly relevant for all subtypes of DLBCLs, we identified highly 
significant transcriptional downregulation of MYC and E2F1 target genes and the 
selective depletion of BRD4-loaded promoters and enhancers. 
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BET inhibition decreased the abundance of multiple functionally defined E2F 
target genes but did not measurably alter E2F1 protein levels. Epigenomic analyses 
confirmed the co-localization of BRD4 and E2F1 at active promoters and the selective 
decrease in BRD4 loading and transcriptional elongation of E2F1-driven genes following 
JQ1 treatment. Given the recently identified genetic signature of structural deregulated 
cell cycle and increased E2F activity in poor prognosis DLBCLs 13, BET inhibition may 
represent a promising targeted treatment strategy. Previous studies suggested a role of 
BET proteins in E2F1-mediated transcription 52,53. 
 
Studies from our lab and others have highlighted the important role of BRD4 as a 
co-activator of MYC mediated transcription 30,32,33. In multiple myeloma cell lines with 
Ig/MYC translocations, BRD4 was postulated to function via long-range interactions with 
the distal IgH enhancer 30. However, emerging data indicate that BET inhibitors 
suppress MYC transcription in the context of translocated, amplified or wild-type MYC 
alleles and BRD4 localizes to MYC promoter and enhancer elements 2,30,32,33. In the 
current studies, we identify a BRD4-loaded MYC enhancer and find that BET inhibition 
decreases MYC transcription and expression in DLBCL cell lines with translocated, 
amplified or wild-type MYC alleles. In this extensive DLBCL cell line panel, the 
functional consequences of BET inhibition – cell cycle arrest and decreased cellular 
proliferation – were largely comparable. Although JQ1 treatment broadly downregulated 
the transcriptional targets of MYC and E2F, we sought additional bases for the effect of 
BET inhibition across multiple DLBCL subtypes.  
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We observed that a small subset of genes had a disproportionately high BRD4 
load at their proximal enhancers. These unusual regulatory elements were ≅ 12-fold 
larger than typical enhancer regions. Integrated epigenomic and transcriptional studies 
established that such super enhancer-marked genes were particularly sensitive to BET 
inhibition. As SEs were found adjacent to genes encoding known lineage factors and 
DLBCL oncoproteins, we surmised that SE analysis may identify novel, unrecognized 
tumor dependencies. The functional exploration of OCA-B, encoded by SE-marked 
POU2AF1, validates this factor as a cancer dependency in DLBCL. Mechanistic 
research has established OCA-B as a co-activator protein which binds into the OCT1-
OCT2 transcriptional complex, enhancing IgH promoter-enhancer communication 54,55. 
Mice lacking OCA-B expression due to germline knock-out of POU2AF1 are 
developmentally normal, even capable of early transcription from immunoglobulin 
promoters, however they lack an apparent germinal center reaction to antigen 42,56. 
Collectively, the earlier studies and the current research support a putative therapeutic 
window to targeting OCA-B, potentially by protein-protein inhibition via the POU domain. 
More generally, these studies establish a rationale to systematically explore SEs for 
unrecognized tumor dependencies, and potentially use SEs as biomarkers for targeted 
therapeutic development. 
 
In this first comparative epigenomic analysis of human DLBCL cell lines, primary 
tumor specimens and normal lymphoid samples, we analyzed patterns of H3K27ac 
enrichment to understand the relevance of enhancer variation and function. These 
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studies reveal SEs as characteristic features of human lymphoid tissues, both benign 
and malignant. Preservation of tissue-specific SEs is observed comparing non-
malignant nodal tissue to primary DLBCL samples, as well as in patient-derived human 
DLBCL cell lines. 
 
In summary, our data suggest that the BET inhibition limits the growth of DLBCLs 
by at least two complementary activities: a specific effect on genes that define a given 
cell type by high BRD4 loading at enhancers and a more general suppression of 
transcription at E2F- and MYC-driven target genes. Thus, an E2F/MYC pathway effect 
is combined with massive depletion of proteins driven by BRD4 overloaded enhancers 
preventing cell cycle progression and leading to growth arrest. The majority of DLBCLs 
have a structural basis for increased E2F1-mediated cell cycle progression; however, 
these tumors may differ in BRD4 super-loading of cell fate-determining enhancers, 
including MYC, depending on their molecular context. This framework of BET inhibition 
explains its broad subclass- and tumor-type independent mechanism of action and 
reconciles the apparent pleiotropic effects and cell type-specific outcomes. Importantly, 
these data provide a compelling rationale for further human clinical investigation. 
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Experimental procedures 
High throughput screening of BET bromodomain inhibitors in B-cell lymphoma 
cell line panel  
Using a semi-automated screen we tested the indicated compounds in 34 human 
lymphoma lines in a 384-well format. Cell viability at 72 hr was evaluated using ATPlite 
(Perkin Elmer). The mean of absolute EC50s from two independent screens were 
visualized and clustered using GENE 
(http://www.broadinstitute.org/cancer/software/GENE-E/index.html). 
 
Animal Studies 
All animal studies were performed according to Dana-Farber Cancer Institute 
Institutional Animal Care and Use Committee (IACUC)-approved protocols as previously 
described 13 and Supplemental Experimental Procedures.  
 
Analyses of cellular proliferation and apoptosis, immunohistochemistry, 
immunoblotting, transcriptional profiling, GSEA and lentiviral mediated shRNA, 
chromatin immunoprecipitation with massively parallel sequencing (CHIP-Seq) 
and analysis of CHIP-Seq data 
A full description of these methods is listed in Supplemental Experimental Procedures. 
 
Accession Numbers 
The Gene Expression Omnibus accession numbers for the gene expression and CHIP-
Seq data reported in this paper is GSE45630 and GSE46663, respectively.  
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Cell Culture 
The identities of the diffuse large B-cell and Hodgkin lymphoma cell lines used in this 
study were confirmed via STR profiling (PowerPlex ®1.2 system [Promega]) and the 
online verification services of the cell banks JCRB, DSMZ 
(http://cellbank.nibio.go.jp/cellbank_e.html, http://www.dsmz.de/STRanalysis) and the 
Arizona Lymphoid Tissue and Blood Repository (L. Rimsza). The Burkitt lymphoma cell 
lines were recently purchased from the German Cell Line bank DSMZ (Braunschweig, 
Germany). HBL1 was kindly provided by Georg Lenz (Charité, Berlin, Germany). 
All cell lines were cultured at 37°C in 5% CO2. Balm3, BL2, BL41, CA46, CTB-1, Daudi, 
Dogkit, DB, HBL1, HDLM2, KM-H2, L428, L1236, L540, Namalwa, Pfeiffer, Raji, SU-
DHL-5, SU-DHL-6 (hereafter DHL6), SU-DHL-7, SU-DHL-8, SU-DHL-10, Toledo and 
WSU-NHL were propagated in RPMI (Cellgro); OCI-Ly1 (hereafter Ly1), OCI-Ly3, OCI-
Ly4 (hereafter Ly4), OCI-Ly7, OCI-Ly8, OCI-Ly10, OCI-Ly18 and OCI-Ly19 were grown 
in IMDM (Invitrogen). SUP-HD-1 was cultured in McCoy’s media (Invitrogen). HEK293T 
cells for lentiviral particle production were cultured in DMEM (Cellgro). All media were 
supplemented with 10mM HEPES buffer, 2mM L-glutamine, 50U/mL penicillin, 50U/mL 
streptomycin and 10% heat-inactivated fetal bovine serum (FBS, all from Invitrogen); 
only BL2, L540, OCI-Ly10, HDLM2, SUP-HD1 were cultured in 20% FBS.  The growth 
media of HBL1 was supplemented with 1mM sodium pyruvate. All cell lines were 
adjusted to 200,000 cells/ml 48 hr prior to an experiment.  
 
Compounds 
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All compounds used in this study were resynthesized in-house or by contract with 
ChemPartner. Materials were stored as dry powders or 10 mM DMSO stock aliquots. 
JQ1 in this document refers to the JQ1S active species. The inactive JQ1R enantiomer 
is noted as such where used. 
 
Screening of BET bromodomain inhibitors in B-cell lymphoma cell line panel 
On the day of the experiment, cells were counted and adjusted to 60,000 cells/ml in 
appropriate growth media. Using a Biotek EL406, 50 μl of cells were distributed into 
white 384-well plates (Thermo). Immediately after plating, compound in DMSO was 
distributed to plates. For large plate sets, cells were returned to 37oC incubator while 
not in use. Compounds were added to plates using a 100 nl 384-well pin transfer 
manifold on a Janus workstation. Stocks were arrayed in 10 point quadruplicate dose 
response in DMSO stock in 384-well Greiner compound plates. After addition of 
compound, plates were incubated for 72 hr in a 37oC incubator. 
Cell viability was read out using ATPlite (Perkin Elmer). Plates were removed from the 
incubator and brought to room temperature prior to use. Lyophilized powder was 
resuspended in lysis buffer and diluted 1:2 with distilled water. 25 μl of this solution was 
added to each well using the Biotek liquid handler. Plates were sealed with adherent 
aluminum seals prior to vortexing and spinning down at 1000g for 1 min. Plates were 
incubated for 15 min at room temperature before the luminescence signal was read on 
an Envision Plate Reader. 
Data acquired as described was stored and grouped in Microsoft’s Excel and analyzed 
using GraphPad Prism Software. Curve fits to calculate EC50 were done in GraphPad 
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Prism version 6.0a using four parameter (Hill slope not assumed to be equal to 1) non-
linear regressions of the data with the log10 transformed data of the compound 
concentrations plotted against the percent viability of the cells when normalized to 
DMSO only treated wells included on the plate. Edge wells were excluded. The mean of 
absolute EC50s from two independent screen experiments were visualized and 
clustered in a color-coded heat map using GENE 
(http://www.broadinstitute.org/cancer/software/GENE-E/index.html). 
 
Assessment of proliferation, cell cycle and apoptosis following BET 
Bromodomain Inhibition 
Proliferation of a smaller panel of cell lines (as listed in Figure 4.1) following treatment 
with increasing doses of JQ1 was assessed with the alamarBlue assay (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s recommendation. Briefly, 10,000 cells 
were plated in a round-bottom 96-well with indicated final concentrations of JQ1 or 
-containing alamar 
blue solution per well, plates were incubated for 2h at 37C to allow reduction to 
resorufin. Viability was determined compared to background on subsequent days by 
reading the fluorescence emission of resorufin on a Spectramax M3 plate reader 
(Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 544 nm and 
reading the emission at 590 nm with 10 readings per well. 
Cell cycle analysis was performed 72 hr after JQ1 treatment using Hoechst 33342. Cells 
were resuspended in 1 ml of growth medium supplemented with 10µg/ml Hoechst 
33342 (Molecular Probes, Invitrogen) as final concentration. After 60 min at 37ºC in the 
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dark, analysis was performed on a FACS AriaII cytometer (BD Biosciences) using the 
UV laser 350 nm with 20 mW. The cell cycle was plotted as histogram after excluding 
doublets. 
Cellular apoptosis was analyzed with an APC AnnexinV/7ADD Apoptosis Detection kit 
(BD Pharmingen). AnnexinV/7AAD assessments and cell cycle graphics were 
generated using FlowJo software V7.6.1 for Windows (Tree Star). 
  
In vivo studies 
All animal studies were performed according to Dana-Farber Cancer Institute 
Institutional Animal Care and Use Committee (IACUC)-approved protocols as previously 
described 13. The DLBCL cell lines, Toledo and Ly1, were engineered for in vivo 
imaging by transduction with the VSV-G-pseudotyped lentivirus encoding the firefly 
luciferase, mCherry, and a puromycin-N-acetyltransferase, each separated by 
picornavirus ribosomal slippage peptides as previously described 13. Subsequently, 
5x106 viable Luc-mCherry-
injected via the lateral tail veins of 8- null mice (Charles River 
Laboratories, Wilmington, MA).  
Disease burden was quantified using bioluminescence imaging as previously described 
13 and data are presented as mean ±  SEM with statistical significance determined by 
one-sided t-test. One week following tumor inoculation, animals with established 
disease documented by imaging were divided into two cohorts with equal mean 
bioluminescence and treated with 30 mg/kg JQ1S or vehicle (10% DMSO in D5W) BID 
by intraperitoneal injection.  Following 16 days of treatment, the entire Toledo cohort 
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was sacrificed and subjected to a complete hematologic analysis. One third of the 
spleen and one tibia were fixed in 10% neutral-buffered formalin over night and then 
stored in preparation for immunohistochemical analyses in 70% ethanol. Flow cytometry 
was used to analyze single cell suspensions of spleen and bone marrow for the 
presence of mCherry-positive Toledo cells (excitation of 561 nm using a yellow-green 
laser on a BD LSRFortessa [BD Biosciences]), which were confirmed to co-express 
human CD45 and CD19 by flow cytometry with anti-human CD45-FITC (BD) and anti-
human CD19-PE-Cy7 (BD) antibodies (data not shown, see 13).  
To measure survival as endpoint, we used a second independent DLBCL cell line, Ly1, 
which were injected into 25 mice (see details above). At day 13 of treatment three 
animals from each group were sacrificed and subjected to a full hematological analysis 
with vehicle or JQ1,  validate the PD of the drug and mirror our analysis in Toledo. The 
remainder of the cohort was treated until the end point of the study (overall survival) 
were reached. Animals with paralysis, emaciation or severe dyspnea were scarified 
according to the protocol. 
 
Immunohistochemistry of mouse tissues  
Immunohistochemistry (IHC) for human CD20 and Ki67 was performed using 4-μm-
thick, formalin-fixed, paraffin-embedded tissue sections of explanted mice spleen or 
tibia as previously described (Monti et al., Cancer Cell 2012). Prior to embedding, mice 
tibia was subjected to decalcification following standard protocols in order to soften the 
bone tissue for sectioning. Slides were baked, deparaffinized in xylene, passed through 
graded alcohols, and then antigen retrieved with either 10mM citrate buffer, pH6.0 
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(Invitrogen), for CD20 or 1mM EDTA, pH8.0 (Invitrogen), for Ki67 in a steam pressure 
cooker (Decloaking Chamber; BioCare Medical) as per manufacturer’s instruction. All 
further steps were carried out at room temperature in a hydrated chamber. Slides were 
pretreated with Peroxidase Block (Dako) for 5 minutes to quench endogenous 
peroxidase activity, and then washed in 50mM Tris-Cl, pH7.4. Slides were blocked 
using Protein Block (Dako) as per manufacturer’s instruction, and subsequently 
incubated with αCD20cy (clone L26 , ready to use; Dako) and αKi67 (clone MIB-1, 
1:500 dilution; in diluent (Dako)) for 1 hr. Slides were then washed in 50mM Tris-Cl, 
pH7.4 and treated with anti-mouse horseradish peroxidase-conjugated antibody 
(Envision Plus; Dako) for 30 min. After further washing, immunoperoxidase staining was 
developed using a 3,3’diaminobenzidine (DAB) chromogen (Dako) for 5 min. Slides 
were counterstained with hematoxylin, dehydrated in graded alcohol and xylene, and 
mounted and coverslipped. Slides were loaded into an Aperio ScanScope XT and 
scanned at 40x magnification (0.25 µm/pixel) via the semi-automated method. Slides 
were checked for image quality using visual inspection. 
 
Gene expression profiling  
The 5 DLBCL cell lines, Ly1, DHL6, Ly4, Toledo and HBL1, were incubated in biological 
triplicates for 2, 6, 12 and 24 hr with 500nM of JQ1 or DMSO at a concentration of 
1x106 cells/ml. Untreated cells in triplicates per cell line at baseline (0 hr) were 
harvested directly without treatment. Total RNA was extracted using the standard Trizol 
extraction method. RNAs were measured and quality controlled on a Bioanalyzer, and 
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subsequently profiled on an Affymetrix human ST1.0 gene chip in the Dana-Farber 
Microarray Core (http://chip.dfci.harvard.edu).  
Data processing 
The gene-by-sample expression matrix used for subsequent analyses was obtained 
from the raw ‘.CEL’ files by performing Robust Multichip Average (RMA) normalization 
57 using a custom CDF based on entrez annotation 58. Variation filtering was performed 
by ranking genes according to an F-statistic measuring the ratio of their between- to 
within-replicate variation, and by then selecting the top 8000 transcripts 6. 
Temporal response analysis 
At each time point (2, 6, 12, and 24 hours), differential analysis was performed between 
the DMSO-treated and the JQ1-treated samples, using a t-statistic and a permutation-
based p-value calculation to identify the transcripts most significantly up- and down-
regulated in response to the treatment 59. Permutations were constrained so as to 
control for cell type (Good P Springer book). The up-regulation and down-regulation 
signatures at each time point were defined as the sets of genes with FDR-corrected q-
value ≤ .01 and fold-change ≥ 1.3.  
Enrichment analysis 
The signatures thus defined were then tested for enrichment based on the hyper-
geometric distribution with respect to the canonical pathways included in the MSigDB 
c2_cp compendium, as well as with respect to the list of transcription factor targets 
included in the MSigDB c3_tft compendium 60. Gene sets significantly enriched with 
FDR q-value ≤ 0.25 were reported, with the multiple-hypothesis correction accounting 
both for the multiple gene sets as well as the multiple signatures tested. Functionally 
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defined gene sets were derived from the C2.CGP MSigDB depository 
(http://www.broadinstitute.org/ gsea/msigdb/index.jsp). For OCA-B, we curated a gene 
signature from previously published work. The ChiP-Seq defined E2F1 target gene set 
was composed of the top 100 genes with transcription factor-occupied proximal 
regulatory regions, defined as signal +5kb of the transcription start side in vehicle-
treated Ly1 cells. The binding signal of the E2F1 chip was normalized to the signal of 
the whole cell lysate. To define a developmental signature of germinal center B-cells, 
we utilized publically available gene expression profiles of purified human B-cell subsets 
(GSE12453) 61. We performed a differential analysis between the union of 
centrocytes/centroblasts and plasma cells in gene pattern (Broad Institute, 62) using the 
comparative marker selection module. The 150 most up-regulated genes in normal 
germinal center centrocytes and centroblasts vs. normal plasma cells were defined as 
(UP_in_GCB_vs_PC). 
 
SDS-PAGE Western Bot  
SDS-PAGE and Western Blot was performed as previously described in 13 with the 
following antibodies in 0.1% Tween 20/PBS: BCL6, sc-858 (N-3, 1:500); BACH2, sc-
14702 (1:500); GAPDH, sc-25778 (FL-335, 1:2000) (all from Santa Cruz 
Biotechnology). BRD2 was analyzed with HPA042816 (1:1000) from Sigma and BRD4 
(A301-985A, 1:500) with a commercial antibody from Bethyl. POU2AF1 (OCA-B) was 
detected with PA5-26105 (1:1000) from Thermo Scientific, PAX5 from BD (#610863, 
1:500), IRF8 from Cell Signaling (D20D8, 1:1000) and alpha-Tubulin with the clone 
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DM1A (CP06, 1:2000) from Calbiochem. Secondary antibodies were purchased from 
Santa Cruz Biotechnology.  
 
Chromatin immunoprecipitation with massively parallel sequencing from cell 
lines (ChIP-Seq) 
ChIP-Seq was performed as described 63 with minor changes. In brief, approximately 
1x108 cells were treated per condition at a concentration of 1x106 cells/ml with 500 nM 
JQ1 or DMSO for 24 hr and then cross-linked with 1.1% formaldehyde (10 X crosslink 
solution contains: 11% formaldehyde, 50 mM HEPES pH 7.3, 100 mM NaCl, 1 mM 
EDTA pH 8.0, 0.5 mM EGTA pH 8.0) followed by two washes with PBS. Cells were 
pelleted, flash frozen in dry ice/isopropanol and stored at -80°C until final use. 
100 μl of Dynal magnetic beads per sample (Invitrogen) were blocked with 0.5% BSA 
(w/v) in PBS. Magnetic beads were loaded with 10 μg of each antibody over night at 4 
oC. Antibodies used were as follows: Pol II (Rpb1 N-terminus): Santa Cruz sc-899; 
Histone H3K27Ac: Abcam ab4729; Histone H3K4me3: Millipore 07-473; Histone 
H3K27me3: Abcam ab6002; E2F1: Cell Signaling #3742; BRD4: Bethyl A301-985A; 
BCL6: Santa Cruz sc-858. Cross-linked cells were lysed with lysis buffer 1 (50 mM 
HEPES pH 7.3, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25% 
Triton X-100) for a total of 4.5 min on with 30 s pulses separated by 1 min pauses at 18 
amps. Pellets were then washed with lysis buffer 2 (10 mM Tris-HCl pH 8.0, 200 mM 
NaCl, 1 mM EDTA pH 8.0 and 0.5 mM EGTA pH 8.0). Cells were resuspended and 
sonicated in lysis buffer 3 (50 mM Tris-HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS) on ice for 10 cycles at 30 s 
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(18 W) with 60 s on ice between cycles. All lysis and sonication buffers contain 
Complete Protease Inhibitor Cocktail (Roche). Sonicated lysates were cleared by 
centrifuging at 20,000g for 10 min and incubated overnight on a spinning wheel at 4oC 
with magnetic beads prebound with antibody. Beads were washed three times with 
sonication buffer, one time with sonication buffer with 500 mM NaCl added, one time 
with LiCl wash buffer (20 mM Tris pH 8.0, 1 mM EDTA, 250mMLiCl, 0.5% NP-40, 0.5% 
Na-deoxycholate) and once with TE. DNA was eluted in elution buffer (50 mM Tris-HCl 
pH 8, 10mM EDTA, and 1% SDS). Cross-links were reversed overnight at 65oC. RNA 
and protein were digested with 0.2mg/mL RNase A for two hr followed by 0.2mg/mL 
Proteinase K for one hr. DNA was purified with phenol chloroform extraction and 
ethanol precipitation.  
Libraries for Illumina sequencing were prepared following the Illumina TruSeqTM DNA 
Sample Preparation v2 kit protocol with the following exceptions. After end-repair and A-
tailing, immunoprecipitated DNA (~10-50ng) or whole cell extract DNA (50ng) was 
ligated to a 1:50 dilution of Illumina Adapter Oligo Mix assigning one of 24 unique 
indexes in the kit to each sample. Following ligation, libraries were amplified by 18 
cycles of PCR using the HiFi NGS Library Amplification kit KAPA Biosystems. Amplified 
libraries were then size-selected using a 2% gel cassette in the Pippin PrepTM system 
from Sage Science set to capture fragments between 200 and 400 bp. Libraries were 
quantified by qPCR using the KAPA Biosystems Illumina Library Quantification kit 
according to kit protocols. Libraries with distinct TruSeq indexes were multiplexed by 
mixing at equimolar ratios and running together in a lane on the Illumina HiSeq 2000 for 
40 bases in single read mode. 
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ChIP-Seq from primary tissue 
Primary tissue samples from two ABC-DLBCL, two GCB-DLBCL flash-frozen and stored 
(300g, 5 min), these were then cross-linked with 1.1% formaldehyde in PBS for 10 min. 
The formaldehyde was quenched by adding 60 ul/ml of 2.5 M glycine. Glycine and 
fixative were removed with two washes in cold PBS. Samples were homogenized with a 
Dounce homogenizer using 10 strokes with pestle A and 10 strokes pestle B in a 
solution of 10 mM Tris HCl pH8, 10 mM NaCl, 3 mM MgCl2, and 1% NP40. Sample was 
then transferred to a 15 ml conical tube and rotated in the cold room for 60 min. After 
this incubation, nuclei were spun down at 1350g for 10 min and transferred to a 3.5 ml 
tube in 50 mM Tris-HCl pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 0.1% Na-deoxycholate, 0.7% SDS. Samples were then sonicated on ice for 10 
cycles at 30 s (18 W) with 60 s on ice between cycles. All lysis and sonication buffers 
contain Complete protease inhibitor cocktail (Roche). Sonicated lysates were cleared by 
centrifuging at 20,000g for 10 min and incubated overnight on a spinning wheel at 4oC 
with magnetic beads prebound with antibody after diluting sample to 0.1% SDS final. 
100 μl of Dynal magnetic beads per sample (Invitrogen) were blocked with 0.5% BSA 
(w/v) in PBS. Magnetic beads were loaded with 10 μg of each antibody overnight at 4 
oC. Antibodies used were as follows: Histone H3K27Ac: Abcam ab4729 ; BRD4: Bethyl 
A301-985A. 
Beads were washed three times with sonication buffer, one time with sonication buffer 
supplemented with 500 mM NaCl, one time with LiCl wash buffer (20 mM Tris pH 8.0, 1 
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mM EDTA, 250 mMLiCl, 0.5% NP-40, 0.5% Na-deoxycholate) and once with TE. DNA 
was eluted in elution buffer (50 mM Tris-HCl pH 8, 10mM EDTA, and 1% SDS). Cross-
links were reversed overnight at 65oC. RNA and protein were digested with 0.2mg/mL 
RNase A for two hr followed by 0.2 mg/ml Proteinase K for one hr. DNA was purified 
with phenol chloroform extraction and ethanol precipitation.  
Library preparation and sequencing was performed as described for ChIP-Seq from cell 
lines.  
  
Analysis of ChIP-Seq data 
Gene sets and annotations 
All analyses were performed using RefSeq (NCBI36/HG18) 64 human gene annotations.  
ChIP-Seq data processing 
All ChIP-Seq datasets were aligned using Bowtie (version 0.12.2) 65 to build version 
NCBI36/HG18 of the human genome. Alignments were performed using the following 
criteria: -n2, -e70, -m1, -k1, --best. These criteria preserved only reads that mapped 
uniquely to the genome with 1 or fewer mismatches.  
Calculating read density 
We used a previously described method to calculate the normalized read density of a 
ChIP-Seq dataset in any region 66. ChIP-Seq reads aligning to the region were extended 
by 200bp and the density of reads per base pair (bp) was calculated. In order to 
eliminate PCR bias, multiple reads of the exact same sequence aligning to a single 
position were collapsed into a single read. Only positions with at least 2 overlapping 
extended reads contributed to the overall region density. The density of reads in each 
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region was normalized to the total number of million mapped reads producing read 
density in units of reads per million mapped reads per bp (rpm/bp). 
Identifying ChIP-Seq enriched regions 
We used the MACS version 1.4.1 (Model based analysis of ChIP-Seq) 67 peak finding 
algorithm to identify regions of ChIP-Seq enrichment over background. A p value 
threshold of enrichment of 1e-9 was used for all datasets.  
Defining transcribed genes 
A gene was defined as transcribed if an enriched region for either H3K4me3 or RNA Pol 
II was located within +/- 5kb of the TSS. H3K4me3 is a histone modification associated 
with transcription initiation 68. 
Defining E2F1 target genes 
Because E2F1 has been shown to regulate genes through binding at cis-regulatory 
elements near genes, we defined E2F1 target genes based on total E2F1 ChIP-Seq 
occupancy near transcription start sites of genes.  We first calculated total E2F1 
occupancy at E2F1 enriched regions genome wide.  For the top 5,000 transcribed 
genes (determined by RNA Pol II occupancy in the +/- 1kb TSS region), the total E2F1 
occupancy was summed for all E2F1 enriched regions within +/- 50kb of the TSS.  The 
top 1,000 genes ranked by total TSS proximal E2F1 occupancy were called “E2F1 
target genes”, whereas the bottom 1,000 genes ranked by TSS proximal E2F1 
occupancy were called “E2F1 non-target genes”.  See Figure 4.9C.  
Defining active enhancers 
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Active enhancers were defined as in 66 as regions of enrichment for H3K27Ac outside of 
promoters (greater than 5kb away from any TSS). H3K27Ac is a histone modification 
associated with active enhancers 69,70. 
Heatmap representations of ChIP-Seq data 
In order to display ChIP-Seq levels at promoters or enhancers, we used a heat map 
representation. In the heatmap representation, each row represents the +/- 5kb 
centered on the TSS (for promoter heatmaps) or H3K27Ac enriched region center (for 
enhancer heatmaps). Each 50bp bin in each row was shaded based on intensity of 
ChIP-Seq occupancy (in units of rpm/bp). See Figure 4.9A and Figure 4.11A 
Creating meta representations of ChIP-Seq occupancy at active enhancers and 
promoters 
Genome-wide average “meta” representations of ChIP-Seq occupancy at active 
enhancers and promoters were created by mapping ChIP-Seq read density to the 5kb 
regions flanking the center of active enhancer regions or transcription start sites (TSS) 
of active genes.  Each active enhancer or TSS region was split into one hundred 50bp 
bins.  All active enhancer or TSS regions were then aligned and the average 
background subtracted ChIP-Seq factor density in each bin was calculated to create a 
meta genome-wide average in units of rpm/bp.  See Figure 4.9B and Figure 4.11B. 
Determination of RNA Pol II traveling ratio 
We determined the ratio of background subtracted RNA Pol II ChIP-Seq levels in 
initiating to elongating regions, a measure known as the traveling ratio (TR) 63 in each 
cell line. We defined the initiating region as +/-300bp around the TSS. We defined the 
elongating region as +300bp from the TSS to +3,000bp after the gene end.  In order to 
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make higher confidence comparisons, we limited our analysis to genes with detectable 
signal above noise in the initiating and elongating regions across all samples. The 
statistical significance of changes in the distribution of traveling ratios was determined 
using a Welch’s two-tailed t test.  See Figure 4.9C. 
 
 
BRD4 and H3K27Ac overlap 
BRD4 and H3K27Ac regions were considered overlapping if they were within 5kb of one 
another.  See Figure 4.11B. 
BRD4 location analysis 
We examined the location of BRD4 enriched region centers relative to active promoters 
and enhancers.  Promoters and enhancer regions were defined as the +/- 5kb region 
flanking the TSS or +/-5kb region flanking the center of enhancers respectively. See 
Figure 4.11D. 
Calculating BRD4 load at enhancers 
In order to accurately capture dense clusters of BRD4 bound enhancers, we allowed 
TSS distal BRD4 regions within 12.5kb of one another to be stitched together, a method 
described in 2,71. This analysis defined BRD4 bound enhancer regions in the Ly1 
genome.  The total BRD4 ChIP-Seq occupancy signal at BRD4 bound enhancers was 
calculated by first determining the average ChIP-Seq read density in the entire 
enhancer region (rpm/bp).  This value was multiplied by the length of the region to 
produce total ChIP-Seq occupancy in units of total rpm. See Figure 4.11E. 
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Identifying super-enhancers 
We observed disproportionately high occupancy of BRD4 at a subset of enhancers, 
similar to recent descriptions of “super-enhancers” 72. In Ly1 cells, super-enhancers 
were defined similarly to.  Briefly, we first ranked all enhancers by increasing total 
background subtracted ChIP-Seq occupancy of BRD4 (x-axis), and plotted the total 
background subtracted ChIP-Seq occupancy of BRD4 in units of total rpm (y-axis).  This 
representation revealed a clear inflection point in the distribution of BRD4 at enhancers 
(Figure 4.11E).  We geometrically defined the inflection point and used it to establish the 
cut off for super-enhancers.   
Assigning enhancers to genes 
Enhancers tend to loop to and associate with adjacent genes in order to activate their 
transcription 73. Using a simple proximity rule, we assigned the closest expressed and 
transcriptionally active gene (distance from enhancer center to TSS) within 1mb to each 
enhancer as its most likely target gene. 
Clustering of super-enhancers 
DLBCL super-enhancers were hierarchically clustered to display relationships between 
individual enhancers and samples. Within a set of DLBCLs, all unique super-enhancer 
containing regions were identified.  In each super-enhancer containing region, for each 
sample, background subtracted H3K27Ac was calculated relative to the median 
enhancer.  Pairwise pearson correlations were determined for all patterns of H3K27Ac 
signal and this correlation score was used to hierarchically cluster super-enhancer 
containing regions together.  Individual DLBCLs were also clustered together using the 
pearson correlation of H3K27Ac signal across all super-enhancer containing 
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regions.  Patterns of H3K27Ac signal at super-enhancer containing regions were 
displayed in two-dimensionally clustered heatmaps with each super-enhancer 
containing region displayed as a row color encoded by H3K27Ac fold signal over the 
median enhancer. Likewise, similarities between DLBCLs were displayed in 
hierarchically clustered two dimensional heatmaps in which each cell was colored by 
pairwise pearson correlation of H3K27Ac signal at all super-enhancer containing 
regions. 
Lentiviral-mediated knockdown of BRD2, BRD4, E2F1 and OCA-B. 
Hairpin-containing PLKO.1 plasmids were obtained from the RNAi platform at the Broad 
Institute. The following hairpins were used:  
Gene Hairpin TRC number 
BRD2 #sh1 0000006312 
 #sh2 0000006310 
BRD4 #sh1 0000199427 
 #sh2 0000196576 
E2F1 #sh1 0000010328 
 #sh4 0000000250 
POU2AF1 (OCA-B) #sh1 0000431764 
 #sh2 0000423580 
Control ev (=empty vector) 025 
 
The lentivirus was packaged by co-transfection of the lentiviral hairpin containing 
plasmid PLKO.1 and the helper plasmids. pCMV-dR8.91 and pMD2.G-VSV-G into 
HEK293T cells using Lipofectamin (Invitrogen), as previously described 13 with minor 
modifications. Following transduction via spinoculation for 2 hr at 1000g and 300C in the 
presence of 8 ug/ml hexadimethrine bromide (Sigma, St. Louis, MO) and selection with 
1 ug/ml puromycin for 48 hr (Sigma, St. Louis, MO), knockdown efficacy was 
determined by western blotting and cells were seeded for proliferation assays as 
described above. 
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Enforced Expression of MYC and OCA-B. 
Enforced expression of OCA-B was conducted with the pMSCV-IRES-GFP (pMig) 
vector. POU2AF1 (OCA-B) was obtained from the DF/HCC DNA Resource Core 
(http://plasmid.med.harvard.edu/PLASMID/Home.jsp) in pDONR221 (HsCD00042886) 
and subsequently cloned into pMig using a standard Gateway LR reaction according to 
the manufacturer’s recommendation.  
The vector pMX-MYC was ordered from Addgene (plasmid #17220, 74) and pDONR-
GFP was obtained from the Broad ORF consortium. MYC was subcloned into 
pDONR223 using a Gateway BP reaction according to the manufacturer’s 
recommendation. Both, GFP and MYC, were then subsequently subcloned with a 
Gateway LR reaction into the final destination vector for enforced expression of MYC 
and GFP, pMSCV-puro. All inserts used for enforced expression were confirmed to 
contain the reference sequence by classical Sanger sequencing. 
Retroviral particles were packaged by cotransfecting HEK293T cells with the pMSCV 
construct, VSV-G and PKAT in the ratio 10:5:10 ug using TransIT following the 
manufacturer’s recommendation. Viral particles were collected for 48 hr in DMEM 
supplemented with 30% FBS before indicated cell lines were transduced in a 
spinocculation for 1 hr/1000g/30°C.  
Ly1, Toledo and HBL1 cells were selected 48 hr after infection with its pMSCV-puro 
romycin before plated for an experiment. Ly1 cells 
transduced with OCA-B or control vector (pMMSCV-GFP) were sorted 48hr after 
infection using the concordant expressed GFP as marker. 
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Acetyl-Histone Binding Assay.  
Assays were performed with minor modifications from the manufacturer’s protocol 
(PerkinElmer, USA). All reagents were diluted in 50 mM HEPES, 150 mM NaCl, 0.1% 
w/v BSA, 0.01% w/v Tween20, pH 7.5 and allowed to equilibrate to room temperature 
prior to addition to plates. After addition of Alpha beads to master solutions all 
subsequent steps were performed in low light conditions. A 2x solution of components 
with final concentrations of 6xHis-tagged bromodomain protein at 80 nM, Ni-coated 
Acceptor Bead at 25 μg/ml, and 80 nM biotinylated Histone 4-tetra acetyl tail was added 
in 10 μL to 384-well plates (AlphaPlate - 384, PerkinElmer, USA). Biotinylated peptide 
for BRD4.1 was synthesized in-house on a CEM Liberty 9008005 microwave peptide 
synthesizer: H4-tetra acetyl, Biotin-PEG2-SGRGKacGGKacGLGKacGGAKacRHRK-
COOH. Addition to wells was performed with a Biotek EL406 liquid handler. After a 1 
min 1000rpm spin-down, 100 nL of compounds from stock plates were added by pin 
transfer using a Janus Workstation (PerkinElmer, USA). The streptavidin-coated donor 
beads (25 μg/ml final) were added as with previous solution in a 2x, 10 μL volume. 
Following this addition, the plates were sealed with foil to block light exposure and to 
prevent evaporation. The plates were spun down again at 1000rpm for 1 min. Next, the 
plates were incubated in the room with the plate reader (for temperature equilibration) 
for 1.5 hr prior to reading the assay. AlphaScreen measurements were performed on an 
Envision 2104 (PerkinElmer, USA) utilizing the manufacturer’s protocol. 
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ChIP-qPCR  
 
ChIP-qPCR analysis for BRD4 was performed on Ly1. Following treatment of 1x106 
cells/ml with 500 nM JQ1 or DMSO for 24 hr in growth medium, 1x106 cells were fixed 
with 1.1% formaldehyde (10 X crosslink solution contains: 11% formaldehyde, 50 mM 
HEPES pH 7.3, 100 mM NaCl, 1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0) followed by 
two washes with PBS. Cells were pelleted and flash frozen in dry ice/isopropanol. 50 μl 
of Dynal magnetic beads per sample (Invitrogen) were blocked with 0.5% BSA (w/v) in 
PBS. Magnetic beads were bound with 2μg of an anti-BRD4 antibody (Bethyl A301-
985A). Cross-linked cell pellets were lysed with 10% SDS, 0.5M EDTA, 1M Tris, and 
Roche Complete protease cocktail at pH 7.5. Samples at 500µL were sonicated at 35 
amps for a total of five min with 1 s pulses followed by 2 s off. Lysates were cleared and 
incubated overnight at 4oC with magnetic beads preloaded with antibody. Beads were 
washed three times with sonication buffer, once with sonication buffer supplemented 
with 500 mM NaCl, once with LiCl wash buffer (20 mM Tris pH 8.0, 1 mM EDTA, 
250mMLiCl, 0.5% NP-40, 0.5% Na-deoxycholate) and one time with TE. DNA was 
eluted in elution buffer before cross-links were reversed overnight at 65oC. RNA and 
protein were digested using RNase A and Proteinase K, respectively, and DNA was 
purified with phenol chloroform extraction and subsequent ethanol precipitation. ChIP 
and input DNA were analyzed using SYBR Green real-time PCR analysis (Applied 
Biosystems).  
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Real Time SYBR Green primer For CHIP-PCR: 
 
 
Gene Symbol Primer 
PPIA IDT Hs.PT.51.23155197 
BCL6-promoter-pair 1 
 
BCL6-promoter-pair 2 
 
forward        5’- CAA CCT GAA ACA CAG CTT GTC-3’ 
reverse        5’- CAC TCT GGC TGG TTC TAC TAC T-3’ 
forward        5’- CAG TAT CAC AGA TAC TGC CTG T -3’ 
 
reverse        5’- GGA AAG AAT TTC TCC TTC TTC TCT AC-3’ 
BCL6-enhancer-pair 1 
 
BCL6-enhancer-pair 2 
forward        5’- GCA TAT CAG TTA CAC TAT TTC TGA GC-3’ 
reverse        5’- AGC CAC GCA CAG GAA AGT GAG AG-3’ 
forward        5’- AGT GGG TAG CAG AGA ACA TGA GAC AT-3’ 
reverse        5’- TAC ACT TGC ATC TGG TTG CGC AGC T-3’ 
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